

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Role of Gut Microbe Composition in Psychosocial Symptom Response to Exercise Training in Breast Cancer Survivors (ROME) Study - protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081660
Article Type:	Protocol
Date Submitted by the Author:	02-Nov-2023
Complete List of Authors:	<p>Little, Rebecca; The University of Alabama at Birmingham, Medicine - Division of Preventive Medicine  Carter, Stephen J.; Indiana University Bloomington  Motl, Robert; University of Illinois at Chicago, Department of Kinesiology and Nutrition  Hunter, Gary; University of Alabama System,  Cook, Abby; Baylor Scott &amp; White Medical Center Temple  Liu, Nianjun; Indiana University Bloomington  Krontiras, Helen; The University of Alabama at Birmingham Heersink School of Medicine  Lefkowitz, Elliot; The University of Alabama at Birmingham  Turan, Bulent; Koc University, Department of Psychology  Schleicher, Erica ; The University of Alabama at Birmingham  Rogers, Laura; The University of Alabama at Birmingham Heersink School of Medicine</p>
Keywords:	Breast tumours < ONCOLOGY, ONCOLOGY, MICROBIOLOGY, Exercise Test

SCHOLARONE™  
Manuscripts

1  
2  
3 Role of Gut Microbe Composition in Psychosocial Symptom Response to Exercise  
4 Training in Breast Cancer Survivors (ROME) Study - protocol for a randomised  
5 controlled trial  
6  
7  
8  
9

10 *Rebecca B. Little PhD, RDN, Stephen J. Carter PhD, Robert W. Motl PhD, Gary R. Hunter PhD,*  
11 *Abby Cook DO, Nianjun Liu PhD, Helen Krontiras MD, Elliot J. Lefkowitz PhD, Bulent Turan*  
12 *PhD, Erica Schleicher MS, and Laura Q. Rogers MD, MPH*  
13  
14  
15

16 Manuscript correspondence:

Laura Q. Rogers, MD, MPH  
Department of Medicine  
The University of Alabama at Birmingham  
1720 2<sup>nd</sup> Ave South  
Medical Towers 614  
Birmingham, AL 35294-4410

17  
18  
19  
20  
21  
22  
23  
24  
25 Phone: (205) 934-9735

26  
27 Email: [lqrogers@uabmc.edu](mailto:lqrogers@uabmc.edu)

28  
29  
30 Running title: The ROME Study

31  
32 Word Count: 7,770 excluding abstract (272), 2 tables, 4 figures, 136 references

33  
34 Keywords: Aerobic Exercise, Breast Cancer, Cancer Survivorship, Gut Microbiota, Oncology

35  
36  
37 Scientific Meeting Presentation: None

38  
39 Funding: primary funding is from the National Cancer Institute R01CA235598, with additional  
40 funding from National Institutes of Health grants P30DK056336, T32 A047888, UL1TR003096,  
41 and R25CA76023.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction** Breast cancer survivors are at increased risk for chronic fatigue and altered gut microbiota composition, both of which negatively affect health and quality of life. Exercise has been shown to modestly improve fatigue and is linked to gut microbial diversity and production of beneficial metabolites. Previous studies suggest the gut microbiota composition is a potential mechanism underlying fatigue response to exercise. Randomised controlled trials testing the effects of exercise on the gut microbiome are limited and there is a scarcity of findings specific to breast cancer survivors. The objective of this study is to determine if fitness-related modifications to gut microbiota occur and, if so, mediate the effects of aerobic exercise on fatigue response.

**Methods and Analysis** The research is a randomised controlled trial of 10-weeks of aerobic exercise training vs. flexibility/toning standard attention control testing aerobic exercise effects on gut microbiota composition among breast cancer survivors aged 18-74 with fatigue. All participants receive a standardized controlled feeding diet. Assessments occur at baseline, 5 weeks, 10 weeks, and 15 weeks (5 weeks after completion of exercise intervention and controlled feeding). The gut microbiota is collected by fecal samples and 16S gene sequencing will identify the microbiome. Fatigue is measured by a 13-item multi-dimensional fatigue scale. Serum cytokines, heart rate variability, and hair cortisol assays will also be obtained.

**Ethics and Dissemination** The University of Alabama at Birmingham Institutional Review Board (IRB) approved this study, 15 May 2019, UAB IRB#30000320. A Data and Safety Monitoring Board (DSMB) convenes annually or more often if indicated. Findings will be disseminated in peer-reviewed journals and conference presentations.

**Trial registration number** NCT04088708, posted 13 September 2019.

## ARTICLE SUMMARY

### Strengths and limitations of this study

- This study focuses on a prevalent symptom suffered by breast cancer survivors (fatigue) and the potential role of the gut microbiome in exercise effects on fatigue.
- This study is one of the very few randomized controlled trials testing the effects of exercise on the gut microbiome, especially in cancer survivors.
- A standardized, energy balanced diet reduces diet and body weight induced variance on gut microbiota yet no prior randomized exercise and gut microbiome study has provided the same diet for all participants, as being done in our study.
- More fully understanding the mechanistic links between exercise and the gut microbiome, as proposed here, can inform future strategies to enhance the benefits of exercise on fatigue.
- Although assessors are masked to study group allocation and a standard attention control condition is used, the intervention precludes participant masking to exercise type.

## INTRODUCTION

Nearly 8 million individuals worldwide are living with a history of breast cancer.<sup>1,2</sup> Breast cancer survivors are at increased risk of altered gut microbiota composition (i.e., dysbiosis) that may worsen future cancer risk, comorbidities, and quality of life.<sup>3</sup> Factors that may contribute to the persistent gut microbiota composition changes include reduced physical activity and aerobic fitness, and detrimental changes in body composition after breast cancer diagnosis.<sup>4-7</sup> Given its importance on health and well-being,<sup>8-12</sup> strategies for reversing gut microbiota dysbiosis are needed, especially in breast cancer survivors.

While elucidating gut microbiota dysbiosis in breast cancer survivors remains imperative, it is relevant that the gut microbiome is associated with fatigue in breast cancer survivors<sup>13</sup> and survivors rank fatigue as the number one priority related to quality of life.<sup>14</sup> Additionally, breast cancer survivors are more likely to report fatigue than their age matched controls<sup>15</sup> and one in four suffer persistent fatigue years after their cancer diagnosis,<sup>16</sup> which exacerbates post-cancer disability and reduces quality of life.<sup>17,18</sup> Furthermore, fatigue is associated with greater risk of cancer recurrence and mortality.<sup>19</sup> Interestingly, the benefits of supervised exercise for breast cancer survivors extend beyond the expected improvements in cardio-metabolic parameters to include improvements in fatigue and other domains of quality of life.<sup>20</sup> As we (and others) have reported, exercise is a well-established non-pharmacologic therapy for fatigue, yet effects are somewhat modest (weighted effect size of 0.30 in a recent meta-analysis).<sup>21-24</sup> Hence, elucidating mechanisms underlying fatigue response is needed to optimize fatigue reductions for non-responders and increase effect sizes achievable with exercise.<sup>24-27</sup> Moreover, our prior work and that of others suggest the gut microbiota composition is one such mechanism, but further research is needed.<sup>13,28</sup>

1  
2  
3 Exercise training also presents as a promising strategy for reversing dysbiosis as it is  
4 linked to gut microbial diversity, abundance of select microbes, and production of beneficial  
5 metabolites (e.g., acetate, butyrate, propionate), albeit, these phenomena are currently limited to  
6 animal models or cross-sectional<sup>29-36</sup> and non-randomized prospective human studies.<sup>37</sup>  
7  
8 Randomized controlled trials testing the effects of exercise on the gut microbiome are limited<sup>38</sup>  
9 and there is a scarcity of findings specific to breast cancer survivors.<sup>7</sup> One randomized controlled  
10 trial in healthy overweight and obese individuals found vigorous-intensity exercise training was  
11 associated with increased microbe diversity.<sup>38</sup> To support the importance of intensity in exercise  
12 training, we recently showed in breast cancer survivors, cardiorespiratory fitness was a better  
13 correlate of gut microbe diversity compared to free-living activity energy expenditure.<sup>7</sup> It is  
14 unknown if the modulation of the microbiota by exercise occurs solely through direct means  
15 such as alterations to colonic transit time,<sup>39,40</sup> or indirectly through inflammation,<sup>41-43</sup> autonomic  
16 nervous system,<sup>44,45</sup> or hypothalamic-pituitary-adrenal (HPA) axis.<sup>46-48</sup> Additionally other  
17 lifestyle interventions such diet<sup>49</sup> and body weight changes<sup>50</sup> independently affect gut  
18 microbiota, making controls for these variables critical in exercise trials. Rigorously testing the  
19 dysbiosis-exercise link while also exploring the bidirectional gut-brain axis pathways responsible  
20 for exercise effects<sup>51,52</sup> can inform future exercise recommendations and multimodal  
21 interventions to counter the adverse effects of gut dysbiosis.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Given the potential benefits of exercise training on the gut microbiome and fatigue, a  
45 better understanding of their relationships in response to an exercise intervention among breast  
46 cancer survivors is warranted. Herein, we describe our ongoing randomized controlled trial  
47 testing aerobic exercise training as a potential strategy to attenuate dysbiosis in breast cancer  
48 survivors with fatigue while also standardizing diet intake and maintaining energy balance. We  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 further propose to determine if fitness-related modifications to gut microbiota mediate the effects  
4  
5 of aerobic exercise on fatigue response. This is a critical next step for several reasons. First, to  
6  
7 our knowledge there are currently no completed randomized controlled trials utilizing exercise  
8  
9 training as a potential modifier for dysbiosis in breast cancer survivors.<sup>53</sup> Additionally, no other  
10  
11 trials exploring these variables have been performed with a standardized diet to: 1) mitigate the  
12  
13 underlying variance on gut microbiota and 2) promote weight maintenance.<sup>54,55</sup> Therefore, we  
14  
15 describe our methods to facilitate future replicability.  
16  
17  
18  
19  
20

## 21 **METHODS**

### 22 **Aims and hypotheses**

23  
24  
25  
26 The primary study aim is to determine the effects of a 10-week aerobic exercise training  
27  
28 intervention compared to a flexibility/toning standard attention control on gut microbiota  
29  
30 composition among breast cancer survivors with fatigue. All participants are following an energy  
31  
32 balanced controlled feeding diet. The gut microbiome is being collected by fecal sample and  
33  
34 assessed by 16S rRNA at baseline, week 5 to explore interim changes, week 10 as our primary  
35  
36 time point, and week 15 to explore durability of effects. We hypothesize that compared to the  
37  
38 control, the exercise training group will demonstrate significant differences in gut microbial  
39  
40 diversity with increased Firmicutes (p), *Bacteroides* (g),<sup>7,56</sup> and *Bifidobacterium* (g),<sup>57</sup> and  
41  
42 decreased Actinobacteria (p) and Proteobacteria (p).<sup>7</sup>  
43  
44  
45  
46

47 A secondary study aim is to test if exercise training affects the gut microbiota  
48  
49 composition directly and/or indirectly through inflammation, autonomic nervous system, or  
50  
51 hypothalamic-pituitary-adrenal (HPA) axis mediators. We hypothesize that exercise training will  
52  
53 have direct and indirect effects on gut microbiota composition through markers of the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 hypothesized mechanisms (interleukin [IL]-6, IL-10,<sup>41-43</sup> heart rate variability,<sup>44-46</sup> cortisol<sup>46-48</sup>).  
4  
5 Another secondary study aim is to test if the exercise training effect on fatigue is direct and/or  
6  
7 indirect through changes in the gut microbiota composition. We hypothesize that exercise effects  
8  
9 on fatigue will be mediated by changes in beta diversity,<sup>13,58</sup> specifically frequency of Firmicutes  
10  
11 (p),<sup>7</sup> Actinobacteria (p),<sup>13</sup> and *Bacteroides* (g).<sup>13,41,59</sup>  
12  
13

### 14 **Overall mechanistic framework**

15  
16 Given the relationships between cardiorespiratory fitness and gut microbiota composition,<sup>7</sup> we  
17  
18 have chosen an exercise intervention applying the principles of exercise prescription required to  
19  
20 achieve an increase in cardiorespiratory fitness.<sup>60</sup> The biological plausibility of a dysbiosis-  
21  
22 exercise link also common to fatigue (e.g., inflammation, autonomic nervous system, and HPA  
23  
24 axis)<sup>48,61-66</sup> supports testing these potential mechanistic links in breast cancer survivors with  
25  
26 fatigue. Thus, the overall mechanistic framework for our trial depicted in Figure 1 can be applied  
27  
28 to potentially optimizing exercise interventions for treatment of fatigue.  
29  
30  
31

### 32 **Study overview and eligibility criteria**

33  
34 This 2-arm, parallel group-controlled trial is randomising breast cancer survivors to 10 weeks of  
35  
36 supervised aerobic exercise training or standard attention control (flexibility/toning) while on a  
37  
38 controlled feeding diet. The trial is taking place at the University of Alabama at Birmingham  
39  
40 (UAB) in Birmingham, AL. Participant enrollment commenced 1 January 2020, was paused  
41  
42 between March 2020 and August of 2020 due to the COVID-19 pandemic, and is projected to  
43  
44 end 1 January 2025. Institutional Review Board (IRB) approval has been obtained and all  
45  
46 participants provide informed consent prior to participation. Assessments occur at baseline and  
47  
48 then at 5, 10, and 15 weeks. A study schema is provided in Figure 2 and an overview of  
49  
50 participants' activities is provided in Table 1. An electronic study manual of procedures is kept  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 on a shared, HIPAA compliant cloud server accessible to all study staff.  
4

5 Inclusion criteria are as followed: 1) female breast cancer survivors ages 18 to 74 years with a  
6 history of ductal carcinoma in situ (DCIS) or stage 0, I, II, III breast cancer, 2) who are  $\geq 1$  year  
7 post-primary cancer treatment completion (chemotherapy and/or radiation), 3) average fatigue  
8 over the past week rated as  $\geq 3$  on a 1 to 10 Likert scales,<sup>67</sup> 4) English speaking, 5) physician  
9 medical clearance for study participation, 6) able to ambulate without assistance, 7) no  
10 antibiotics for the past 90 days, 8) willing to avoid taking probiotics for the duration of the study,  
11 and 9) after all other criteria are met, lab-based screening is used to confirm low fitness level  
12 ( $VO_{2peak} < 30$  mL/kg/min). Exclusion criteria are as follows: 1) metastatic or recurrent cancer, 2)  
13 another diagnosis of cancer in the past 5 years (not including skin or cervical cancer *in situ*), 3)  
14 unstable angina, 4) New York Heart Association class II, III, IV congestive heart failure, 5)  
15 uncontrolled asthma, 6) interstitial lung disease, 7) current steroid use, 8) having been told by a  
16 physician to only do exercise prescribed by a physician, 9) dementia or organic brain syndrome,  
17 10) schizophrenia or active psychosis, 11) connective tissue or rheumatologic disease, 12)  
18 anticipate elective surgery during the study period, 13) anticipate changes in usual medications  
19 during the study period, 14) plan to move residence out of the local area during the study period,  
20 15) plan to travel out of the local area  $> 1$  week during study participation, 16) contraindication to  
21 engaging in moderate-to-vigorous intensity aerobic exercise, 17) current or anticipated  
22 pregnancy during study participation, 18) live or work  $> 50$  miles from study site or do not have  
23 transportation to study site, 19) body mass index (BMI)  $> 50$  (confirmed during lab-based  
24 screening), 20) anticipate needing antibiotics during the study period, or 21) any social,  
25 psychological, or physical condition that interferes with the participant's ability to complete  
26 study activities or unduly increases study risk.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Recruitment and screening

Participants are being recruited through multiple recruitment strategies (e.g., recruitment letters mailed to breast cancer survivors identified through the UAB O'Neal Comprehensive Cancer Center registry, UAB investigators' waiting lists of cancer survivors inquiring about exercise and weight loss studies, newspaper advertising, cancer support groups, institutional websites and group emails, relevant non-institutional websites, flyers in waiting areas [hospitals, physicians' offices]). Referrals from oncologists and other relevant health care providers are being requested using messaging (i.e., electronic health records or institutional email) and face-to-face meetings; recruitment materials such as patient flyers are provided, as appropriate. Potential participants are given a description of the study and screened for eligibility based on a pre-determined telephone script. In addition to questions related to the above eligibility criteria, participants are asked the following diet questions in the prescreening telephone screen to assess potential controlled feeding adherence and safety issues: 1) *do you have any food allergies, restrictions, preferences or special diet (vegetarian, gluten-free, etc.)*, 2) *are you willing to eat the meals we provide*, 3) *do you drink alcohol? If yes, are you willing to refrain from alcohol during your participation in this study*, and 4) *do you foresee any barriers to picking up the food, storing food, or doing minimal meal preparation?*

## Enrollment and randomization

Interested potential participants who pass the pre-screening telephone interview are invited to an orientation visit (in person or by videoconference) to complete administrative forms, sign lab-based screening consent, and complete release forms for obtaining medical clearance with the study coordinator. Once medical clearance is received, the participant is scheduled for a lab-based screening visit which includes  $VO_{2peak}$  to confirm cardiorespiratory fitness  $< 30$  ml/kg/min

1  
2  
3 and BMI  $\leq 50$  (see Section 3.5.3 for methods). If deemed eligible at the lab-based screening visit,  
4 informed consent for full study participation is obtained, including optional permission to retain  
5 health information and biospecimens for future research. The participant is scheduled for  
6 initiation of controlled feeding and baseline assessment visits #1 and #2 (Figure 3).  
7  
8  
9  
10  
11

12 Participant randomization is based on computer generated random numbers and  
13 performed in blocks of 4 to facilitate an equal distribution between the two study groups. BMI is  
14 an important biological variable associated with gut microbiota composition,<sup>18,68</sup> hence  
15 randomization is stratified by BMI ( $< 30$  vs.  $\geq 30$ ). The study statistician performed the computer  
16 generation of random numbers which were placed in sealed, opaque envelopes and delivered to  
17 the recruiting staff with written protocol for use. Assignments are made in the order in which  
18 participants complete baseline testing and are kept in the sealed envelope until the participant has  
19 completed all baseline testing. Once the study coordinator confirms completion of baseline  
20 testing, the coordinator chooses the next envelope with group allocation. Participants remain  
21 partially blinded to study condition (e.g., will not be told which study condition [exercise  
22 training or flexibility/toning intervention] is expected to yield more benefits and all receive  
23 controlled diet which is potentially perceived as a “treatment”.) Assessments, assays, and data  
24 entry are conducted using objective and validated measures by staff who will remain blinded to  
25 study arm status.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## 47 **Assessments**

### 48 ***Schedule and masking***

49 Assessments occur at baseline (pre-intervention), 5 weeks (mid-point intervention), 10  
50 weeks (immediately post intervention), and 15 weeks (5 weeks post intervention) and are  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 performed by staff who are masked to participant study group allocation. Table 1 presents the  
4  
5 timeline of data and measures collected at each assessment visit. If eligible based on lab-based  
6  
7 screening and participant consents to full study participation, then controlled feeding  
8  
9 preparations are made and the baseline visit #1 is scheduled for one week after controlled  
10  
11 feeding begins (Figure 3). For each assessment, the participant completes two visits to the  
12  
13 exercise testing laboratory. In preparation for assessment visit #1, participants are provided  
14  
15 instructions for the lab-based measurements (location, parking, 12-hour fast, appropriate  
16  
17 clothing, etc.). During assessment visit #1, the participant provides a hair sample, completes the  
18  
19 fasted blood draw, resting energy expenditure by indirect calorimeter, resting heart rate  
20  
21 variability (Actiheart), dual-energy X-ray absorptiometry (DXA), and walking economy (i.e., net  
22  
23  $VO_2$ ). Because the  $VO_{2peak}$  and BMI measurements are taken at the screening visit, these are not  
24  
25 repeated at baseline but are repeated at the follow-up assessments. During assessment visit #1,  
26  
27 study staff provide the participant with the additional assessment materials (survey,  
28  
29 accelerometer with log, 3-day diet record, medication log, fecal sample kit, etc.) and related  
30  
31 instructions. The participant ships the fecal sample back to the UAB microbiome laboratory  
32  
33 within 7 days of visit #1 and returns the remaining assessment materials at assessment visit #2.  
34  
35 To better align the temporal relationship between the gut microbiome and fatigue, the fatigue  
36  
37 scale is collected at assessment visit #2 (i.e., several days after fecal sample collection).  
38  
39  
40  
41  
42  
43

#### 44 ***Gut microbiota composition***

45  
46 Participants are provided with a stool collection kit at each baseline and follow up assessment  
47  
48 visit #1 to self-collect the stool sample at home according to provided instructions. Briefly, the  
49  
50 instructions are to collect the sample in a clean dry study-provided collection hat and scoop a  
51  
52 small amount into the provided ParaPak vials (Meridian Biosciences, Inc; Cincinnati, OH) pre-  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 labelled with participant identification and assessment timepoint, and then ship the sample back  
4  
5 to our site via pre-paid overnight shipping materials. Once received by the microbiome lab, each  
6  
7 sample is aliquoted into labelled cryovials and stored at  $-80^{\circ}\text{C}$  until time for DNA extraction and  
8  
9 16S rRNA processing. One cryovial of precisely 100  $\mu\text{L}$  is retained and labeled for future  
10  
11 metabolomics assays (if indicated and funds can be obtained).  
12  
13

14  
15 With each sample collection, the participant completes a fecal sample questionnaire<sup>69</sup> and  
16  
17 returns it to the research staff. The questionnaire asks the participant to report changes in normal  
18  
19 diet and vitamin supplements; recent gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea,  
20  
21 and constipation); and usual frequency or changes in probiotic supplements, yogurt intake, and  
22  
23 high fiber foods or fiber supplements. Participants also report recent medical treatments such as  
24  
25 antibiotics, chemotherapy, or radiation therapy, and if they have ever had a major bowel  
26  
27 resection, gastric bypass surgery, an inflammatory bowel disease (such as Crohn's disease,  
28  
29 ulcerative colitis, indeterminate colitis), or irritable bowel syndrome. The participant is also  
30  
31 asked to complete a 3-day diet record capturing dietary intake 2 days prior to and the day of fecal  
32  
33 sample.  
34  
35  
36

### 37 ***Cardiorespiratory fitness ( $\text{VO}_{2\text{peak}}$ )***

38  
39 Participants perform a graded treadmill (TrackMaster TMX428CP; Full Vision, Inc.; Newton,  
40  
41 KS) test in accordance with the modified-Balke protocol to elicit  $\text{VO}_{2\text{peak}}$  (i.e., the highest  
42  
43 measured rate of oxygen uptake expressed in  $\text{mL}/\text{kg}/\text{min}$ . Initially,  $\text{VO}_2$  is stabilized over a 3-  
44  
45 minute period of standing rest, after which, participants begin walking at 2.0 mph at 0% grade  
46  
47 for 2 minutes. Grade is then increased 3.5% every 2 minutes until the 12<sup>th</sup> minute, at which point,  
48  
49 grade is decreased to 12% and speed increased to 3.0 mph. Grade is increased by 2.5% each  
50  
51 minute (as needed) until volitional exhaustion.  $\text{VO}_2$  and related gas exchange measures are  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 aggregated in 30-s bins and determined by open-circuit spirometry (True One 2400 system;  
4 ParvoMedics, Salt Lake City, UT). Gas analyzers and flowmeter are calibrated prior to each test  
5 using standard gases and 3-L syringe, respectively. Heart rate and Rating-of-Perceived Exertion  
6 (RPE; Borg 6-20, 6 = *no exertion at all, relaxed* and 20 = *maximal exertion*)<sup>70</sup> are recorded in the  
7 final 30 seconds of each stage. Blood pressure is measured via auscultation at minutes 6, 10, 14,  
8 16 and/or final stage of the graded treadmill test.  
9

### 16 ***Serum cytokines***

17 Inflammatory cytokines, interleukin (IL)-6 and IL-10, are collected by blood samples.  
18  
19 Participants are instructed to abstain from vigorous exercise, smoking, and alcohol for 24 hours  
20 prior and fast for 12 hours prior to the blood draw. Blood samples are collected, processed and  
21 stored (-80°C) using standard operating procedure consistent with expert consensus  
22 recommendations<sup>71</sup> and batch analyzed according to manufacturer's instructions by staff who are  
23 blinded to the participant's group allocation.<sup>64</sup> Serum cytokine assays will be analyzed by the  
24 UAB Metabolism Core using a MSD imager (MesoScale Discovery, Gaithersburg, MD;  
25 chemiluminescence technology; multiplex platform). Blood and serum samples are being  
26 processed and stored so that future metabolomic/functional metabolic studies can be done if  
27 indicated and funds can be obtained. A 7-day medication log is collected with each blood sample  
28 for medication changes between assessments that may influence study outcomes (e.g., anti-  
29 inflammatory agents, etc.).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 ***Heart rate variability***

47 Heart rate variability is evaluated with the Actiheart 5 (CamNtech Ltd., Cambridgeshire, UK)  
48 device. First, a urine sample is collected from participants to measure urine specific gravity – an  
49 indicator of hydration status. In accordance with manufacturer guidelines, skin is prepped with a  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 70% isopropyl alcohol wipe before positioning a two-lead electrode arrangement in the upper  
4  
5 left quadrant across the participant's chest. Measurements are collected during 5-minutes of quiet  
6  
7 rest in the seated position. High-frequency sampling is used to measure inter-beat intervals  
8  
9 wherein Actiheart® software is used to perform offline analyses. The primary variables of  
10  
11 interest include heart rate and root mean square of successive RR interval differences (RMSSD)  
12  
13 as well as the low-frequency (LF), high-frequency (HF) components derived from the fast-  
14  
15 Fourier transform. Procedures are performed in the morning hours in a dimly-lit, temperature-  
16  
17 controlled room.  
18  
19

### 20 21 ***Hair cortisol***

22  
23 Hair specimens are collected by trained study staff. For participants whose hair is longer than 1.5  
24  
25 to 3 cm, a thin layer of hair (1-2 hairs thick) parallel to the floor is cut from a point close to the  
26  
27 scalp across a 4-5 cm length (laterally), to obtain a minimum of 50 strands of hair. For  
28  
29 participants with shorter hair, the lateral cut is 6-8 cm (2 cm vertical x 5 cm lateral for long hair,  
30  
31 > 2 cm vertical x 7 cm lateral for shorter hair). String is used to indicate the end of the hair  
32  
33 closest to the scalp; hair specimens are folded tightly into aluminum foil and placed in a small  
34  
35 labeled bag at room temperature until being sent for assay at the Department of Biopsychology at  
36  
37 Technische Universität Dresden in Dresden, Germany.  
38  
39

### 40 41 ***Fatigue***

42  
43 Fatigue is measured by a 13-item multi-dimensional fatigue scale (i.e., Fatigue Symptom  
44  
45 Inventory).<sup>72</sup> On a 1 to 10 scale (1 = *not at all fatigued*, 10 = *as fatigued as I could be*),  
46  
47 participants are asked to rate their level of fatigue on the day they felt most and least fatigued in  
48  
49 the last week, the average level of fatigue in the last week, and the level of fatigue at the time of  
50  
51 survey. Participants report how much fatigue interferes (1 = *no interference*, 10 = *extreme*  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *interference*) with their general level of activity, ability to bathe and dress, their normal work  
4  
5 activity, ability to concentrate, relations with other people, enjoyment of life, and mood.  
6

7  
8 Participants report how many days in the past week they felt fatigued for any part of the day and  
9  
10 how much of the day on average the participant experienced fatigue (1 = *none of the day*, 10 =  
11  
12 *the entire day*). Since our prior studies have demonstrated that exercise effects on fatigue may  
13  
14 vary by dimension (i.e., intensity vs. interference; intensity = mean of 4 items; interference =  
15  
16 mean of 6 items, 0 to 10 scale) our final analyses will focus on fatigue interference.  
17  
18

### 19 ***Potential covariates***

20  
21 Self-administered survey measures age, race/ethnicity, education level, annual household  
22  
23 income, marital status, smoking history, alcohol intake, employment status and number of recent  
24  
25 sick days, cancer-related factors (date of diagnosis, stage, subtypes [e.g., receptor status], current  
26  
27 and past cancer treatment type [including, but not limited to, radiation, chemotherapy, and anti-  
28  
29 estrogen therapy]), caffeine intake, dietary supplements (including prebiotic, probiotic, and  
30  
31 vitamins), current medications (including over the counter medications), any antibiotic  
32  
33 medications over the last 6 months, any steroid medications or injections over the last 6 months,  
34  
35 current/past diagnosis of and treatment for anxiety or depression, treatment duration, time  
36  
37 since treatment completion), medical comorbidities<sup>73</sup> (including but not limited to endocrine  
38  
39 or hormone disorders), history of surgeries, menopausal status,<sup>6</sup> and history of COVID-19  
40  
41 diagnosis. If a participant is not able to recall medical-related information, a medical release  
42  
43 form is completed allowing study staff to request this information from the participant's  
44  
45 physician.  
46  
47  
48  
49  
50

51 Because depression, anxiety, sleep quality, pain and fatigue may cluster and be associated  
52  
53 with inflammation,<sup>74-76</sup> depression and anxiety is measured by 14-item Hospital Anxiety and  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Depression Scale [HADS]),<sup>77</sup> sleep dysfunction is measured subjectively using the Pittsburgh  
4 Sleep Quality Index (PSQI)<sup>78</sup>, and pain is measured by the Patient Reported Outcomes  
5 Measurement Information System (PROMIS®; <http://www.nihpromis.org/default.aspx>).<sup>79</sup>  
6  
7 Because post-traumatic stress symptoms are associated with psychosocial outcomes and gut  
8 microbiota composition,<sup>80,81</sup> post-traumatic stress is measured using the Posttraumatic Stress  
9 Disorder Checklist (PCL).<sup>82-85</sup>

10  
11 To assess free-living physical activity, participants are given the same ActiGraph  
12 accelerometer (ActiGraph LLC; Pensacola, FL) device for each assessment to be worn at the  
13 waist for seven consecutive days during waking hours (non-dominant hip; same side each time).  
14 Participants are instructed to remove the accelerometer while bathing, showering, or swimming  
15 and are asked to complete an accelerometer log (times device removed, exercise not detectable  
16 by device, sleep times, etc.). The accelerometer is set for 30 second epochs and monitoring is  
17 repeated if less than four valid days are recorded. Non-wear time is defined when no motion is  
18 detected for 60 minutes. A valid day is defined as at least 10 hours of valid wear time. The  
19 following cut points are planned: Sedentary: 0 – 99 counts/min; Inactive: 100 – 499 counts/min;  
20 Light: 500 – 1951 counts/min; Moderate: 1952 – 5724 counts/min; and Vigorous: 5725+  
21 counts/min.<sup>86,87</sup> Leisure-time physical activity is measured using the Godin Leisure Time  
22 Exercise Questionnaire which asks for average weekly frequency of leisure-time exercise for  
23 periods exceeding 10 minutes over the past month per three activity intensity levels (light,  
24 moderate, or vigorous).<sup>88,89</sup>

25  
26 Body mass index (BMI) is calculated from weight and height [weight (kg)/height (m<sup>2</sup>)]  
27 obtained from a scale (in light clothing) and wall stadiometer (without shoes). Dual-energy X-ray  
28 absorptiometry (DXA) scans assess lean mass and fat mass using the Lunar Dual Energy X-ray

1  
2  
3 Absorptiometry Scanner (iDXA; Lunar Radiation Corp. Madison, WI). Pre-menopausal women  
4  
5 at risk for pregnancy undergo a urine pregnancy test prior to each DXA scan.  
6

### 7 ***Other relevant measurements***

8  
9  
10 Resting energy expenditure measurement is required to more accurately assess participant's  
11  
12 calorie needs for the controlled feeding which facilitates energy balance and resultant weight  
13  
14 maintenance during the study. Hence, resting energy expenditure is measured by ventilated hood  
15  
16 indirect calorimetry (True One 2400 system; ParvoMedics, Salt Lake City, UT) while lying  
17  
18 quietly on an exam table. Participants must fast for at least 6 hours prior (4 hours if they are  
19  
20 diabetic), avoid physical activity for 12 hours and avoid any caffeine or nicotine for at least 2  
21  
22 hours prior to this test.  
23  
24  
25

26 Although not originally proposed, walking economy (i.e., net  $\text{VO}_2$ ) was added because it  
27  
28 reflects oxygen uptake during ambulation, an important alternative measure of (mobility)  
29  
30 independence in older women.<sup>90</sup> Participants wear a hip-worn accelerometer and complete a  
31  
32 fixed-workload task by walking on a treadmill at 2.0 mph (0% grade) for six minutes during  
33  
34 which steady-state  $\text{VO}_2$  is reached. RPE (Borg 6-20, 6 = *no exertion at all*, relaxed and 20 =  
35  
36 *maximal exertion*)<sup>70</sup> is collected at minutes three and six. At minute 5, the participant reports  
37  
38 perceived difficulty of the test using a visual analogue scale (100 mm line). Blood pressure is  
39  
40 measured at rest and while standing. Blood pressure is also measured at the 1-, 2-, and 5-minute  
41  
42 timepoints during walking. Participants remain quietly seated for at least 10 minutes between the  
43  
44 walking economy and  $\text{VO}_{2\text{peak}}$  tests during the follow-up assessments.  
45  
46  
47  
48

49 Quality of life is measured with The Functional Assessment of Cancer Therapy-Breast (FACT-  
50  
51 B)<sup>91</sup> because of its relation to fatigue, relevance for breast cancer populations, and repeated use  
52  
53 in prior studies which allow for comparison of study results. The FACT-B is a 37-item  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 instrument using 5-point Likert scales and includes the subscales of physical well-being, social  
4 well-being, emotional well-being, functional well-being, and additional concerns.<sup>91</sup>

5  
6  
7 Since cognitive function is associated with the gut microbiome<sup>92</sup> and physical activity in breast  
8 cancer survivors,<sup>93</sup> cognitive function is measured with the 10-item Frequency of Forgetting  
9 scale.<sup>94</sup> The summed score will assess subjective memory impairment (Total score) along with 4  
10 memory subscales (general memory, frequency of forgetting, frequency of forgetting when  
11 reading, and remembering past events).  
12  
13  
14  
15  
16  
17  
18

19 To improve adherence to future, similar exercise training protocols, the self-administered  
20 survey assesses social cognitive theory constructs: exercise self-efficacy (barriers and walking),  
21 enjoyment, social support, barriers, and outcome expectations. Barriers self-efficacy (i.e.,  
22 confidence in ability to overcome barriers) is measured utilizing a 9-item scale specifically  
23 designed for breast cancer patients.<sup>95</sup> The scale utilizes frequently reported barriers among breast  
24 cancer patients (e.g., “*How confident are you that you can exercise when you are tired?*”).  
25  
26 Walking task self-efficacy scale is assessed with a 6-item scale asking participants to rate  
27 confidence in their ability to walk at a moderately fast pace for 5, 10, 15, 20, 25, and 30  
28 minutes.<sup>96</sup> Analyses for barriers and walking task self-efficacy are using the mean score for the  
29 Likert scale (0% = *not at all confident* to 100% = *extremely confident*). Perceived exercise  
30 barriers (or barriers interference) are measured by asking participants to rate on a 5-point Likert  
31 scale (1 = *never* to 5 = *very often*) how often 21 different barriers (e.g., lack of time, weather)  
32 interfere with exercise. The items are summed for a perceived barriers score.<sup>97-99</sup> Physical  
33 activity enjoyment is measured with a single question (5-point Likert scale).<sup>99</sup> Social support is  
34 measured by asking for the frequency with which friends (two items) or family (two items)  
35 encourage or offer to exercise with the participant. Items are summed for a friends, family, and  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 total social support score.<sup>100,101</sup> For outcome expectations, participants are asked to rate their  
4 agreement on a 5-point Likert scale (1 = *strongly disagree* to 5 = *strongly agree*) with the  
5 statement that exercise would result in 17 potential benefits or risks. Fourteen positive benefits  
6 (e.g., feel less depressed) and 3 negative outcomes (e.g., increased joint pain) are included.  
7  
8 Responses are summed for positive outcome expectations and negative outcome expectations.<sup>99</sup>  
9  
10 The participants answer the outcome expectation questions twice: once considering stretching  
11 and light resistance exercises and again considering aerobic exercise.  
12  
13

### 14 ***Participant satisfaction***

15 At the 15-week assessment, participants are asked to provide a written evaluation of the study  
16 staff and procedures. All participants are asked to report their agreement (Likert scale; 1 =  
17 *strongly disagree* to 5 = *strongly agree*) with 10 statements relating to the clarity of study  
18 information, helpfulness of staff interactions, palatability of the provided food and ease of  
19 following the menu, likelihood of recommending this study to others, and overall satisfaction  
20 with the study staff and activities. One open-ended question seeks any additional information  
21 they would like to share with the study team.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 ***Data quality control***

39 Multiple strategies are being used to minimize missing data (e.g., baseline testing and controlled  
40 feeding before randomization provides a “*run-in*” period, monetary and non-monetary  
41 incentives, up to date contact information, ongoing review of source documents by study  
42 coordinator for immediate rectification of missing data, etc.).<sup>102</sup> Study staff are trained by the  
43 investigator with the relevant expertise using electronic manual of procedures with regular  
44 review of source documents for quality. Multiple trained staff are present during in-person  
45 assessment activities increasing accountability and immediate identification of potential drift in  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 protocol adherence. All most recent IRB approved study forms are stored on a shared, HIPAA  
4 compliant cloud server.  
5  
6  
7  
8  
9

## 10 **Interventions**

### 11 *Supervised exercise sessions*

12  
13  
14 Participants are randomized to 10 weeks of either an aerobic exercise intervention or a  
15 flexibility/toning attention control condition. Sessions occur on nonconsecutive days of the week  
16  
17 at the study site and are supervised by experienced exercise specialists who are not involved in  
18  
19 the collection of outcome assessments.  
20  
21  
22

### 23 *Aerobic exercise sessions*

24  
25  
26 Aerobic exercise sessions, supervised by trained exercise specialists, are primarily performed  
27  
28 using the treadmill. However, the cycle ergometer may be used if preferred by the participant.  
29  
30 The training target heart rate zone for each session corresponds with the heart rate at a given  
31  
32 percentage of  $VO_{2peak}$  measured at the most recent assessment. Training sessions commence with  
33  
34 a 5-minute warm-up consisting of light treadmill walking and stretching. During the 1<sup>st</sup> week of  
35  
36 training, after warm-up, participants perform 20 minutes of exercise at  $\approx 60\%$  maximum heart  
37  
38 rate (equivalent to  $\approx 45-50\% VO_{2peak}$ ). Over the next 3 weeks, *exercise duration* is increased by  
39  
40 5-minute intervals, as tolerated, so that by the beginning of the 5<sup>th</sup> week participants are  
41  
42 exercising for 40 minutes. This coincides with an elevation in *exercise intensity* equating to  
43  
44  $\approx 75\%$  of maximum heart rate ( $\approx 55-60\%$  of  $VO_{2peak}$ ) by the 5<sup>th</sup> week. Following each exercise  
45  
46 bout, participants cool down for 3-5 minutes. To mitigate stagnation, and facilitate continued  
47  
48 improvement of  $VO_{2peak}$ ,<sup>103</sup> high-intensity interval exercise is added during weeks 5-10 as  
49  
50 described in Table 2. Eight to ten work-intervals are performed at a workload to elicit  $\approx 85-90\%$   
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 maximum heart rate for 60 seconds with rest intervals of 3 minutes with the total exercise  
4  
5 duration ranging from 20 to 40 minutes.  
6

### 7 ***Standard attention controls***

8  
9  
10 The non-aerobic exercise attention control condition controls for the effects of attention and  
11  
12 social interaction through administration of flexibility/range-of-motion activities using light  
13  
14 resistance bands delivered at the same frequency as the aerobic condition (i.e., 3 times per week).  
15  
16 The sessions last about 40 minutes and target the head/neck, shoulder, elbow/forearm,  
17  
18 hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period  
19  
20 involves performing additional exercises and sets (i.e., Thera-bands) that provide minimal  
21  
22 resistance (i.e. sham). The first 5 weeks of the control condition involve performing body  
23  
24 stretches without resistance (20-30 seconds for 1-2 sets). In weeks 6-7, the light resistance Thera-  
25  
26 band is used to perform the stretches for the upper-extremities once per week for 8-10 repetitions  
27  
28 for 2 sets, and the other two sessions are body stretches without resistance. In weeks 8-10, the  
29  
30 light resistance Thera-band is used twice per week for 8-10 repetitions for 2 sets, and one session  
31  
32 will be body weight stretches without resistance. Such a progression is not expected to induce  
33  
34 aerobic fitness adaptations and is designed to maintain participant interest and expectation of  
35  
36 treatment benefit. Control condition participants are asked to not undertake additional exercise  
37  
38 (e.g., not join a gym and begin exercising) during the 10-week intervention period.  
39  
40  
41  
42  
43

### 44 ***Missed exercise and control sessions***

45  
46 Session attendance is tracked weekly and missed sessions are made up as soon as possible  
47  
48 during the intervention period. No more than four supervised aerobic sessions will occur in one  
49  
50 week. Exercise specialists encourage exercise adherence by discussing social cognitive theory  
51  
52 based educational newsletters with participants at six time points during the 10 weeks of aerobic  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 exercise and standard attention control.<sup>104</sup>  
4

### 5 ***Controlled feeding***

6  
7 Controlled feeding provided by the UAB Center for Clinical and Translational Science (CCTS)  
8  
9 Metabolic Kitchen standardizes dietary intake across all participants. The menus are designed to  
10  
11 provide 55% of energy as carbohydrate primarily through complex sources (fiber: 21-38 g/day),  
12  
13 23% as fat, and a minimum of 22% as protein ( $\approx 0.8$  g/kg). Dietary sodium intake and the  
14  
15 polyunsaturated:saturated (P:S) fat ratio are held constant (sodium  $< 3500$  mg/d, P:S fat ratio of  
16  
17 1, and saturated fat less than 30% of total fat intake).  
18  
19

20  
21 Prior to initiating controlled feeding, the participant meets with a study registered  
22  
23 dietitian to review the study menu and collect information about food allergies and intolerances.  
24  
25 Changes to the menu based on dietary preferences are attempted if substitutions are accessible to  
26  
27 the Metabolic Kitchen and maintain the standardized diet protocol. The participant and study  
28  
29 dietitian meet a second time to review the final menus and discuss approved beverages and  
30  
31 seasonings. Each participant starts weekly meal pick up from the Metabolic Kitchen at least one  
32  
33 week before baseline assessment visit #1.  
34  
35

36  
37 To allow the Metabolic Kitchen time to prepare the controlled feeding, the daily calorie  
38  
39 need (total energy expenditure) is estimated pre-baseline using the Harris Benedict equation and  
40  
41 an activity factor to promote weight maintenance. This estimate is then updated once resting  
42  
43 energy expenditure data is available at the baseline assessment. The estimate of total energy  
44  
45 expenditure is further updated for participants randomized to the aerobic exercise condition using  
46  
47 the individual's  $VO_{2peak}$  and resting energy expenditure data based on prior work by the  
48  
49 investigative team (equation provided in Supplemental Material 1).<sup>105,106</sup> The total energy  
50  
51 expenditure estimates for all participants are updated, if appropriate, based on the week 5  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 assessment of  $VO_{2peak}$  and resting energy expenditure. A study registered dietitian monitors body  
4 weight weekly and uses these changes and participant dietary preferences to further refine the  
5 calorie content and menus.  
6  
7

### 8 9 10 ***Controlled feeding adherence***

11  
12 Menu checklists are included with each weekly food pick up and participants are asked to log  
13 how much of the provided foods they consume and report additional foods and beverages along  
14 with the amounts consumed. The menu checklists are returned at exercise and control sessions  
15 on a weekly basis and reviewed by the dietitian for adherence. Participants with potential  
16 adherence issues or missing or incomplete checklists are called by a study dietitian for reminders  
17 and instruction.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 29 **Staff training**

30  
31 Staff are trained using a variety of electronic manuals, protocols, and up-to-date IRB approved  
32 study forms and scripts. An electronic manual of procedures is maintained in a shared, HIPAA  
33 compliant cloud server for reference by staff. Given the range of staff responsibilities (i.e.,  
34 exercise intervention, diet, etc.), additional supplemental role-specific protocols are also  
35 maintained (e.g., exercise progression prescription for exercise specialist and controlled feeding  
36 menu review scripts for dietitian).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 48 **Intervention fidelity plan**

49  
50 The exercise and controlled feeding intervention fidelity plans include the five domains  
51 recommended by NIH Behavior Change Consortium<sup>107</sup> (i.e., study design, provider training,  
52 treatment delivery, treatment receipt, and enactment of treatment skills). Fidelity is facilitated  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 with the electronic manual of procedures, standardized scripts, and participant education  
4 materials. Data sources for tracking exercise intervention include review of all exercise session  
5 record sheets (i.e., attendance, if exercise goals met, and if exercise progression administered  
6 according to protocol) and direct observation by each interventionist at least once a month. The  
7 main data source for tracking controlled feeding fidelity are menu checklists on which the  
8 participant reports the provided foods consumed and any additional foods/beverages consumed.  
9 The food included in each controlled feeding pick up is reviewed for accuracy and completeness  
10 by a trained research staff before the food is given to the participant. Further, study registered  
11 dietitians offer the same food substitutions for all participants requesting a change. Monthly  
12 reports are presented to the study team to monitor fidelity of both the exercise and controlled  
13 feeding so that fidelity concerns can be rectified in a timely manner.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## 31 **Statistical analysis**

### 32 *Sample size and power considerations*

33 Sample size is based on detecting alpha diversity and beta diversity taxa comparisons. The power  
34 calculation is based on two-tailed test at power of 0.8 using software G\*Power version  
35 3.1.9.2.<sup>108,109</sup> Our pre-COVID pandemic sample size was estimated at 126 (63 in each group)  
36 with 100 (50 per study group) remaining after drop outs. This sample size would have allowed us  
37 to detect a medium effect size ( $d = .57$ ; power of 0.8,  $p < 0.05$ ) in alpha diversity which is  
38 sufficient for detecting effects related to associations with fatigue and intervention effects falling  
39 midway between that found in our two pilot studies. Relevant to taxa comparisons, we have >  
40 0.8 power to detect the effect of any of the taxa after multiple testing correction ( $q$  value <  
41 0.05).<sup>110-112</sup> Due to the detrimental impact of the COVID-19 pandemic on recruitment into on-  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 site, supervised exercise trials, we provide revised contingency power calculations in Figure 4,  
4  
5 where we can see that with sample size decreasing, the effect size we can detect changes from  
6  
7 moderate to large. For example, for enrolling at 100%, 75% (74 samples with 37 per group), and  
8  
9 50%, the effect size that can be detected changes from 0.57, to 0.67, and to 0.81 (with power of  
10  
11 0.8 and alpha of 0.05). Of note, larger effect sizes are possible in this study (compared to our  
12  
13 pilot studies) because the study will provide controlled feeding (reducing variability), select low  
14  
15 fit individuals (greater chance of improvement), and manipulate the exercise exposure  
16  
17 (standardize the exercise exposure). Also relevant, the sample sizes in our pilot studies (N = 12  
18  
19 and 37) were smaller than our proposed study even with dropped enrollment yet yielded  
20  
21 statistically significant results (e.g., a significant association between alpha diversity and  
22  
23 cardiorespiratory fitness in 37 breast cancer survivors).<sup>7,13</sup>

### 24 25 26 27 28 ***Data management and analysis considerations***

29  
30 Microbiome 16S gene sequence data is analyzed using the QIIME<sup>113</sup> analysis package, our in-  
31  
32 house developed automated analysis pipeline QWRAP,<sup>69</sup> and DADA2<sup>114</sup> to provide a robust  
33  
34 error model for sample filtering and clustering. Data quality is assessed using FASTQC, with  
35  
36 low-quality data filtered out using the FASTX toolset. Filtering, denoising, and clustering of  
37  
38 reads into Amplicon Sequence Variants (ASVs) is done using DADA2. Taxon assignment is  
39  
40 performed using Mothur<sup>115</sup> and the SILVA 16S rDNA database.<sup>116</sup> Alignment and phylogenetic  
41  
42 inference is then performed using PyNAST<sup>117</sup> and Fasttree.<sup>118</sup> Comparative analytical tools such  
43  
44 as UniFrac<sup>119</sup> are used to assess differences between samples and sample groups using principal  
45  
46 coordinates analysis. To expedite sample processing and reporting, QWRAP automates the  
47  
48 running of these tools using a single command line argument on UAB's high-performance  
49  
50 computing cluster, Cheaha.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Survey and other data entry and checking is conducted by trained research staff masked  
4  
5 to study group allocation using password protected Research Electronic Data Capture (REDCap).  
6  
7 Data analyses will be carried out on an intent-to-treat basis. A multiple imputation approach will  
8  
9 be employed to handle any missing data that cannot be rectified and we will conduct sensitivity  
10  
11 analysis to assess the robustness of our findings.<sup>102,120</sup> SAS software, Version 9.3 (SAS Institute  
12  
13 Inc., Cary, NC) and R software, version 4.3.1<sup>121</sup> will be used for data analysis. Transformations  
14  
15 and non-parametric procedures will be performed when needed. The false discovery rate (FDR)  
16  
17 will be used for multiple testing correction and the statistical significance threshold will be FDR  
18  
19  $q \leq 0.05$  ( $q$  value is a  $p$  value after FDR correction). Each element (i.e., alpha diversity, beta  
20  
21 diversity, and taxa level comparisons) describes a different perspective on gut microbiota  
22  
23 changes and are integrated for interpretation (e.g., does exercise change the relative abundance of  
24  
25 organisms and, if so, which organisms). We will assess the microbiota composition change over  
26  
27 time using mixed-effects models.<sup>122</sup> All mediation analyses will conduct indirect effects analysis  
28  
29 with the bootstrap method developed by Hayes.<sup>123</sup> Week 10 is our primary time point yet we will  
30  
31 also analyze week 5 to assess interim changes that occur and week 15 to assess durability.  
32  
33  
34  
35  
36  
37  
38  
39

## 40 **Participant safety and withdrawal**

### 41 ***Risk management and safety***

42  
43 Participant safety is facilitated by obtaining medical clearance, limiting to a BMI < 50, collecting  
44  
45 a medical history and the PAR-Q (physical activity readiness questionnaire) before the lab-based  
46  
47 screening, and consulting clinical investigators, if indicated. Exercise sessions are supervised by  
48  
49 exercise specialists who have experience training cancer survivors or chronic disease  
50  
51 populations. Additionally, physician supervision is provided during fitness testing when deemed  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 appropriate based on ACSM guidelines.<sup>124</sup> Information about food allergies and intolerances are  
4  
5 screened for and collected before initiating controlled feeding and throughout participation and  
6  
7 these are communicated to the Metabolic Kitchen to minimize allergen contamination.  
8  
9

### 10 ***Adverse event reporting***

11  
12 Adverse events are identified spontaneously (e.g., reported to research staff during contact time)  
13  
14 or non-spontaneously (structured interview done at each assessment time-point). Reported  
15  
16 adverse events are reviewed promptly by the PI and reported to the IRB according to local  
17  
18 requirements. A Data and Safety Monitoring Board (DSMB) is convened annually or more often  
19  
20 if indicated.  
21  
22

### 23 ***Handling of withdrawals***

24  
25 Participants are informed of their right to withdraw at any time without consequences in the  
26  
27 informed consent forms and during the signing of consent forms. Participants will be withdrawn  
28  
29 from the study if any social, psychological, or physical conditions arise that may unduly increase  
30  
31 risk of participating in the study. Data will be analysed on an intention-to-treat basis.  
32  
33

### 34 ***Unexpected Required Antibiotics***

35  
36 Given the effect of antibiotics on the gut microbiota composition, participants unexpectedly  
37  
38 requiring intensive antibiotic therapy while enrolled in the study will be withdrawn from the  
39  
40 study. Intensive antibiotic therapy is defined as intravenous, extended use (i.e.,  $\geq 2$  weeks), or  
41  
42 combined therapy (multiple broad-spectrum agents). Less intensive antibiotic use will be tracked  
43  
44 by self-administered survey and considered during the analyses.  
45  
46  
47  
48  
49  
50

### 51 **Patient and public involvement**

52 Patients and members of the public were not involved in the design of the trial.  
53  
54  
55  
56  
57  
58  
59  
60

## Ethics and dissemination

The University of Alabama at Birmingham Institutional Review Board (IRB) approved this study, 15 May 2019, UAB IRB#30000320. The trial is registered with ClinicalTrials.gov: NCT04088708. A Data and Safety Monitoring Board (DSMB) convenes annually or more often if indicated. Any amendments will be submitted to the IRB and DSMB for approval. Research findings will be disseminated in peer-reviewed journals and conference presentations.

## DISCUSSION

The ROME study is the first randomized controlled exercise training study in fatigued breast cancer survivors testing exercise effects on gut microbiota composition while standardizing dietary intake with rigorous attention to energy balance. Our careful attention to diet and energy balance is critical to more fully understanding the role that exercise can play in altering dysbiosis in breast cancer survivors, a group at increased risk for detrimental changes in gut microbiota composition. Also, understanding the potential mechanistic links between aerobic exercise training, gut microbiota composition, and fatigue in cancer survivors has great potential to improve the lives of the breast cancer survivors suffering fatigue.

Thus, we describe a highly rigorous trial that is especially appropriate for studying exercise, gut microbiome and fatigue in breast cancer survivors because it integrates a standard attention control condition and energy balanced controlled feeding. The standard attention control condition is critical to detecting exercise effects on this patient-reported outcome beyond staff attention alone.<sup>125</sup> Further, few randomized trials testing exercise effects on the gut microbiome have attempted to standardize diet intake with energy balanced controlled feeding, a critical

1  
2  
3 element given the strong association between diet, body weight, and the gut microbiome  
4 characteristics.<sup>49,53,126</sup>  
5  
6

7  
8 Given the careful attention to the temporal relationships and randomized study design,  
9  
10 this study will explore mechanistic pathways heretofore most frequently studied in animal  
11 models rather than humans. With regard to the potential mechanisms through which exercise  
12 influences the gut microbiome, we will explore exercise induced changes to inflammation, the  
13 autonomic nervous system, and the HPA axis. Exercise training in breast cancer survivors  
14 positively impacts inflammatory markers.<sup>127</sup> In particular we have previously observed beneficial  
15 changes in IL-10 and tumor necrosis factor (TNF)- $\alpha$ .<sup>25</sup> A better understanding of the  
16 bidirectional communication between the microbiome and inflammation, HPA, and autonomic  
17 nervous system is needed. Microbes influence cytokine production and T cell activation<sup>33,128</sup> and  
18 they and their metabolic by-products can also directly stimulate immune cells with a resultant  
19 influence on cytokine release.<sup>33,129</sup> Similarly, pro-inflammatory cytokines influence serotonin  
20 availability, serotonin and norepinephrine synaptic reuptake pumps, HPA axis, and regional  
21 brain activity.<sup>42</sup> Gut microbes also influence the autonomic nervous system through the vagus  
22 nerve,<sup>48</sup> as exemplified by reduced anxiety and depression-related behavior in mice given  
23 *Lactobacillus rhamnosus*, with this effect absent in vagotomized mice.<sup>130</sup> In a separate animal  
24 study, mice pre-treated with a probiotic formulation (*Lactobacillus helveticus* R0052 and  
25 *Bifidobacterium longum* R0175), then exposed to a water avoidance stressor, exhibited  
26 attenuated HPA axis and autonomic nervous system activity.<sup>131</sup> Given that exercise alters the  
27 microbiome, inflammation, HPA, and autonomic nervous system, a better understanding of the  
28 direct and/or indirect relationships are needed.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54 Recent interest related to our primary aim to test exercise effects on gut microbiome has  
55  
56  
57  
58  
59  
60

grown. Allen et al.<sup>58</sup> observed significant changes in gut microbiome beta diversity after 6 weeks of supervised exercise training in healthy adults (20 to 45 years old) and showed the changes reversed post-intervention. Additionally, positive changes to the gut microbiome have been observed in older adults participating in exercise interventions.<sup>57,59</sup> Yet, the literature in cancer populations connecting exercise to changes in the microbiome warrants additional scrutiny. Sampsell et al.<sup>132</sup> recently conducted a 12-week exercise intervention in 10 breast cancer survivors with reassessment after a 12-week washout period. No statistically significant pre-post differences in alpha or beta diversity were detected yet a follow-up mouse study yielded a trend toward lower tumor development in mice colonized with post-exercise microbiota vs. those colonized with pre-exercise microbiota.

Others report on the relationship between fatigue and gut microbiota composition in cancer survivors,<sup>133,134</sup> but we were the first to focus on breast cancer survivors and observe fatigue was associated with alpha diversity and differences in beta diversity representing shifts in taxa relative abundance.<sup>13</sup> Additionally, understanding the role of exercise on the gut microbiota composition in fatigue response can be leveraged to identify new therapeutic strategies warranting testing in larger trials. Further, exercise is a well-known therapy for alleviating fatigue<sup>135</sup> yet not all cancer survivors report fatigue improvements with exercise.<sup>26</sup> Thus, a better understanding of the potential mediating effects of the microbiome can lead to exercise recommendations that optimize fatigue reductions.

## LIMITATIONS

As no research study is perfect, several limitations warrant discussion. Notably, the high scientific rigor made possible by the supervised exercise and controlled feeding may limit

1  
2  
3 translatability of the results to less controlled interventions. However, this is offset by the  
4  
5 opportunities for exploring potential mechanistic links related to exercise, gut microbiome, and  
6  
7 fatigue. Moreover, the study inclusion and exclusion criteria may limit generalizability of the  
8  
9 results to other cancer types or individuals with higher baseline cardiorespiratory fitness or BMI  
10  
11 over 50. Finally, the COVID-19 pandemic's detrimental impact on our anticipated sample size  
12  
13 may preclude detecting smaller effect sizes and mediating factors. This is offset by several a  
14  
15 priori design features that enhance study power: 1) controlled feeding (reduces variability), 2)  
16  
17 selecting low fit and fatigued individuals (greater chance of improvement), 3) manipulating the  
18  
19 exercise exposure (standardizes the exercise exposure), and 4) stratifying randomization by BMI  
20  
21 (reduces type 1 error and improves study power in trials with < 200 participants per study  
22  
23 condition<sup>136</sup>).

## 30 31 **CONCLUSIONS**

32  
33 The ROME study is a novel randomized controlled aerobic exercise training study in fatigued  
34  
35 breast cancer survivors that integrates energy balanced controlled feeding and tests exercise  
36  
37 effects on gut microbiota composition. Identifying microbiota composition changes resulting  
38  
39 from exercise will inform trials integrating other modalities (e.g., probiotics) for optimizing  
40  
41 exercise benefits, especially in breast cancer survivors with blunted beneficial fatigue responses to  
42  
43 exercise. Collectively, this and future trials building on this trial, target the substantial public  
44  
45 health problem of fatigue, a persistent and prevalent concern for millions of breast cancer  
46  
47 survivors worldwide.<sup>2,14,16</sup>



## REFERENCES

1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. *Int J Cancer*. Apr 5 2021;doi:10.1002/ijc.33588
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. May 2021;71(3):209-249. doi:10.3322/caac.21660
3. Bodai BI, Nakata TE. Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship. *Perm J*. 2020;24doi:10.7812/TPP/19.129
4. Sabiston CM, Brunet J, Vallance JK, Meterissian S. Prospective examination of objectively assessed physical activity and sedentary time after breast cancer treatment: sitting on the crest of the teachable moment. *Cancer Epidemiol Biomarkers Prev*. Jul 2014;23(7):1324-30. doi:10.1158/1055-9965.Epi-13-1179
5. Pradhan KR, Stump TE, Monahan P, Champion V. Relationships among attention function, exercise, and body mass index: a comparison between young breast cancer survivors and acquaintance controls. *Psychooncology*. Mar 2015;24(3):325-32. doi:10.1002/pon.3598
6. Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. *Obes Rev*. Apr 2011;12(4):282-94. doi:10.1111/j.1467-789X.2010.00805.x
7. Carter SJ, Hunter GR, Blackston JW, et al. Gut microbiota diversity is associated with cardiorespiratory fitness in post-primary treatment breast cancer survivors. *Exp Physiol*. Apr 2019;104(4):529-539. doi:10.1113/EP087404
8. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J*. May 16 2017;474(11):1823-1836. doi:10.1042/bcj20160510
9. Kelly DL, Lyon DE, Yoon SL, Horgas AL. The Microbiome and Cancer: Implications for Oncology Nursing Science. *Cancer Nurs*. May-Jun 2016;39(3):E56-62. doi:10.1097/ncc.0000000000000286
10. Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav Immun*. Aug 2015;48:186-94. doi:10.1016/j.bbi.2015.03.016
11. Fu J, Bonder MJ, Cenit MC, et al. The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. *Circ Res*. Oct 9 2015;117(9):817-24. doi:10.1161/circresaha.115.306807
12. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. *CA Cancer J Clin*. Jul 8 2017;67(4):326-344. doi:10.3322/caac.21398
13. Paulsen JA, Ptacek TS, Carter SJ, et al. Gut microbiota composition associated with alterations in cardiorespiratory fitness and psychosocial outcomes among breast cancer survivors. *Support Care Cancer*. May 2017;25(5):1563-1570. doi:10.1007/s00520-016-3568-5
14. Hollen PJ, Msaouel P, Gralla RJ. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. *Breast Cancer Res Treat*. Jun 2015;151(3):679-86. doi:10.1007/s10549-015-3420-5
15. Carreira H, Williams R, Dempsey H, Stanway S, Smeeth L, Bhaskaran K. Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of

- 1  
2  
3 patient-reported outcomes in the United Kingdom. *J Cancer Surviv.* Aug 2021;15(4):564-575.  
4 doi:10.1007/s11764-020-00950-3
- 5  
6 16. Maass S, Brandenbarg D, Boerman LM, Verhaak PFM, de Bock GH, Berendsen AJ.  
7 Fatigue among Long-Term Breast Cancer Survivors: A Controlled Cross-Sectional Study.  
8 *Cancers (Basel).* Mar 15 2021;13(6)doi:10.3390/cancers13061301
- 9  
10 17. Jones JM, Olson K, Catton P, et al. Cancer-related fatigue and associated disability in  
11 post-treatment cancer survivors. *J Cancer Surviv.* Feb 2016;10(1):51-61. doi:10.1007/s11764-  
12 015-0450-2
- 13  
14 18. Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. *Nat Rev Clin*  
15 *Oncol.* Oct 2014;11(10):597-609. doi:10.1038/nrclinonc.2014.127
- 16  
17 19. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT.  
18 Psychological distress and fatigue predicted recurrence and survival in primary breast cancer  
19 patients. *Breast Cancer Res Treat.* Oct 2007;105(2):209-19. doi:10.1007/s10549-006-9447-x
- 20  
21 20. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, et al. Aerobic and  
22 resistance exercise improves physical fitness, bone health, and quality of life in overweight and  
23 obese breast cancer survivors: a randomized controlled trial. *Breast Cancer Res.* Oct 19  
24 2018;20(1):124. doi:10.1186/s13058-018-1051-6
- 25  
26 21. Rogers LQ, Courneya KS, Anton PM, et al. Effects of a multicomponent physical activity  
27 behavior change intervention on fatigue, anxiety, and depressive symptomatology in breast  
28 cancer survivors: randomized trial. *Psychooncology.* Nov 2017;26(11):1901-1906.  
29 doi:10.1002/pon.4254
- 30  
31 22. Dennett AM, Peiris CL, Shields N, Prendergast LA, Taylor NF. Moderate-intensity  
32 exercise reduces fatigue and improves mobility in cancer survivors: a systematic review and  
33 meta-regression. *J Physiother.* Apr 2016;62(2):68-82. doi:10.1016/j.jphys.2016.02.012
- 34  
35 23. Mustian KM, Alfano CM, Heckler C, et al. Comparison of Pharmaceutical,  
36 Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. *JAMA*  
37 *Oncol.* Jul 1 2017;3(7):961-968. doi:10.1001/jamaoncol.2016.6914
- 38  
39 24. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in  
40 adults. *Cochrane Database Syst Rev.* Nov 14 2012;11(11):Cd006145.  
41 doi:10.1002/14651858.CD006145.pub3
- 42  
43 25. Rogers LQ, Fogleman A, Trammell R, et al. Effects of a physical activity behavior  
44 change intervention on inflammation and related health outcomes in breast cancer survivors:  
45 pilot randomized trial. *Integr Cancer Ther.* Jul 2013;12(4):323-35.  
46 doi:10.1177/1534735412449687
- 47  
48 26. Rogers LQ, Vicari S, Trammell R, et al. Biobehavioral factors mediate exercise effects  
49 on fatigue in breast cancer survivors. *Med Sci Sports Exerc.* Jun 2014;46(6):1077-88.  
50 doi:10.1249/mss.0000000000000210
- 51  
52 27. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled  
53 physical activity trials in cancer survivors: a systematic review and meta-analysis. *J Cancer*  
54 *Surviv.* Jun 2010;4(2):87-100. doi:10.1007/s11764-009-0110-5
- 55  
56 28. Inglis JE, Lin PJ, Kerns SL, et al. Nutritional Interventions for Treating Cancer-Related  
57 Fatigue: A Qualitative Review. *Nutr Cancer.* 2019;71(1):21-40.  
58 doi:10.1080/01635581.2018.1513046
- 59  
60 29. Matsumoto M, Inoue R, Tsukahara T, et al. Voluntary running exercise alters microbiota  
composition and increases n-butyrate concentration in the rat cecum. *Biosci Biotechnol Biochem.*  
Feb 2008;72(2):572-6. doi:10.1271/bbb.70474

- 1  
2  
3 30. Clarke SF, Murphy EF, O'Sullivan O, et al. Exercise and associated dietary extremes  
4 impact on gut microbial diversity. *Gut*. Dec 2014;63(12):1913-20. doi:10.1136/gutjnl-2013-  
5 306541
- 6 31. Lambert JE, Myslicki JP, Bomhof MR, Belke DD, Shearer J, Reimer RA. Exercise  
7 training modifies gut microbiota in normal and diabetic mice. *Appl Physiol Nutr Metab*. Jul  
8 2015;40(7):749-52. doi:10.1139/apnm-2014-0452
- 9 32. Choi JJ, Eum SY, Rampersaud E, Daunert S, Abreu MT, Toborek M. Exercise attenuates  
10 PCB-induced changes in the mouse gut microbiome. *Environ Health Perspect*. Jun  
11 2013;121(6):725-30. doi:10.1289/ehp.1306534
- 12 33. Bermon S, Petriz B, Kajėnienė A, Prestes J, Castell L, Franco OL. The microbiota: an  
13 exercise immunology perspective. *Exerc Immunol Rev*. 2015;21:70-9.
- 14 34. Campbell SC, Wisniewski PJ, Noji M, et al. The Effect of Diet and Exercise on Intestinal  
15 Integrity and Microbial Diversity in Mice. *PLoS One*. 2016;11(3):e0150502.  
16 doi:10.1371/journal.pone.0150502
- 17 35. Estaki M, Pither J, Baumeister P, et al. Cardiorespiratory fitness as a predictor of  
18 intestinal microbial diversity and distinct metagenomic functions. *Microbiome*. Aug 8  
19 2016;4(1):42. doi:10.1186/s40168-016-0189-7
- 20 36. Houghton D, Stewart CJ, Stamp C, et al. Impact of Age-Related Mitochondrial  
21 Dysfunction and Exercise on Intestinal Microbiota Composition. *J Gerontol A Biol Sci Med Sci*.  
22 Apr 17 2018;73(5):571-578. doi:10.1093/gerona/glx197
- 23 37. Verheggen RJHM, Konstanti P, Smidt H, Hermus ARMM, Thijssen DHJ, Hopman MTE.  
24 Eight-week exercise training in humans with obesity: Marked improvements in insulin  
25 sensitivity and modest changes in gut microbiome. *Obesity*. 2021;29(10):1615-1624.  
26 doi:<https://doi.org/10.1002/oby.23252>
- 27 38. Kern T, Blond MB, Hansen TH, et al. Structured exercise alters the gut microbiota in  
28 humans with overweight and obesity-A randomized controlled trial. *Int J Obes (Lond)*. Jan  
29 2020;44(1):125-135. doi:10.1038/s41366-019-0440-y
- 30 39. Roager HM, Hansen LB, Bahl MI, et al. Colonic transit time is related to bacterial  
31 metabolism and mucosal turnover in the gut. *Nat Microbiol*. Jun 27 2016;1(9):16093.  
32 doi:10.1038/nmicrobiol.2016.93
- 33 40. Dainese R, Serra J, Azpiroz F, Malagelada JR. Effects of physical activity on intestinal  
34 gas transit and evacuation in healthy subjects. *Am J Med*. Apr 15 2004;116(8):536-9.  
35 doi:10.1016/j.amjmed.2003.12.018
- 36 41. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social  
37 stressor alters the structure of the intestinal microbiota: implications for stressor-induced  
38 immunomodulation. *Brain Behav Immun*. Mar 2011;25(3):397-407.  
39 doi:10.1016/j.bbi.2010.10.023
- 40 42. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune  
41 mechanisms of behavioral comorbidities in patients with cancer. *J Clin Oncol*. Feb 20  
42 2008;26(6):971-82. doi:10.1200/jco.2007.10.7805
- 43 43. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects  
44 of exercise. *J Physiol Pharmacol*. Nov 2006;57 Suppl 10:43-51.
- 45 44. Lavín-Pérez AM, Collado-Mateo D, Hinojo González C, et al. High-intensity exercise  
46 prescription guided by heart rate variability in breast cancer patients: a study protocol for a  
47 randomized controlled trial. *BMC Sports Sci Med Rehabil*. Mar 8 2023;15(1):28.  
48 doi:10.1186/s13102-023-00634-2
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 45. Niederer D, Vogt L, Thiel C, et al. Exercise effects on HRV in cancer patients. *Int J Sports Med*. Jan 2013;34(1):68-73. doi:10.1055/s-0032-1314816
- 4 46. Toohey K, Pumpa K, McKune A, et al. The impact of high-intensity interval training  
5 exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and  
6 biomarkers of the stress systems. *BMC Cancer*. Aug 20 2020;20(1):787. doi:10.1186/s12885-  
7 020-07295-1
- 8 47. Russell E, Koren G, Rieder M, Van Uum S. Hair cortisol as a biological marker of  
9 chronic stress: current status, future directions and unanswered questions.  
10 *Psychoneuroendocrinology*. May 2012;37(5):589-601. doi:10.1016/j.psyneuen.2011.09.009
- 11 48. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the  
12 barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders.  
13 *Front Cell Neurosci*. 2015;9:392. doi:10.3389/fncel.2015.00392
- 14 49. Asnicar F, Berry SE, Valdes AM, et al. Microbiome connections with host metabolism  
15 and habitual diet from 1,098 deeply phenotyped individuals. *Nat Med*. Feb 2021;27(2):321-332.  
16 doi:10.1038/s41591-020-01183-8
- 17 50. Remely M, Tesar I, Hippe B, Gnauer S, Rust P, Haslberger AG. Gut microbiota  
18 composition correlates with changes in body fat content due to weight loss. *Benef Microbes*.  
19 2015;6(4):431-9. doi:10.3920/bm2014.0104
- 20 51. Ribeiro FM, Silva MA, Lyssa V, et al. The molecular signaling of exercise and obesity in  
21 the microbiota-gut-brain axis. *Front Endocrinol (Lausanne)*. 2022;13:927170.  
22 doi:10.3389/fendo.2022.927170
- 23 52. Javed I, Cui X, Wang X, et al. Implications of the Human Gut-Brain and Gut-Cancer  
24 Axes for Future Nanomedicine. *ACS Nano*. Nov 24 2020;14(11):14391-14416.  
25 doi:10.1021/acsnano.0c07258
- 26 53. Sampsell K, Hao D, Reimer RA. The Gut Microbiota: A Potential Gateway to Improved  
27 Health Outcomes in Breast Cancer Treatment and Survivorship. *Int J Mol Sci*. Dec 3  
28 2020;21(23)doi:10.3390/ijms21239239
- 29 54. Ryu J, Lee EY, Min J, et al. Effect of a 1-year tailored exercise program according to  
30 cancer trajectories in patients with breast cancer: study protocol for a randomized controlled trial.  
31 *BMC Cancer*. Mar 2 2023;23(1):200. doi:10.1186/s12885-023-10664-1
- 32 55. Newton RU, Christophersen CT, Fairman CM, et al. Does exercise impact gut microbiota  
33 composition in men receiving androgen deprivation therapy for prostate cancer? A single-  
34 blinded, two-armed, randomised controlled trial. *BMJ Open*. Apr 14 2019;9(4):e024872.  
35 doi:10.1136/bmjopen-2018-024872
- 36 56. Yang Y, Shi Y, Wiklund P, et al. The Association between Cardiorespiratory Fitness and  
37 Gut Microbiota Composition in Premenopausal Women. *Nutrients*. Jul 25  
38 2017;9(8)doi:10.3390/nu9080792
- 39 57. Erlandson KM, Liu J, Johnson R, et al. An exercise intervention alters stool microbiota  
40 and metabolites among older, sedentary adults. *Ther Adv Infect Dis*. Jan-Dec  
41 2021;8:20499361211027067. doi:10.1177/20499361211027067
- 42 58. Allen JM, Mailing LJ, Niemi GM, et al. Exercise Alters Gut Microbiota Composition  
43 and Function in Lean and Obese Humans. *Med Sci Sports Exerc*. Apr 2018;50(4):747-757.  
44 doi:10.1249/MSS.0000000000001495
- 45 59. Morita E, Yokoyama H, Imai D, et al. Aerobic Exercise Training with Brisk Walking  
46 Increases Intestinal Bacteroides in Healthy Elderly Women. *Nutrients*. Apr 17  
47 2019;11(4)doi:10.3390/nu11040868

- 1  
2  
3 60. McArdle WD, Katch FI, Katch VL. *Exercise Physiology: Nutrition, Energy, and Human*  
4 *Performance*. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015.
- 5 61. Fagundes C, LeRoy A, Karuga M. Behavioral Symptoms after Breast Cancer Treatment:  
6 A Biobehavioral Approach. *J Pers Med*. Aug 3 2015;5(3):280-95. doi:10.3390/jpm5030280
- 7 62. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms,  
8 contributing factors, and treatment implications. *Brain Behav Immun*. Mar 2013;30  
9 Suppl(0):S48-57. doi:10.1016/j.bbi.2012.06.011
- 10 63. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and  
11 therapeutic modulation of the gut microbiota. *Clin Exp Immunol*. Mar 2015;179(3):363-77.  
12 doi:10.1111/cei.12474
- 13 64. Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic  
14 inflammation. *Clin Chim Acta*. Jun 3 2010;411(11-12):785-93. doi:10.1016/j.cca.2010.02.069
- 15 65. Al-Majid S, Gray DP. A biobehavioral model for the study of exercise interventions in  
16 cancer-related fatigue. *Biol Res Nurs*. Apr 2009;10(4):381-91. doi:10.1177/1099800408324431
- 17 66. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. *Nat*  
18 *Rev Immunol*. Aug 5 2011;11(9):625-32. doi:10.1038/nri3042
- 19 67. Donovan KA, Jacobsen PB, Small BJ, Munster PN, Andrykowski MA. Identifying  
20 clinically meaningful fatigue with the Fatigue Symptom Inventory. *J Pain Symptom Manage*.  
21 Nov 2008;36(5):480-7. doi:10.1016/j.jpainsymman.2007.11.013
- 22 68. Dieli-Conwright CM, Mortimer JE, Schroeder ET, et al. Randomized controlled trial to  
23 evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer  
24 survivors: rationale, design, and methods. *BMC Cancer*. 2014/04/03 2014;14(1):238.  
25 doi:10.1186/1471-2407-14-238
- 26 69. Kumar R, Eipers P, Little RB, et al. Getting started with microbiome analysis: sample  
27 acquisition to bioinformatics. *Curr Protoc Hum Genet*. Jul 14 2014;82:18 8 1-29.  
28 doi:10.1002/0471142905.hg1808s82
- 29 70. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*.  
30 1982;14(5):377-81.
- 31 71. Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma  
32 collection: early detection research network consensus statement standard operating procedure  
33 integration working group. *J Proteome Res*. Jan 2009;8(1):113-7. doi:10.1021/pr800545q
- 34 72. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients:  
35 development and validation of the Fatigue Symptom Inventory. *Qual Life Res*. May  
36 1998;7(4):301-10. doi:10.1023/a:1024929829627
- 37 73. Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with  
38 physical function as the outcome. *J Clin Epidemiol*. Jun 2005;58(6):595-602.  
39 doi:10.1016/j.jclinepi.2004.10.018
- 40 74. Saligan LN, Kim HS. A systematic review of the association between immunogenomic  
41 markers and cancer-related fatigue. *Brain Behav Immun*. Aug 2012;26(6):830-48.  
42 doi:10.1016/j.bbi.2012.05.004
- 43 75. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a  
44 social signal transduction theory of depression. *Psychol Bull*. May 2014;140(3):774-815.  
45 doi:10.1037/a0035302
- 46 76. Thomas BC, Waller A, Malhi RL, et al. A longitudinal analysis of symptom clusters in  
47 cancer patients and their sociodemographic predictors. *J Pain Symptom Manage*. Mar  
48 2014;47(3):566-78. doi:10.1016/j.jpainsymman.2013.04.007
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 77. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*  
4 *Scand.* Jun 1983;67(6):361-70. doi:10.1111/j.1600-0447.1983.tb09716.x
- 5 78. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep  
6 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* May  
7 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4
- 8 79. Cook KF, Dunn W, Griffith JW, et al. Pain assessment using the NIH Toolbox.  
9 *Neurology.* 2013;80(11 Supplement 3):S49-S53. doi:10.1212/WNL.0b013e3182872e80
- 10 80. Morrill EF, Brewer NT, O'Neill SC, et al. The interaction of post-traumatic growth and  
11 post-traumatic stress symptoms in predicting depressive symptoms and quality of life.  
12 *Psychooncology.* Sep 2008;17(9):948-53. doi:10.1002/pon.1313
- 13 81. Leclercq S, Forsythe P, Bienenstock J. Posttraumatic Stress Disorder: Does the Gut  
14 Microbiome Hold the Key? *Can J Psychiatry.* Apr 2016;61(4):204-13.  
15 doi:10.1177/0706743716635535
- 16 82. Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA. Psychometric properties of  
17 the PTSD Checklist (PCL). *Behav Res Ther.* Aug 1996;34(8):669-73. doi:10.1016/0005-  
18 7967(96)00033-2
- 19 83. Cordova MJ, Andrykowski MA, Kenady DE, McGrath PC, Sloan DA, Redd WH.  
20 Frequency and correlates of posttraumatic-stress-disorder-like symptoms after treatment for  
21 breast cancer. *J Consult Clin Psychol.* Dec 1995;63(6):981-6. doi:10.1037//0022-006x.63.6.981
- 22 84. Forbes D, Creamer M, Biddle D. The validity of the PTSD checklist as a measure of  
23 symptomatic change in combat-related PTSD. *Behav Res Ther.* Aug 2001;39(8):977-86.  
24 doi:10.1016/s0005-7967(00)00084-x
- 25 85. Parikh D, De Ieso P, Garvey G, et al. Post-traumatic stress disorder and post-traumatic  
26 growth in breast cancer patients--a systematic review. *Asian Pac J Cancer Prev.* 2015;16(2):641-  
27 6. doi:10.7314/apjcp.2015.16.2.641
- 28 86. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and  
29 Applications, Inc. accelerometer. *Med Sci Sports Exerc.* May 1998;30(5):777-81.  
30 doi:10.1097/00005768-199805000-00021
- 31 87. Sirard JR, Melanson EL, Li L, Freedson PS. Field evaluation of the Computer Science  
32 and Applications, Inc. physical activity monitor. *Med Sci Sports Exerc.* Mar 2000;32(3):695-700.  
33 doi:10.1097/00005768-200003000-00022
- 34 88. Godin G, Jobin J, Bouillon J. Assessment of leisure time exercise behavior by self-report:  
35 a concurrent validity study. *Can J Public Health.* Sep-Oct 1986;77(5):359-62.
- 36 89. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community.  
37 *Can J Appl Sport Sci.* Sep 1985;10(3):141-6.
- 38 90. Carter SJ, Baranuskas MN, Singh H, Martins C, Hunter GR. ARTE index revisited:  
39 linking biomarkers of cardiometabolic health with free-living physical activity in  
40 postmenopausal women. *Am J Physiol Regul Integr Comp Physiol.* Apr 1 2022;322(4):R292-  
41 R298. doi:10.1152/ajpregu.00075.2021
- 42 91. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of  
43 Cancer Therapy-Breast quality-of-life instrument. *J Clin Oncol.* Mar 1997;15(3):974-86.  
44 doi:10.1200/jco.1997.15.3.974
- 45 92. Gareau MG. Cognitive Function and the Microbiome. *Int Rev Neurobiol.* 2016;131:227-  
46 246. doi:10.1016/bs.irm.2016.08.001
- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 93. Ehlers DK, Rogers LQ, Courneya KS, Robbs RS, McAuley E. Effects of BEAT Cancer  
4 randomized physical activity trial on subjective memory impairments in breast cancer survivors.  
5 *Psychooncology*. Feb 2018;27(2):687-690. doi:10.1002/pon.4438  
6  
7 94. Zelinski EM, Gilewski MJ. A 10-item Rasch modeled memory self-efficacy scale. *Aging*  
8 *Ment Health*. Jul 2004;8(4):293-306. doi:10.1080/13607860410001709665  
9  
10 95. Rogers LQ, Courneya KS, Verhulst S, Markwell S, Lanzotti V, Shah P. Exercise barrier  
11 and task self-efficacy in breast cancer patients during treatment. *Support Care Cancer*. Jan  
12 2006;14(1):84-90. doi:10.1007/s00520-005-0851-2  
13  
14 96. McAuley E, Mihalko S. Advances in sport and exercise psychology measurement.  
15 *Measuring exercise-related self-efficacy Fitness Information Technology*. 1998;1998:371-89.  
16  
17 97. Lewis CE, Raczynski JM, Heath GW, Levinson R, Hilyer Jr JC, Cutter GR. Promoting  
18 physical activity in low-income African-American communities: the PARR project. *Ethnicity &*  
19 *disease*. 1993:106-118.  
20  
21 98. Rogers LQ, McAuley E, Courneya KS, Verhulst SJ. Correlates of physical activity self-  
22 efficacy among breast cancer survivors. *Am J Health Behav*. Nov-Dec 2008;32(6):594-603.  
23 doi:10.5555/ajhb.2008.32.6.594  
24  
25 99. Rogers LQ, Shah P, Dunnington G, et al. Social cognitive theory and physical activity  
26 during breast cancer treatment. *Oncol Nurs Forum*. Jul 1 2005;32(4):807-15.  
27 doi:10.1188/05.Onf.807-815  
28  
29 100. Sallis JF, Grossman RM, Pinski RB, Patterson TL, Nader PR. The development of scales  
30 to measure social support for diet and exercise behaviors. *Preventive medicine*. 1987;16(6):825-  
31 836.  
32  
33 101. Sallis JF, Hovell MF, Hofstetter CR, et al. A multivariate study of determinants of  
34 vigorous exercise in a community sample. *Preventive medicine*. 1989;18(1):20-34.  
35  
36 102. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data  
37 in clinical trials. *N Engl J Med*. Oct 4 2012;367(14):1355-60. doi:10.1056/NEJMsr1203730  
38  
39 103. Martin EA, Battaglini CL, Hands B, Naumann F. Higher-Intensity Exercise Results in  
40 More Sustainable Improvements for VO<sub>2</sub>peak for Breast and Prostate Cancer Survivors. *Oncol*  
41 *Nurs Forum*. May 2015;42(3):241-9. doi:10.1188/15.ONF.42-03AP  
42  
43 104. Motl RW, Backus D, Neal WN, et al. Rationale and design of the STEP for MS Trial:  
44 Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for  
45 Multiple Sclerosis. *Contemp Clin Trials*. Jun 2019;81:110-122. doi:10.1016/j.cct.2019.04.013  
46  
47 105. Hunter GR, Bickel CS, Fisher G, Neumeier WH, McCarthy JP. Combined aerobic and  
48 strength training and energy expenditure in older women. *Med Sci Sports Exerc*. Jul  
49 2013;45(7):1386-93. doi:10.1249/MSS.0b013e3182860099  
50  
51 106. Hunter GR, Fisher G, Neumeier WH, Carter SJ, Plaisance EP. Exercise Training and  
52 Energy Expenditure following Weight Loss. *Med Sci Sports Exerc*. Sep 2015;47(9):1950-7.  
53 doi:10.1249/MSS.0000000000000622  
54  
55 107. Bellg AJ, Borrelli B, Resnick B, et al. Enhancing treatment fidelity in health behavior  
56 change studies: best practices and recommendations from the NIH Behavior Change Consortium.  
57 *Health Psychol*. Sep 2004;23(5):443-51. doi:10.1037/0278-6133.23.5.443  
58  
59 108. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G\*Power 3.1:  
60 tests for correlation and regression analyses. *Behav Res Methods*. Nov 2009;41(4):1149-60.  
doi:10.3758/BRM.41.4.1149

- 1  
2  
3 109. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power  
4 analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. May  
5 2007;39(2):175-91. doi:10.3758/bf03193146  
6  
7 110. Bi R, Liu P. Sample size calculation while controlling false discovery rate for differential  
8 expression analysis with RNA-sequencing experiments. *BMC Bioinformatics*. Mar 31  
9 2016;17:146. doi:10.1186/s12859-016-0994-9  
10  
11 111. Pounds S, Cheng C. Sample size determination for the false discovery rate.  
12 *Bioinformatics*. Dec 1 2005;21(23):4263-71. doi:10.1093/bioinformatics/bti699  
13  
14 112. Liu P, Hwang JT. Quick calculation for sample size while controlling false discovery rate  
15 with application to microarray analysis. *Bioinformatics*. Mar 15 2007;23(6):739-46.  
16 doi:10.1093/bioinformatics/btl664  
17  
18 113. Navas-Molina JA, Peralta-Sanchez JM, Gonzalez A, et al. Advancing our understanding  
19 of the human microbiome using QIIME. *Methods Enzymol*. 2013;531:371-444.  
20 doi:10.1016/B978-0-12-407863-5.00019-8  
21  
22 114. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2:  
23 High-resolution sample inference from Illumina amplicon data. *Nat Methods*. Jul  
24 2016;13(7):581-3. doi:10.1038/nmeth.3869  
25  
26 115. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-  
27 independent, community-supported software for describing and comparing microbial  
28 communities. *Appl Environ Microbiol*. Dec 2009;75(23):7537-41. doi:10.1128/AEM.01541-09  
29  
30 116. Yilmaz P, Parfrey LW, Yarza P, et al. The SILVA and "All-species Living Tree Project  
31 (LTP)" taxonomic frameworks. *Nucleic Acids Res*. Jan 2014;42(Database issue):D643-8.  
32 doi:10.1093/nar/gkt1209  
33  
34 117. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R.  
35 PyNASt: a flexible tool for aligning sequences to a template alignment. *Bioinformatics*. Jan 15  
36 2010;26(2):266-7. doi:10.1093/bioinformatics/btp636  
37  
38 118. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for  
39 large alignments. *PLoS One*. Mar 10 2010;5(3):e9490. doi:10.1371/journal.pone.0009490  
40  
41 119. Lozupone C, Hamady M, Knight R. UniFrac--an online tool for comparing microbial  
42 community diversity in a phylogenetic context. *BMC Bioinformatics*. Aug 7 2006;7:371.  
43 doi:10.1186/1471-2105-7-371  
44  
45 120. Li P, Stuart EA, Allison DB. Multiple Imputation: A Flexible Tool for Handling Missing  
46 Data. *Jama*. Nov 10 2015;314(18):1966-7. doi:10.1001/jama.2015.15281  
47  
48 121. *R: A Language and Environment for Statistical Computing*. 2022. [https://www.R-  
49 project.org/](https://www.R-project.org/).  
50  
51 122. Chen EZ, Li H. A two-part mixed-effects model for analyzing longitudinal microbiome  
52 compositional data. *Bioinformatics*. Sep 1 2016;32(17):2611-7.  
53 doi:10.1093/bioinformatics/btw308  
54  
55 123. Hayes AF. *Introduction to mediation, moderation, and conditional process analysis: A  
56 regression-based approach*. Guilford publications; 2017.  
57  
58 124. Liguori G, & American College of Sports Medicine. . *ACSM's guidelines for exercise  
59 testing and prescription*. 11 ed. Lippincott Williams & Wilkins; 2020.  
60  
61 125. Tock WL, Maheu C, Johnson NA. Considerations of Control Conditions Designs in  
62 Randomized Controlled Trials of Exercise Interventions for Cancer Survivors. *Can J Nurs Res*.  
63 Dec 2022;54(4):377-391. doi:10.1177/08445621211062467



- 1  
2  
3 126. Hossain F, Majumder S, David J, Bunnell BA, Miele L. Obesity Modulates the Gut  
4 Microbiome in Triple-Negative Breast Cancer. *Nutrients*. Oct 19  
5 2021;13(10)doi:10.3390/nu13103656  
6  
7 127. de Jesus Leite MA, Goncalves A, Portari G, et al. Application of physical exercise  
8 therapies in breast cancer survivors and their effects on the inflammatory profile: A narrative  
9 review. *J Bodyw Mov Ther*. Oct 2020;24(4):536-545. doi:10.1016/j.jbmt.2020.08.002  
10  
11 128. Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol*.  
12 2002;20:197-216. doi:10.1146/annurev.immunol.20.083001.084359  
13  
14 129. Rescigno M. Intestinal microbiota and its effects on the immune system. *Cell Microbiol*.  
15 Jul 2014;16(7):1004-13. doi:10.1111/cmi.12301  
16  
17 130. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates  
18 emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proc*  
19 *Natl Acad Sci U S A*. Sep 20 2011;108(38):16050-5. doi:10.1073/pnas.1102999108  
20  
21 131. Ait-Belgnaoui A, Colom A, Braniste V, et al. Probiotic gut effect prevents the chronic  
22 psychological stress-induced brain activity abnormality in mice. *Neurogastroenterol Motil*. Apr  
23 2014;26(4):510-20. doi:10.1111/nmo.12295  
24  
25 132. Sampsell K, Wang W, Ohland C, et al. Exercise and Prebiotic Fiber Provide Gut  
26 Microbiota-Driven Benefit in a Survivor to Germ-Free Mouse Translational Model of Breast  
27 Cancer. *Cancers (Basel)*. May 31 2022;14(11)doi:10.3390/cancers14112722  
28  
29 133. Hajjar J, Mendoza T, Zhang L, et al. Associations between the gut microbiome and  
30 fatigue in cancer patients. *Sci Rep*. Mar 12 2021;11(1):5847. doi:10.1038/s41598-021-84783-9  
31  
32 134. Xiao C, Fedirko V, Beitler J, et al. The role of the gut microbiome in cancer-related  
33 fatigue: pilot study on epigenetic mechanisms. *Support Care Cancer*. Jun 2021;29(6):3173-3182.  
34 doi:10.1007/s00520-020-05820-3  
35  
36 135. Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. Are exercise programs effective  
37 for improving health-related quality of life among cancer survivors? A systematic review and  
38 meta-analysis. *Oncol Nurs Forum*. Nov 1 2014;41(6):E326-42. doi:10.1188/14.Onf.E326-e342  
39  
40 136. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization  
41 for clinical trials. *J Clin Epidemiol*. Jan 1999;52(1):19-26. doi:10.1016/s0895-4356(98)00138-3

## Supplementary materials

Supplemental Material 1. Equations for calculating daily calorie needs for energy balanced controlled feeding used in the ROME study (R01CA235598)

## Acknowledgments

The authors would like to thank Josh Graham, Kaitlyn Waugaman, Sydney McGlawn, Victoria Roughsedge, and Ildiko Nyikos for their administrative assistance in the setup and ongoing management of the study, and David Bryan for administrative support of assessments and conducting fitness tests.

1  
2  
3  
4  
5 **Contributors:** Laura Q. Rogers conceived the study design, led and integrated the  
6  
7 multidisciplinary input, and achieved funding through the National Cancer Institute as the lead  
8  
9 investigator. Stephen J. Carter, Robert W. Motl, Gary R. Hunter, Nianjun Liu, Helen Krontiras,  
10  
11 Elliot J. Lefkowitz, and Bulent Turan helped design the final study protocol and choice of  
12  
13 outcome measures and provided intellectual contributions in their expert areas. Rebecca B. Little  
14  
15 led development of sample process tracking and operationalizing controlled feeding  
16  
17 implementation and fidelity monitoring; she also completed the initial draft of the manuscript.  
18  
19 Abby Cook and Erica Schleicher assisted with exercise intervention fidelity and adherence  
20  
21 tracking protocols. Abby Cook completed a literature review to guide data management related  
22  
23 to current medication use. All authors assisted with drafting the manuscript and have read, edited  
24  
25 and approved the final manuscript.  
26  
27  
28  
29  
30  
31  
32

### 33 **Funding**

34  
35 This study is supported by the following National Institute of Health grants: R01CA235598,  
36  
37 P30DK056336, T32 A047888, UL1TR003096, and R25CA76023.  
38  
39  
40  
41

42 **Competing interests:** None declared.  
43  
44  
45  
46

47 **Patient consent for publication** Not required.  
48  
49  
50

51 **Ethics approval** Ethics approval was obtained from the Institutional Review Board (IRB) of the  
52  
53 University of Alabama at Birmingham (UAB IRB#30000320).  
54  
55  
56  
57  
58  
59  
60

**Table 1. Participant timeline** (Note: To facilitate temporal relationships, data collection is ordered within each assessment period as follows: #1 - outcomes other than fecal sample and fatigue survey, #2 - fecal sample 2 to 3 days after outcomes other than fatigue, and #3 - fatigue survey 2 to 3 days after fecal sample)

	Lab-based screening	Baseline Assessment		Exercise training or control	Follow-up assessments
Study week (preW = week leading up to randomization [0]; W = week after randomization)	preW3	preW2 – preW1	preW1 – 0	W1 – W10	W5, W10, & W15
Lab-based screening consent, obtain medical clearance, complete lab-based screening (e.g., VO <sub>2peak</sub> )	X				
Enrollment (consent for full participation)	X				
Controlled feeding diet (both study groups)		X	X	X	
Self-administered questionnaire		X			X
Fatigue survey			X		X
Fecal sample collection for gut microbiota composition (with 3-day diet record)			X		X
Medication log (7 days prior to blood draw)		X			X
Fasted blood draw, heart rate variability, hair sample		X			X
Resting energy expenditure		X			X
Walking economy		X			X
VO <sub>2peak</sub> , weight, body mass index (BMI)	X				X
Accelerometer with log sheet (7 days)		X			X
Dual-energy X-ray absorptiometry (DXA)		X			X
Randomization			X		
Exercise training or standard attention control				X	

**Table 2.** Aerobic exercise progression (based on maximum heart rate; high intensity added in later weeks to facilitate continued cardiorespiratory fitness improvement)

Week	Intensity	Max Heart Rate (%)	Duration (mins)	Frequency per Week
1 – 4	Moderate-intensity, continuous	60-75	20 - 35	3
5 – 7	Moderate-intensity, continuous	75	40	2
	High-intensity interval	85-90	20-22	1
8 – 10	Moderate-intensity, continuous	75	40	1
	High-intensity interval	85-90	22-28	2

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Framework for testing exercise effects on gut microbiota and mechanistic links between exercise, gut microbiota, and fatigue.

338x190mm (96 x 96 DPI)




Figure 2. Study schema for testing aerobic exercise effects on gut microbiota composition and potential mechanistic links in breast cancer survivors.

338x190mm (96 x 96 DPI)




Figure 3. Participant screening, enrollment, and baseline assessment. A pre-screening telephone interview determines the potential eligibility of the participant. The orientation visit includes completion of administrative forms, lab-based screening informed consent, and release forms for obtaining medical clearance. Once medical clearance is received by the study team, the participant completes the lab-based screening visit, which includes collecting  $VO_2$  peak and BMI. If deemed eligible based on the screening visit, the individual will be invited to sign the consent for full study participation and be scheduled for controlled feeding initiation. Baseline assessment visit #1 is scheduled for at least one week after initiation of controlled feeding. Within seven days of visit #1, 1) the participant is asked to collect the fecal sample at home 2-3 days after visit #1 and promptly overnight ships it to the laboratory, and then 2) complete the remaining assessment materials (e.g., fatigue survey) 2-3 days after collecting the fecal sample and baseline visit #2 occurs to return these forms.

338x190mm (96 x 96 DPI)




Figure 4. Revised contingency power curve.

226x198mm (72 x 72 DPI)



## Supplemental Material 1

## Equations for calculating daily calorie needs for energy balanced controlled feeding used in the ROME study (R01CA235598)

### Step 1: Calculate a base equation (used for all participants with Step 2 adjusting it for participants randomized to the aerobic exercise condition)

To calculate total energy expenditure (TEE), insert resting energy expenditure (REE) measured by indirect calorimeter from the most recent study assessment into the following equations developed per race based on prior datasets generated in the laboratory of Dr. Gary Hunter.<sup>105,106</sup>

European Americans:  $TEE = 1124 + (.725 * REE)$

African Americans:  $TEE = 1074 + (.725 * REE)$

Note: The ROME study uses the European American equation for individuals of Asian descent.

### Step 2: Refine base equation for participants randomized to the aerobic exercise condition

Exercise energy expenditure for each workout based on the a priori exercise progression protocol ( $VO_{2peak}$  in ml/kg/min and BDW [body weight] in kg) are entered into the equation with the weekly total averaged over 7 days (to get a daily average needed for the daily controlled feeding menu). This daily average is added to the base equation calculated under Step 1 to determine the daily calorie needs for participants randomized to the aerobic exercise condition.

Continuous training	Interval training (added in later weeks per protocol)
WK1: $3 * 0.05 * VO_{2peak} * BDW/7$	
WK2: $3 * 0.0597 * VO_{2peak} * BDW/7$	
WK3: $3 * 0.08 * VO_{2peak} * BDW/7$	
WK4: $3 * 0.103 * VO_{2peak} * BDW/7$	
WK5: $2 * 0.13 * VO_{2peak} * BDW/7$	+ $1 * 0.0675 * VO_{2peak} * BDW/7$
WK6: $2 * 0.13 * VO_{2peak} * BDW/7$	+ $1 * 0.0675 * VO_{2peak} * BDW/7$
WK7: $2 * 0.13 * VO_{2peak} * BDW/7$	+ $1 * 0.0743 * VO_{2peak} * BDW/7$
WK8: $1 * 0.13 * VO_{2peak} * BDW/7$	+ $2 * 0.078 * VO_{2peak} * BDW/7$
WK9: $1 * 0.13 * VO_{2peak} * BDW/7$	+ $2 * 0.0844 * VO_{2peak} * BDW/7$
WK10: $1 * 0.13 * VO_{2peak} * BDW/7$	+ $2 * 0.0911 * VO_{2peak} * BDW/7$

Note: Exercise-related energy expenditure is greater during first 4 weeks (vs. later weeks) because interval training decreases volume and thus, decreases energy expenditure required.

Note: Rationale for coefficients used to estimate energy expenditure during exercise as follows:

- The week 1 coefficient of 0.05 is based on:
  - Subjects train at 50%  $VO_{2peak}$  (60% max heart rate is about 50%  $VO_{2peak}$ ) or the proportion 0.5.
  - The  $VO_{2peak}$  is in ml/kg/min and must be converted to l/kg/min, therefore we must divide by 1000.

- 1  
2  
3           ○ There are 5 kcal burned for each liter of oxygen used and the subjects train for 20  
4           minutes during the first week.

5 Therefore, the equation is  $0.5 * 5 * 20/1000 = 0.05$  for week 1. The same methods are used for  
6 subsequent weeks as the intensity (proportion  $VO_{2peak}$ ) and duration increase.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 **SPIRIT-Outcomes 2022 Checklist (for combined completion of SPIRIT 2013 and SPIRIT-**  
3 **Outcomes 2022 items)<sup>a</sup>**  
4

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
<b>Administrative information</b>				
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	-	
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	-	
	2b	All items from the World Health Organization Trial Registration Data Set	-	
Protocol version	3	Date and version identifier	-	
Funding	4	Sources and types of financial, material, and other support	-	
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	-	
	5b	Name and contact information for the trial sponsor	-	
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	-	
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	-	
<b>Introduction</b>				
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	-	
	6b	Explanation for choice of comparators	-	
Objectives	7	Specific objectives or hypotheses	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	-	
<b>Methods: Participants, interventions, and outcomes</b>				
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	-	
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	-	
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered (for specific guidance see TIDieR checklist and guide)	-	
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	-	
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	-	
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	-	
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
	12.1		Provide a rationale for the selection of the domain for the trial's primary outcome	
	12.2		If the analysis metric for the primary outcome represents within-participant change, define and justify the minimal important change in individuals	
	12.3		If the outcome data collected are continuous but will be analyzed as categorical (method of aggregation), specify the cutoff values to be used	
	12.4		If outcome assessments will be performed at several time points after randomization, state the time points that will be used for analysis	
	12.5		If a composite outcome is used, define all individual components of the composite outcome	
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	-	
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	-	
	14.1		Define and justify the target difference between treatment groups (eg, the minimal important difference)	
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	-	
<b>Methods: Assignment of interventions (for controlled trials)</b>				
Allocation:				
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	-	
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	-	
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	-	
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	-	
<b>Methods: Data collection, management, and analysis</b>				
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	-	
	18a.1		Describe what is known about the responsiveness of the study instruments in a population similar to the study sample	
	18a.2		Describe who will assess the outcome (eg, nurse, parent)	
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	-	
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	-	
	20a.1		Describe any planned methods to account for multiplicity in the analysis or interpretation of the primary and secondary outcomes (eg, coprimary outcomes, same outcome assessed at multiple time points, or subgroup analyses of an outcome)	
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	-	
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	-	
<b>Methods: Monitoring</b>				
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	-	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	-	
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	-	
<b>Ethics and dissemination</b>				
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	-	
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	-	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	-	
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	-	
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	-	
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	-	
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	-	
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	-	
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	-	
	31b	Authorship eligibility guidelines and any intended use of professional writers	-	



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-	
<b>Appendices</b>				
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	-	
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	-	

<sup>a</sup>It is strongly recommended that this checklist be read in conjunction with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement paper for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license and is reproduced with permission.

<sup>b</sup>Indicates page numbers and/or manuscript location: to be completed by authors.

# BMJ Open

## Role of Gut Microbe Composition in Psychosocial Symptom Response to Exercise Training in Breast Cancer Survivors (ROME) Study - protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081660.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Apr-2024
Complete List of Authors:	Little, Rebecca; The University of Alabama at Birmingham, Medicine - Division of Preventive Medicine Carter, Stephen J.; Indiana University Bloomington Motl, Robert; University of Illinois at Chicago, Department of Kinesiology and Nutrition Hunter, Gary; The University of Alabama at Birmingham Cook, Abby; Baylor Scott & White Medical Center Temple Liu, Nianjun; Indiana University Bloomington Krontiras, Helen; The University of Alabama at Birmingham Heersink School of Medicine Lefkowitz, Elliot; The University of Alabama at Birmingham Turan, Bulent; Koc University, Department of Psychology Schleicher, Erica ; The University of Alabama at Birmingham Rogers, Laura; The University of Alabama at Birmingham Heersink School of Medicine
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Sports and exercise medicine
Keywords:	Breast tumours < ONCOLOGY, ONCOLOGY, MICROBIOLOGY, Exercise Test

SCHOLARONE™  
Manuscripts

1  
2  
3 Role of Gut Microbe Composition in Psychosocial Symptom Response to Exercise  
4 Training in Breast Cancer Survivors (ROME) Study - protocol for a randomised  
5 controlled trial  
6  
7  
8

9 *Rebecca B. Little PhD, RDN, Stephen J. Carter PhD, Robert W. Motl PhD, Gary R. Hunter PhD,*  
10 *Abby Cook DO, Nianjun Liu PhD, Helen Krontiras MD, Elliot J. Lefkowitz PhD, Bulent Turan*  
11 *PhD, Erica Schleicher MS, and Laura Q. Rogers MD, MPH*  
12  
13  
14  
15

16 Manuscript correspondence:

Laura Q. Rogers, MD, MPH  
Department of Medicine  
The University of Alabama at Birmingham  
1720 2<sup>nd</sup> Ave South  
Medical Towers 614  
Birmingham, AL 35294-4410

17  
18  
19  
20  
21  
22  
23  
24  
25 Phone: (205) 934-9735

26  
27 Email: [lqrogers@uabmc.edu](mailto:lqrogers@uabmc.edu)

28  
29  
30 Running title: The ROME Study

31  
32 Word Count: 7,724 excluding abstract (299), 3 tables, 4 figures, 137 references

33  
34 Keywords: Aerobic Exercise, Breast Cancer, Cancer Survivorship, Gut Microbiota, Oncology

35  
36  
37 Scientific Meeting Presentation: None

38  
39 Funding: primary funding is from the National Cancer Institute R01CA235598, with additional  
40 funding from National Institutes of Health grants P30DK056336, T32 A047888, UL1TR003096,  
41 and R25CA76023.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction** Breast cancer survivors have increased risk for chronic fatigue and altered gut microbiota composition, both with negative health and quality of life affects. Exercise modestly improves fatigue and is linked to gut microbial diversity and production of beneficial metabolites. Studies suggest the gut microbiota composition is a potential mechanism underlying fatigue response to exercise. Randomised controlled trials testing the effects of exercise on the gut microbiome are limited and there is a scarcity of findings specific to breast cancer survivors. The objective of this study is to determine if fitness-related modifications to gut microbiota occur and, if so, mediate the effects of aerobic exercise on fatigue response.

**Methods and Analysis** The research is a randomised controlled trial among breast cancer survivors aged 18-74 with fatigue. The primary aim is to determine the effects of aerobic exercise training compared to an attention control on gut microbiota composition. The secondary study aims are to test if exercise training a) affects the gut microbiota composition directly and/or indirectly through inflammation (serum cytokines), autonomic nervous system (heart rate variability), or hypothalamic-pituitary-adrenal (HPA) axis mediators (hair cortisol assays), and b) effects on fatigue are direct and/or indirect through changes in the gut microbiota composition. All participants receive a standardized controlled diet. Assessments occur at baseline, 5 weeks, 10 weeks, and 15 weeks (5 weeks post intervention completion). Fecal samples collect the gut microbiome and 16S gene sequencing will identify the microbiome. Fatigue is measured by a 13-item multi-dimensional fatigue scale.

**Ethics and Dissemination** The University of Alabama at Birmingham Institutional Review Board (IRB) approved this study, 15 May 2019, UAB IRB#30000320. A Data and Safety Monitoring Board (DSMB) convenes annually or more often if indicated. Findings will be disseminated in peer-reviewed journals and conference presentations.

**Trial registration number** NCT04088708, posted 13 September 2019.

## ARTICLE SUMMARY

### Strengths and limitations of this study

- This study is one of the very few randomized controlled trials testing the effects of exercise on the gut microbiome, especially in cancer survivors experiencing fatigue.
- A standardized, energy balanced diet reduces diet and body weight induced variance on gut microbiota yet no prior randomized exercise and gut microbiome study has provided the same diet for all participants, as being done in our study.
- This study seeks to understand the mechanistic links (inflammation, autonomic nervous system, or hypothalamic-pituitary-adrenal (HPA) axis mediators) between exercise and the gut microbiome, and determine if the benefits of exercise on fatigue are directly and/or indirectly related to changes in the gut microbiota composition.
- Although assessors are masked to study group allocation and a standard attention control condition is used, the intervention precludes participant masking to exercise type.

## INTRODUCTION

Nearly 8 million individuals worldwide are living with a history of breast cancer.<sup>1,2</sup> Breast cancer survivors are at increased risk of altered gut microbiota composition (i.e., dysbiosis) that may worsen future cancer risk, comorbidities, and quality of life.<sup>3</sup> Factors that may contribute to the persistent gut microbiota composition changes include reduced physical activity and aerobic fitness, and detrimental changes in body composition after breast cancer diagnosis.<sup>4-7</sup> Given its importance on health and well-being,<sup>8-12</sup> strategies for reversing gut microbiota dysbiosis are needed, especially in breast cancer survivors.

While elucidating gut microbiota dysbiosis in breast cancer survivors remains imperative, it is relevant that the gut microbiome is associated with fatigue in breast cancer survivors<sup>13</sup> and survivors rank fatigue as the number one priority related to quality of life.<sup>14</sup> Additionally, breast cancer survivors are more likely to report fatigue than their age matched controls<sup>15</sup> and one in four suffer persistent fatigue years after their cancer diagnosis,<sup>16</sup> which exacerbates post-cancer disability and reduces quality of life.<sup>17,18</sup> Furthermore, fatigue is associated with greater risk of cancer recurrence and mortality.<sup>19</sup> Interestingly, the benefits of supervised exercise for breast cancer survivors extend beyond the expected improvements in cardio-metabolic parameters to include improvements in fatigue and other domains of quality of life.<sup>20</sup> As we (and others) have reported, exercise is a well-established non-pharmacologic therapy for fatigue, yet effects are somewhat modest (weighted effect size of 0.30 in a recent meta-analysis).<sup>21-24</sup> Hence, elucidating mechanisms underlying fatigue response is needed to optimize fatigue reductions for non-responders and increase effect sizes achievable with exercise.<sup>24-27</sup> Moreover, our prior work and that of others suggest the gut microbiota composition is one such mechanism, but further research is needed.<sup>13,28</sup>

1  
2  
3 Exercise training also presents as a promising strategy for reversing dysbiosis as it is  
4 linked to gut microbial diversity, abundance of select microbes, and production of beneficial  
5 metabolites (e.g., acetate, butyrate, propionate), albeit, these phenomena are currently limited to  
6 animal models or cross-sectional<sup>29-36</sup> and non-randomized prospective human studies.<sup>37</sup>  
7  
8 Randomized controlled trials testing the effects of exercise on the gut microbiome are limited<sup>38</sup>  
9 and there is a scarcity of findings specific to breast cancer survivors.<sup>7</sup> One randomized controlled  
10 trial in healthy overweight and obese individuals found vigorous-intensity exercise training was  
11 associated with increased microbe diversity.<sup>38</sup> To support the importance of intensity in exercise  
12 training, we recently showed in breast cancer survivors, cardiorespiratory fitness was a better  
13 correlate of gut microbe diversity compared to free-living activity energy expenditure.<sup>7</sup> It is  
14 unknown if the modulation of the microbiota by exercise occurs solely through direct means  
15 such as alterations to colonic transit time,<sup>39,40</sup> or indirectly through inflammation,<sup>41-43</sup> autonomic  
16 nervous system,<sup>44,45</sup> or hypothalamic-pituitary-adrenal (HPA) axis.<sup>46-48</sup> Additionally other  
17 lifestyle interventions such diet<sup>49</sup> and body weight changes<sup>50</sup> independently affect gut  
18 microbiota, making controls for these variables critical in exercise trials. Rigorously testing the  
19 dysbiosis-exercise link while also exploring the bidirectional gut-brain axis pathways responsible  
20 for exercise effects<sup>51,52</sup> can inform future exercise recommendations and multimodal  
21 interventions to counter the adverse effects of gut dysbiosis.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Given the potential benefits of exercise training on the gut microbiome and fatigue, a  
45 better understanding of their relationships in response to an exercise intervention among breast  
46 cancer survivors is warranted. Herein, we describe our ongoing randomized controlled trial  
47 testing aerobic exercise training as a potential strategy to attenuate dysbiosis in breast cancer  
48 survivors with fatigue while also standardizing diet intake and maintaining energy balance. We  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 further propose to determine if fitness-related modifications to gut microbiota mediate the effects  
4  
5 of aerobic exercise on fatigue response. This is a critical next step for several reasons. First, to  
6  
7 our knowledge there are currently no completed randomized controlled trials utilizing exercise  
8  
9 training as a potential modifier for dysbiosis in breast cancer survivors.<sup>53</sup> Additionally, no other  
10  
11 trials exploring these variables have been performed with a standardized diet to: 1) mitigate the  
12  
13 underlying variance on gut microbiota and 2) promote weight maintenance.<sup>54,55</sup> Therefore, we  
14  
15 describe our methods to facilitate future replicability.  
16  
17  
18  
19  
20

## 21 **METHODS**

### 22 **Aims and hypotheses**

23  
24  
25  
26 The primary study aim is to determine the effects of a 10-week aerobic exercise training  
27  
28 intervention compared to a flexibility/toning standard attention control on gut microbiota  
29  
30 composition among breast cancer survivors with fatigue. All participants are following an energy  
31  
32 balanced controlled feeding diet. The gut microbiome is being collected by fecal sample and  
33  
34 assessed by 16S rRNA at baseline, week 5 to explore interim changes, week 10 as our primary  
35  
36 time point, and week 15 to explore durability of effects. The primary outcome measure will be  
37  
38 the comparison of microbiome composition using standard diversity and taxa comparison  
39  
40 metrics (Table 1). We hypothesize that compared to the control, the exercise training group will  
41  
42 demonstrate significant differences in gut microbial diversity with increased Firmicutes (p),  
43  
44 *Bacteroides* (g),<sup>7,56</sup> and *Bifidobacterium* (g),<sup>57</sup> and decreased Actinobacteria (p) and  
45  
46 Proteobacteria (p).<sup>7</sup>  
47  
48  
49  
50

51 A secondary study aim is to test if exercise training affects the gut microbiota  
52  
53 composition directly and/or indirectly through inflammation, autonomic nervous system, or  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 hypothalamic-pituitary-adrenal (HPA) axis mediators (Table 1). We hypothesize that exercise  
4 training will have direct and indirect effects on gut microbiota composition through markers of  
5 the hypothesized mechanisms (interleukin [IL]-6, IL-10,<sup>41-43</sup> heart rate variability,<sup>44-46</sup> cortisol<sup>46-</sup>  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
48). Another secondary study aim is to test if the exercise training effect on fatigue is direct  
and/or indirect through changes in the gut microbiota composition. We hypothesize that exercise  
effects on fatigue will be mediated by changes in beta diversity,<sup>13,58</sup> specifically frequency of  
Firmicutes (p),<sup>7</sup> Actinobacteria (p),<sup>13</sup> and *Bacteroides* (g).<sup>13,41,59</sup>

### Overall mechanistic framework

Given the relationships between cardiorespiratory fitness and gut microbiota composition,<sup>7</sup> we  
have chosen an exercise intervention applying the principles of exercise prescription required to  
achieve an increase in cardiorespiratory fitness.<sup>60</sup> The biological plausibility of a dysbiosis-  
exercise link also common to fatigue (e.g., inflammation, autonomic nervous system, and HPA  
axis)<sup>48,61-66</sup> supports testing these potential mechanistic links in breast cancer survivors with  
fatigue. Thus, the overall mechanistic framework for our trial depicted in Figure 1 can be applied  
to potentially optimizing exercise interventions for treatment of fatigue.

### Study overview and eligibility criteria

This 2-arm, parallel group-controlled trial is randomising breast cancer survivors to 10 weeks of  
supervised aerobic exercise training or standard attention control (flexibility/toning) while on a  
controlled feeding diet. The trial is taking place at the University of Alabama at Birmingham  
(UAB) in Birmingham, AL. Participant enrollment commenced 1 January 2020, was paused  
between March 2020 and August of 2020 due to the COVID-19 pandemic, and is projected to  
end 1 January 2025. Institutional Review Board (IRB) approval has been obtained and all  
participants provide informed consent prior to participation (Supplemental Materials 1 and 2).



1  
2  
3 Assessments occur at baseline and then at 5, 10, and 15 weeks. A study schema is provided in  
4  
5 Figure 2 and an overview of participants' activities is provided in Table 2. An electronic study  
6  
7 manual of procedures is kept on a shared, HIPAA compliant cloud server accessible to all study  
8  
9 staff.

10  
11  
12 Inclusion criteria are as followed: 1) female breast cancer survivors ages 18 to 74 years with a  
13  
14 history of ductal carcinoma in situ (DCIS) or stage 0, I, II, III breast cancer, 2) who are  $\geq 1$  year  
15  
16 post-primary cancer treatment completion (chemotherapy and/or radiation), 3) average fatigue  
17  
18 over the past week rated as  $\geq 3$  on a 1 to 10 Likert scales,<sup>67</sup> 4) English speaking, 5) physician  
19  
20 medical clearance for study participation, 6) able to ambulate without assistance, 7) no  
21  
22 antibiotics for the past 90 days, 8) willing to avoid taking probiotics for the duration of the study,  
23  
24 and 9) after all other criteria are met, lab-based screening is used to confirm low fitness level  
25  
26 ( $VO_{2peak} < 30$  mL/kg/min). Exclusion criteria are as follows: 1) metastatic or recurrent cancer, 2)  
27  
28 another diagnosis of cancer in the past 5 years (not including skin or cervical cancer *in situ*), 3)  
29  
30 unstable angina, 4) New York Heart Association class II, III, IV congestive heart failure, 5)  
31  
32 uncontrolled asthma, 6) interstitial lung disease, 7) current steroid use, 8) having been told by a  
33  
34 physician to only do exercise prescribed by a physician, 9) dementia or organic brain syndrome,  
35  
36 10) schizophrenia or active psychosis, 11) connective tissue or rheumatologic disease, 12)  
37  
38 anticipate elective surgery during the study period, 13) anticipate changes in usual medications  
39  
40 during the study period, 14) plan to move residence out of the local area during the study period,  
41  
42 15) plan to travel out of the local area  $> 1$  week during study participation, 16) contraindication to  
43  
44 engaging in moderate-to-vigorous intensity aerobic exercise, 17) current or anticipated  
45  
46 pregnancy during study participation, 18) live or work  $> 50$  miles from study site or do not have  
47  
48 transportation to study site, 19) body mass index (BMI)  $> 50$  (confirmed during lab-based  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 screening), or 20) anticipate needing antibiotics during the study period.

### 4 5 **Recruitment and screening**

6  
7 Participants are being recruited through multiple recruitment strategies (e.g., recruitment letters  
8  
9 mailed to breast cancer survivors identified through the UAB O'Neal Comprehensive Cancer  
10  
11 Center registry, UAB investigators' waiting lists of cancer survivors inquiring about exercise and  
12  
13 weight loss studies, newspaper advertising, cancer support groups, institutional websites and  
14  
15 group emails, relevant non-institutional websites, flyers in waiting areas [hospitals, physicians'  
16  
17 offices]). Referrals from oncologists and other relevant health care providers are being requested  
18  
19 using messaging (i.e., electronic health records or institutional email) and face-to-face meetings;  
20  
21 recruitment materials such as patient flyers are provided, as appropriate. Potential participants  
22  
23 are given a description of the study and screened for eligibility based on a pre-determined  
24  
25 telephone script. In addition to questions related to the above eligibility criteria, participants are  
26  
27 asked the following diet questions in the prescreening telephone screen to assess potential  
28  
29 controlled feeding adherence and safety issues: 1) *do you have any food allergies, restrictions,*  
30  
31 *preferences or special diet (vegetarian, gluten-free, etc.),* 2) *are you willing to eat the meals we*  
32  
33 *provide,* 3) *do you drink alcohol? If yes, are you willing to refrain from alcohol during your*  
34  
35 *participation in this study,* and 4) *do you foresee any barriers to picking up the food, storing*  
36  
37 *food, or doing minimal meal preparation?*

### 38 39 40 41 42 43 **Enrollment and randomization**

44  
45 Interested potential participants who pass the pre-screening telephone interview are invited to an  
46  
47 orientation visit (in person or by videoconference) to complete administrative forms, sign lab-  
48  
49 based screening consent (Supplemental Material 1), and complete release forms for obtaining  
50  
51 medical clearance with the study coordinator. Once medical clearance is received, the participant  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 is scheduled for a lab-based screening visit which includes  $VO_{2peak}$  to confirm cardiorespiratory  
4 fitness  $< 30$  ml/kg/min and  $BMI \leq 50$  (see Section 3.5.3 for methods). If deemed eligible at the  
5 lab-based screening visit, informed consent for full study participation is obtained (Supplemental  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Material 2), including optional permission to retain health information and biospecimens for future research. The participant is scheduled for initiation of controlled feeding and baseline assessment visits #1 and #2 (Figure 3).

Participant randomization is based on computer generated random numbers and performed in blocks of 4 to facilitate an equal distribution between the two study groups. BMI is an important biological variable associated with gut microbiota composition,<sup>18,68</sup> hence randomization is stratified by BMI ( $< 30$  vs.  $\geq 30$ ). The study statistician performed the computer generation of random numbers which were placed in sealed, opaque envelopes and delivered to the recruiting staff with written protocol for use. Assignments are made in the order in which participants complete baseline testing and are kept in the sealed envelope until the participant has completed all baseline testing. Once the study coordinator confirms completion of baseline testing, the coordinator chooses the next envelope with group allocation. Participants remain partially blinded to study condition (e.g., will not be told which study condition [exercise training or flexibility/toning intervention] is expected to yield more benefits and all receive controlled diet which is potentially perceived as a “treatment”.) Assessments, assays, and data entry are conducted using objective and validated measures by staff who will remain blinded to study arm status.

## Assessments

### *Schedule and masking*

1  
2  
3 Assessments occur at baseline (pre-intervention), 5 weeks (mid-point intervention), 10  
4 weeks (immediately post intervention), and 15 weeks (5 weeks post intervention) and are  
5 performed by staff who are masked to participant study group allocation. Table 2 presents the  
6 timeline of data and measures collected at each assessment visit. If eligible based on lab-based  
7 screening and participant consents to full study participation (Supplemental Material 2), then  
8 controlled feeding preparations are made and the baseline visit #1 is scheduled for one week  
9 after controlled feeding begins (Figure 3). For each assessment, the participant completes two  
10 visits to the exercise testing laboratory. In preparation for assessment visit #1, participants are  
11 provided instructions for the lab-based measurements (location, parking, 12-hour fast,  
12 appropriate clothing, etc.). During assessment visit #1, the participant provides a hair sample,  
13 completes the fasted blood draw, resting energy expenditure by indirect calorimeter, resting heart  
14 rate variability (Actiheart), dual-energy X-ray absorptiometry (DXA), and walking economy  
15 (i.e., net  $\text{VO}_2$ ). Because the  $\text{VO}_{2\text{peak}}$  and BMI measurements are taken at the screening visit, these  
16 are not repeated at baseline but are repeated at the follow-up assessments. During assessment  
17 visit #1, study staff provide the participant with the additional assessment materials (survey,  
18 accelerometer with log, 3-day diet record, medication log, fecal sample kit, etc.) and related  
19 instructions. The participant ships the fecal sample back to the UAB microbiome laboratory  
20 within 7 days of visit #1 and returns the remaining assessment materials at assessment visit #2.  
21 To better align the temporal relationship between the gut microbiome and fatigue, the fatigue  
22 scale is collected at assessment visit #2 (i.e., several days after fecal sample collection).

### 23 ***Gut microbiota composition***

24 Participants are provided with a stool collection kit at each baseline and follow up assessment  
25 visit #1 to self-collect the stool sample at home according to provided instructions. Briefly, the  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 instructions are to collect the sample in a clean dry study-provided collection hat and scoop a  
4 small amount into the provided ParaPak vials (Meridian Biosciences, Inc; Cincinnati, OH) pre-  
5 labelled with participant identification and assessment timepoint, and then ship the sample back  
6  
7  
8 labelled with participant identification and assessment timepoint, and then ship the sample back  
9  
10 to our site via pre-paid overnight shipping materials. Once received by the microbiome lab, each  
11 sample is aliquoted into labelled cryovials and stored at -80°C until time for DNA extraction and  
12  
13 16S rRNA processing. One cryovial of precisely 100 uL is retained and labeled for future  
14  
15 metabolomics assays (if indicated and funds can be obtained).  
16  
17

18  
19 With each sample collection, the participant completes a fecal sample questionnaire<sup>69</sup> and  
20 returns it to the research staff. The questionnaire asks the participant to report changes in normal  
21 diet and vitamin supplements; recent gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea,  
22 and constipation); and usual frequency or changes in probiotic supplements, yogurt intake, and  
23  
24 high fiber foods or fiber supplements. Participants also report recent medical treatments such as  
25  
26 antibiotics, chemotherapy, or radiation therapy, and if they have ever had a major bowel  
27  
28 resection, gastric bypass surgery, an inflammatory bowel disease (such as Crohn's disease,  
29  
30 ulcerative colitis, indeterminate colitis), or irritable bowel syndrome. The participant is also  
31  
32 asked to complete a 3-day diet record capturing dietary intake 2 days prior to and the day of fecal  
33  
34 sample.  
35  
36  
37  
38  
39  
40  
41

#### 42 ***Cardiorespiratory fitness ( $VO_{2peak}$ )***

43  
44 Participants perform a graded treadmill (TrackMaster TMX428CP; Full Vision, Inc.; Newton,  
45  
46 KS) test in accordance with the modified-Balke protocol to elicit  $VO_{2peak}$  (i.e., the highest  
47  
48 measured rate of oxygen uptake expressed in mL/kg/min. Initially,  $VO_2$  is stabilized over a 3-  
49  
50 minute period of standing rest, after which, participants begin walking at 2.0 mph at 0% grade  
51  
52 for 2 minutes. Grade is then increased 3.5% every 2 minutes until the 12<sup>th</sup> minute, at which point,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 grade is decreased to 12% and speed increased to 3.0 mph. Grade is increased by 2.5% each  
4  
5 minute (as needed) until volitional exhaustion.  $\text{VO}_2$  and related gas exchange measures are  
6  
7 aggregated in 30-s bins and determined by open-circuit spirometry (True One 2400 system;  
8  
9 ParvoMedics, Salt Lake City, UT). Gas analyzers and flowmeter are calibrated prior to each test  
10  
11 using standard gases and 3-L syringe, respectively. Heart rate and Rating-of-Perceived Exertion  
12  
13 (RPE; Borg 6-20, 6 = *no exertion at all, relaxed* and 20 = *maximal exertion*)<sup>70</sup> are recorded in the  
14  
15 final 30 seconds of each stage. Blood pressure is measured via auscultation at minutes 6, 10, 14,  
16  
17 16 and/or final stage of the graded treadmill test.  
18  
19  
20

### 21 ***Serum cytokines***

22 Inflammatory cytokines, interleukin (IL)-6 and IL-10, are collected by blood samples.

23  
24 Participants are instructed to abstain from vigorous exercise, smoking, and alcohol for 24 hours  
25  
26 prior and fast for 12 hours prior to the blood draw. Blood samples are collected, processed and  
27  
28 stored (-80°C) using standard operating procedure consistent with expert consensus  
29  
30 recommendations<sup>71</sup> and batch analyzed according to manufacturer's instructions by staff who are  
31  
32 blinded to the participant's group allocation.<sup>64</sup> Serum cytokine assays will be analyzed by the  
33  
34 UAB Metabolism Core using a MSD imager (MesoScale Discovery, Gaithersburg, MD;  
35  
36 chemiluminescence technology; multiplex platform). Blood and serum samples are being  
37  
38 processed and stored so that future metabolomic/functional metabolic studies can be done if  
39  
40 indicated and funds can be obtained. A 7-day medication log is collected with each blood sample  
41  
42 for medication changes between assessments that may influence study outcomes (e.g., anti-  
43  
44 inflammatory agents, etc.).  
45  
46  
47  
48  
49  
50

### 51 ***Heart rate variability***

52 Heart rate variability is evaluated with the Actiheart 5 (CamNtech Ltd., Cambridgeshire, UK)  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 device. First, a urine sample is collected from participants to measure urine specific gravity – an  
4  
5 indicator of hydration status. In accordance with manufacturer guidelines, skin is prepped with a  
6  
7 70% isopropyl alcohol wipe before positioning a two-lead electrode arrangement in the upper  
8  
9 left quadrant across the participant's chest. Measurements are collected during 5-minutes of quiet  
10  
11 rest in the seated position. High-frequency sampling is used to measure inter-beat intervals  
12  
13 wherein Actiheart® software is used to perform offline analyses. The primary variables of  
14  
15 interest include heart rate and root mean square of successive RR interval differences (RMSSD)  
16  
17 as well as the low-frequency (LF), high-frequency (HF) components derived from the fast-  
18  
19 Fourier transform. Procedures are performed in the morning hours in a dimly-lit, temperature-  
20  
21 controlled room.  
22  
23  
24  
25

### 26 ***Hair cortisol***

27  
28 Hair specimens are collected by trained study staff. For participants whose hair is longer than 1.5  
29  
30 to 3 cm, a thin layer of hair (1-2 hairs thick) parallel to the floor is cut from a point close to the  
31  
32 scalp across a 4-5 cm length (laterally), to obtain a minimum of 50 strands of hair. For  
33  
34 participants with shorter hair, the lateral cut is 6-8 cm (2 cm vertical x 5 cm lateral for long hair,  
35  
36 > 2 cm vertical x 7 cm lateral for shorter hair). String is used to indicate the end of the hair  
37  
38 closest to the scalp; hair specimens are folded tightly into aluminum foil and placed in a small  
39  
40 labeled bag at room temperature until being sent for assay at the Department of Biopsychology at  
41  
42 Technische Universität Dresden in Dresden, Germany.  
43  
44  
45  
46

### 47 ***Fatigue***

48  
49 Fatigue is measured by a 13-item multi-dimensional fatigue scale (i.e., Fatigue Symptom  
50  
51 Inventory).<sup>72</sup> On a 1 to 10 scale (1 = *not at all fatigued*, 10 = *as fatigued as I could be*),  
52  
53 participants are asked to rate their level of fatigue on the day they felt most and least fatigued in  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the last week, the average level of fatigue in the last week, and the level of fatigue at the time of  
4 survey. Participants report how much fatigue interferes (1 = *no interference*, 10 = *extreme*  
5 *interference*) with their general level of activity, ability to bathe and dress, their normal work  
6 activity, ability to concentrate, relations with other people, enjoyment of life, and mood.  
7  
8  
9

10 Participants report how many days in the past week they felt fatigued for any part of the day and  
11 how much of the day on average the participant experienced fatigue (1 = *none of the day*, 10 =  
12 *the entire day*). Since our prior studies have demonstrated that exercise effects on fatigue may  
13 vary by dimension (i.e., intensity vs. interference; intensity = mean of 4 items; interference =  
14 mean of 6 items, 0 to 10 scale) our final analyses will focus on fatigue interference.  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 ***Potential covariates***

25  
26 Self-administered survey measures age, race/ethnicity, education level, annual household  
27 income, marital status, smoking history, alcohol intake, employment status and number of recent  
28 sick days, cancer-related factors (date of diagnosis, stage, subtypes [e.g., receptor status], current  
29 and past cancer treatment type [including, but not limited to, radiation, chemotherapy, and anti-  
30 estrogen therapy]), caffeine intake, dietary supplements (including prebiotic, probiotic, and  
31 vitamins), current medications (including over the counter medications), any antibiotic  
32 medications over the last 6 months, any steroid medications or injections over the last 6 months,  
33 current/past diagnosis of and treatment for anxiety or depression, treatment duration, time  
34 since treatment completion), medical comorbidities<sup>73</sup> (including but not limited to endocrine  
35 or hormone disorders), history of surgeries, menopausal status,<sup>6</sup> and history of COVID-19  
36 diagnosis. If a participant is not able to recall medical-related information, a medical release  
37 form is completed allowing study staff to request this information from the participant's  
38 physician.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Because stress, depression, anxiety, sleep quality, pain and fatigue may cluster and be  
4 associated with inflammation,<sup>74-76</sup> stress is measured by Perceived Stress Scale-10 (PSS-10),<sup>77</sup>  
5 depression and anxiety is measured by 14-item Hospital Anxiety and Depression Scale  
6 [HADS]),<sup>78</sup> sleep dysfunction is measured subjectively using the Pittsburgh Sleep Quality Index  
7 (PSQI)<sup>79</sup>, and pain is measured by the Patient Reported Outcomes Measurement Information  
8 System (PROMIS®; <http://www.nihpromis.org/default.aspx>).<sup>80</sup> Because post-traumatic stress  
9 symptoms are associated with psychosocial outcomes and gut microbiota composition,<sup>81,82</sup> post-  
10 traumatic stress is measured using the Posttraumatic Stress Disorder Checklist (PCL).<sup>83-86</sup>

11  
12 To assess free-living physical activity, participants are given the same ActiGraph  
13 accelerometer (ActiGraph LLC; Pensacola, FL) device for each assessment to be worn at the  
14 waist for seven consecutive days during waking hours (non-dominant hip; same side each time).  
15 Participants are instructed to remove the accelerometer while bathing, showering, or swimming  
16 and are asked to complete an accelerometer log (times device removed, exercise not detectable  
17 by device, sleep times, etc.). The accelerometer is set for 30 second epochs and monitoring is  
18 repeated if less than four valid days are recorded. Non-wear time is defined when no motion is  
19 detected for 60 minutes. A valid day is defined as at least 10 hours of valid wear time. The  
20 following cut points are planned: Sedentary: 0 – 99 counts/min; Inactive: 100 – 499 counts/min;  
21 Light: 500 – 1951 counts/min; Moderate: 1952 – 5724 counts/min; and Vigorous: 5725+  
22 counts/min.<sup>87,88</sup> Leisure-time physical activity is measured using the Godin Leisure Time  
23 Exercise Questionnaire which asks for average weekly frequency of leisure-time exercise for  
24 periods exceeding 10 minutes over the past month per three activity intensity levels (light,  
25 moderate, or vigorous).<sup>89,90</sup>

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54 Body mass index (BMI) is calculated from weight and height [weight (kg)/height (m<sup>2</sup>)]  
55  
56  
57  
58  
59  
60

1  
2  
3 obtained from a scale (in light clothing) and wall stadiometer (without shoes). Dual-energy X-ray  
4 absorptiometry (DXA) scans assess lean mass and fat mass using the Lunar Dual Energy X-ray  
5 Absorptiometry Scanner (iDXA; Lunar Radiation Corp. Madison, WI). Pre-menopausal women  
6  
7  
8 at risk for pregnancy undergo a urine pregnancy test prior to each DXA scan.  
9  
10  
11

### 12 ***Other relevant measurements***

13  
14 Resting energy expenditure measurement is required to more accurately assess participant's  
15 calorie needs for the controlled feeding which facilitates energy balance and resultant weight  
16 maintenance during the study. Hence, resting energy expenditure is measured by ventilated hood  
17 indirect calorimetry (True One 2400 system; ParvoMedics, Salt Lake City, UT) while lying  
18 quietly on an exam table. Participants must fast for at least 6 hours prior (4 hours if they are  
19 diabetic), avoid physical activity for 12 hours and avoid any caffeine or nicotine for at least 2  
20 hours prior to this test.  
21  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 Although not originally proposed, walking economy (i.e., net  $\text{VO}_2$ ) was added because it  
32 reflects oxygen uptake during ambulation, an important alternative measure of (mobility)  
33 independence in older women.<sup>91</sup> Participants wear a hip-worn accelerometer and complete a  
34 fixed-workload task by walking on a treadmill at 2.0 mph (0% grade) for six minutes during  
35 which steady-state  $\text{VO}_2$  is reached. RPE (Borg 6-20, 6 = *no exertion at all*, relaxed and 20 =  
36 *maximal exertion*)<sup>70</sup> is collected at minutes three and six. At minute 5, the participant reports  
37 perceived difficulty of the test using a visual analogue scale (100 mm line). Blood pressure is  
38 measured at rest and while standing. Blood pressure is also measured at the 1-, 2-, and 5-minute  
39 timepoints during walking. Participants remain quietly seated for at least 10 minutes between the  
40 walking economy and  $\text{VO}_{2\text{peak}}$  tests during the follow-up assessments.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52  
53  
54 Quality of life is measured with The Functional Assessment of Cancer Therapy-Breast (FACT-  
55  
56  
57  
58  
59  
60

1  
2  
3 B)<sup>92</sup> because of its relation to fatigue, relevance for breast cancer populations, and repeated use  
4  
5 in prior studies which allow for comparison of study results. The FACT-B is a 37-item  
6  
7 instrument using 5-point Likert scales and includes the subscales of physical well-being, social  
8  
9 well-being, emotional well-being, functional well-being, and additional concerns.<sup>92</sup>  
10  
11 Since cognitive function is associated with the gut microbiome<sup>93</sup> and physical activity in breast  
12  
13 cancer survivors,<sup>94</sup> cognitive function is measured with the 10-item Frequency of Forgetting  
14  
15 scale.<sup>95</sup> The summed score will assess subjective memory impairment (Total score) along with 4  
16  
17 memory subscales (general memory, frequency of forgetting, frequency of forgetting when  
18  
19 reading, and remembering past events).  
20  
21  
22  
23

24 To improve adherence to future, similar exercise training protocols, the self-administered  
25  
26 survey assesses social cognitive theory constructs: exercise self-efficacy (barriers and walking),  
27  
28 enjoyment, social support, barriers, and outcome expectations. Barriers self-efficacy (i.e.,  
29  
30 confidence in ability to overcome barriers) is measured utilizing a 9-item scale specifically  
31  
32 designed for breast cancer patients.<sup>96</sup> The scale utilizes frequently reported barriers among breast  
33  
34 cancer patients (e.g., “*How confident are you that you can exercise when you are tired?*”).  
35  
36 Walking task self-efficacy scale is assessed with a 6-item scale asking participants to rate  
37  
38 confidence in their ability to walk at a moderately fast pace for 5, 10, 15, 20, 25, and 30  
39  
40 minutes.<sup>97</sup> Analyses for barriers and walking task self-efficacy are using the mean score for the  
41  
42 Likert scale (0% = *not at all confident* to 100% = *extremely confident*). Perceived exercise  
43  
44 barriers (or barriers interference) are measured by asking participants to rate on a 5-point Likert  
45  
46 scale (1 = *never* to 5 = *very often*) how often 21 different barriers (e.g., lack of time, weather)  
47  
48 interfere with exercise. The items are summed for a perceived barriers score.<sup>98-100</sup> Physical  
49  
50 activity enjoyment is measured with a single question (5-point Likert scale).<sup>100</sup> Social support is  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 measured by asking for the frequency with which friends (two items) or family (two items)  
4 encourage or offer to exercise with the participant. Items are summed for a friends, family, and  
5 total social support score.<sup>101,102</sup> For outcome expectations, participants are asked to rate their  
6 agreement on a 5-point Likert scale (1 = *strongly disagree* to 5 = *strongly agree*) with the  
7 statement that exercise would result in 17 potential benefits or risks. Fourteen positive benefits  
8 (e.g., feel less depressed) and 3 negative outcomes (e.g., increased joint pain) are included.  
9 Responses are summed for positive outcome expectations and negative outcome expectations.<sup>100</sup>  
10  
11 The participants answer the outcome expectation questions twice: once considering stretching  
12 and light resistance exercises and again considering aerobic exercise.  
13  
14

### 15 ***Participant satisfaction***

16  
17 At the 15-week assessment, participants are asked to provide a written evaluation of the study  
18 staff and procedures. All participants are asked to report their agreement (Likert scale; 1 =  
19 *strongly disagree* to 5 = *strongly agree*) with 10 statements relating to the clarity of study  
20 information, helpfulness of staff interactions, palatability of the provided food and ease of  
21 following the menu, likelihood of recommending this study to others, and overall satisfaction  
22 with the study staff and activities. One open-ended question seeks any additional information  
23 they would like to share with the study team.  
24  
25

### 26 ***Data quality control***

27  
28 Multiple strategies are being used to minimize missing data (e.g., baseline testing and controlled  
29 feeding before randomization provides a “*run-in*” period, monetary and non-monetary  
30 incentives, up to date contact information, ongoing review of source documents by study  
31 coordinator for immediate rectification of missing data, etc.).<sup>103</sup> Study staff are trained by the  
32 investigator with the relevant expertise using electronic manual of procedures with regular  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 review of source documents for quality. Multiple trained staff are present during in-person  
4  
5 assessment activities increasing accountability and immediate identification of potential drift in  
6  
7 protocol adherence. All most recent IRB approved study forms are stored on a shared, HIPAA  
8  
9 compliant cloud server.  
10

## 11 **Interventions**

### 12 *Supervised exercise sessions*

13  
14  
15  
16  
17 Participants are randomized to 10 weeks of either an aerobic exercise intervention or a  
18  
19 flexibility/toning attention control condition. Sessions occur on nonconsecutive days of the week  
20  
21 at the study site and are supervised by experienced exercise specialists who are not involved in  
22  
23 the collection of outcome assessments.  
24  
25  
26  
27

### 28 *Aerobic exercise sessions*

29  
30  
31 Aerobic exercise sessions, supervised by trained exercise specialists, are primarily performed  
32  
33 using the treadmill. However, the cycle ergometer may be used if preferred by the participant.  
34  
35 The training target heart rate zone for each session corresponds with the heart rate at a given  
36  
37 percentage of  $VO_{2peak}$  measured at the most recent assessment. Training sessions commence with  
38  
39 a 5-minute warm-up consisting of light treadmill walking and stretching. During the 1<sup>st</sup> week of  
40  
41 training, after warm-up, participants perform 20 minutes of exercise at  $\approx 60\%$  maximum heart  
42  
43 rate (equivalent to  $\approx 45\text{-}50\%$   $VO_{2peak}$ ). Over the next 3 weeks, *exercise duration* is increased by  
44  
45 5-minute intervals, as tolerated, so that by the beginning of the 5<sup>th</sup> week participants are  
46  
47 exercising for 40 minutes (up to a total of 60 minutes with warm-up and stretching time). This  
48  
49 coincides with an elevation in *exercise intensity* equating to  $\approx 75\%$  of maximum heart rate ( $\approx 55\text{-}$   
50  
51  $60\%$  of  $VO_{2peak}$ ) by the 5<sup>th</sup> week. Following each exercise bout, participants cool down for 3-5  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 minutes. To mitigate stagnation, and facilitate continued improvement of  $VO_{2peak}$ ,<sup>104</sup> high-  
4  
5 intensity interval exercise is added during weeks 5-10 as described in Table 3. Eight to ten work-  
6  
7 intervals are performed at a workload to elicit  $\approx 85-90\%$  maximum heart rate for 60 seconds with  
8  
9 rest intervals of 3 minutes with the total exercise duration ranging from 20 to 40 minutes.  
10

### 11 ***Standard attention controls***

12  
13 The non-aerobic exercise attention control condition controls for the effects of attention and  
14  
15 social interaction through administration of flexibility/range-of-motion activities using light  
16  
17 resistance bands delivered at the same frequency as the aerobic condition (i.e., 3 times per week).  
18  
19

20  
21 The sessions last about 40 minutes and target the head/neck, shoulder, elbow/forearm,  
22  
23 hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period  
24  
25 involves performing additional exercises and sets (i.e., Thera-bands) that provide minimal  
26  
27 resistance (i.e. sham). The first 5 weeks of the control condition involve performing body  
28  
29 stretches without resistance (20-30 seconds for 1-2 sets). In weeks 6-7, the light resistance Thera-  
30  
31 band is used to perform the stretches for the upper-extremities once per week for 8-10 repetitions  
32  
33 for 2 sets, and the other two sessions are body stretches without resistance. In weeks 8-10, the  
34  
35 light resistance Thera-band is used twice per week for 8-10 repetitions for 2 sets, and one session  
36  
37 will be body weight stretches without resistance. Such a progression is not expected to induce  
38  
39 aerobic fitness adaptations and is designed to maintain participant interest and expectation of  
40  
41 treatment benefit. Control condition participants are asked to not undertake additional exercise  
42  
43 (e.g., not join a gym and begin exercising) during the 10-week intervention period.  
44  
45  
46  
47  
48

### 49 ***Missed exercise and control sessions***

50  
51 Session attendance is tracked weekly and missed sessions are made up as soon as possible  
52  
53 during the intervention period. No more than four supervised aerobic sessions will occur in one  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 week. Exercise specialists encourage exercise adherence by discussing social cognitive theory  
4 based educational newsletters with participants at six time points during the 10 weeks of aerobic  
5 exercise and standard attention control.<sup>105</sup>  
6  
7

### 8 9 10 ***Controlled feeding***

11  
12 Controlled feeding provided by the UAB Center for Clinical and Translational Science (CCTS)  
13 Metabolic Kitchen standardizes dietary intake across all participants. The menus are designed to  
14 provide 55% of energy as carbohydrate primarily through complex sources (fiber: 21-38 g/day),  
15 23% as fat, and a minimum of 22% as protein ( $\approx 0.8$  g/kg). Dietary sodium intake and the  
16 polyunsaturated:saturated (P:S) fat ratio are held constant (sodium <3500 mg/d, P:S fat ratio of  
17 1, and saturated fat less than 30% of total fat intake).  
18  
19  
20  
21  
22  
23  
24  
25

26 Prior to initiating controlled feeding, the participant meets with a study registered  
27 dietitian to review the study menu and collect information about food allergies and intolerances.  
28 Changes to the menu based on dietary preferences are attempted if substitutions are accessible to  
29 the Metabolic Kitchen and maintain the standardized diet protocol. The participant and study  
30 dietitian meet a second time to review the final menus and discuss approved beverages and  
31 seasonings. Each participant starts weekly meal pick up from the Metabolic Kitchen at least one  
32 week before baseline assessment visit #1.  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 To allow the Metabolic Kitchen time to prepare the controlled feeding, the daily calorie  
43 need (total energy expenditure) is estimated pre-baseline using the Harris Benedict equation and  
44 an activity factor to promote weight maintenance. This estimate is then updated once resting  
45 energy expenditure data is available at the baseline assessment. The estimate of total energy  
46 expenditure is further updated for participants randomized to the aerobic exercise condition using  
47 the individual's  $VO_{2peak}$  and resting energy expenditure data based on prior work by the  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 investigative team (equation provided in Supplemental Material 3).<sup>106,107</sup> The total energy  
4  
5 expenditure estimates for all participants are updated, if appropriate, based on the week 5  
6  
7 assessment of  $\text{VO}_{2\text{peak}}$  and resting energy expenditure. A study registered dietitian monitors body  
8  
9 weight weekly and uses these changes and participant dietary preferences to further refine the  
10  
11 calorie content and menus.  
12  
13

### 14 ***Controlled feeding adherence***

15  
16 Menu checklists are included with each weekly food pick up and participants are asked to log  
17  
18 how much of the provided foods they consume and report additional foods and beverages along  
19  
20 with the amounts consumed. The menu checklists are returned at exercise and control sessions  
21  
22 on a weekly basis and reviewed by the dietitian for adherence. Participants with potential  
23  
24 adherence issues or missing or incomplete checklists are called by a study dietitian for reminders  
25  
26 and instruction.  
27  
28  
29  
30  
31  
32

### 33 **Staff training**

34  
35 Staff are trained using a variety of electronic manuals, protocols, and up-to-date IRB approved  
36  
37 study forms and scripts. An electronic manual of procedures is maintained in a shared, HIPAA  
38  
39 compliant cloud server for reference by staff. Given the range of staff responsibilities (i.e.,  
40  
41 exercise intervention, diet, etc.), additional supplemental role-specific protocols are also  
42  
43 maintained (e.g., exercise progression prescription for exercise specialist and controlled feeding  
44  
45 menu review scripts for dietitian).  
46  
47  
48  
49  
50

### 51 **Intervention fidelity plan**

52  
53 The exercise and controlled feeding intervention fidelity plans include the five domains  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 recommended by NIH Behavior Change Consortium<sup>108</sup> (i.e., study design, provider training,  
4 treatment delivery, treatment receipt, and enactment of treatment skills). Fidelity is facilitated  
5 with the electronic manual of procedures, standardized scripts, and participant education  
6 materials. Data sources for tracking exercise intervention include review of all exercise session  
7 record sheets (i.e., attendance, if exercise goals met, and if exercise progression administered  
8 according to protocol) and direct observation by each interventionist at least once a month. The  
9 main data source for tracking controlled feeding fidelity are menu checklists on which the  
10 participant reports the provided foods consumed and any additional foods/beverages consumed.  
11 The food included in each controlled feeding pick up is reviewed for accuracy and completeness  
12 by a trained research staff before the food is given to the participant. Further, study registered  
13 dietitians offer the same food substitutions for all participants requesting a change. Monthly  
14 reports are presented to the study team to monitor fidelity of both the exercise and controlled  
15 feeding so that fidelity concerns can be rectified in a timely manner.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

## 35 **Statistical analysis**

### 36 *Sample size and power considerations*

37  
38 Sample size is based on detecting alpha diversity and beta diversity taxa comparisons. The power  
39 calculation is based on two-tailed test at power of 0.8 using software G\*Power version  
40 3.1.9.2.<sup>109,110</sup> Our pre-COVID pandemic sample size was estimated at 126 (63 in each group)  
41 with 100 (50 per study group) remaining after drop outs. This sample size would have allowed us  
42 to detect a medium effect size ( $d = .57$ ; power of 0.8,  $p < 0.05$ ) in alpha diversity which is  
43 sufficient for detecting effects related to associations with fatigue and intervention effects falling  
44 midway between that found in our two pilot studies. Relevant to taxa comparisons, we have >  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 0.8 power to detect the effect of any of the taxa after multiple testing correction ( $q$  value <  
4 0.05).<sup>111-113</sup> Due to the detrimental impact of the COVID-19 pandemic on recruitment into on-  
5 site, supervised exercise trials, we provide revised contingency power calculations in Figure 4,  
6 where we can see that with sample size decreasing, the effect size we can detect changes from  
7 moderate to large. For example, for enrolling at 100%, 75% (74 samples with 37 per group), and  
8 50%, the effect size that can be detected changes from 0.57, to 0.67, and to 0.81 (with power of  
9 0.8 and alpha of 0.05). Of note, larger effect sizes are possible in this study (compared to our  
10 pilot studies) because the study will provide controlled feeding (reducing variability), select low  
11 fit individuals (greater chance of improvement), and manipulate the exercise exposure  
12 (standardize the exercise exposure). Also relevant, the sample sizes in our pilot studies ( $N = 12$   
13 and 37) were smaller than our proposed study even with dropped enrollment yet yielded  
14 statistically significant results (e.g., a significant association between alpha diversity and  
15 cardiorespiratory fitness in 37 breast cancer survivors).<sup>7,13</sup>

### 32 ***Data management and analysis considerations***

33  
34  
35 Microbiome 16S gene sequence data is analyzed using the QIIME<sup>114</sup> analysis package, our in-  
36 house developed automated analysis pipeline QWRAP,<sup>69</sup> and DADA2<sup>115</sup> to provide a robust  
37 error model for sample filtering and clustering. Data quality is assessed using FASTQC, with  
38 low-quality data filtered out using the FASTX toolset. Filtering, denoising, and clustering of  
39 reads into Amplicon Sequence Variants (ASVs) is done using DADA2. Taxon assignment is  
40 performed using Mothur<sup>116</sup> and the SILVA 16S rDNA database.<sup>117</sup> Alignment and phylogenetic  
41 inference is then performed using PyNAST<sup>118</sup> and Fasttree.<sup>119</sup> Comparative analytical tools such  
42 as UniFrac<sup>120</sup> are used to assess differences between samples and sample groups using principal  
43 coordinates analysis. To expedite sample processing and reporting, QWRAP automates the  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 running of these tools using a single command line argument on UAB's high-performance  
4  
5 computing cluster, Cheaha.  
6

7  
8 Survey and other data entry and checking is conducted by trained research staff masked  
9  
10 to study group allocation using password protected Research Electronic Data Capture (REDCap).  
11  
12 Data analyses will be carried out on an intent-to-treat basis. A multiple imputation approach will  
13  
14 be employed to handle any missing data that cannot be rectified and we will conduct sensitivity  
15  
16 analysis to assess the robustness of our findings.<sup>103,121</sup> SAS software, Version 9.3 (SAS Institute  
17  
18 Inc., Cary, NC) and R software, version 4.3.1<sup>122</sup> will be used for data analysis. Transformations  
19  
20 and non-parametric procedures will be performed when needed. The false discovery rate (FDR)  
21  
22 will be used for multiple testing correction and the statistical significance threshold will be FDR  
23  
24  $q \leq 0.05$  ( $q$  value is a  $p$  value after FDR correction). Each element (i.e., alpha diversity, beta  
25  
26 diversity, and taxa level comparisons) describes a different perspective on gut microbiota  
27  
28 changes and are integrated for interpretation (e.g., does exercise change the relative abundance of  
29  
30 organisms and, if so, which organisms). We will assess the microbiota composition change over  
31  
32 time using mixed-effects models.<sup>123</sup> All mediation analyses will conduct indirect effects analysis  
33  
34 with the bootstrap method developed by Hayes.<sup>124</sup> Week 10 is our primary time point yet we will  
35  
36 also analyze week 5 to assess interim changes that occur and week 15 to assess durability.  
37  
38  
39  
40  
41  
42  
43

#### 44 **Participant safety and withdrawal**

##### 45 ***Risk management and safety***

46  
47  
48 Participant safety is facilitated by obtaining medical clearance, limiting to a BMI < 50, collecting  
49  
50 a medical history and the PAR-Q (physical activity readiness questionnaire) before the lab-based  
51  
52 screening, and consulting clinical investigators, if indicated. Exercise sessions are supervised by  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 exercise specialists who have experience training cancer survivors or chronic disease  
4  
5 populations. Additionally, physician supervision is provided during fitness testing when deemed  
6  
7 appropriate based on ACSM guidelines.<sup>125</sup> Information about food allergies and intolerances are  
8  
9 screened for and collected before initiating controlled feeding and throughout participation and  
10  
11 these are communicated to the Metabolic Kitchen to minimize allergen contamination.  
12  
13

### 14 ***Adverse event reporting***

15  
16 Adverse events are identified spontaneously (e.g., reported to research staff during contact time)  
17  
18 or non-spontaneously (structured interview done at each assessment time-point). Reported  
19  
20 adverse events are reviewed promptly by the PI and reported to the IRB according to local  
21  
22 requirements. A Data and Safety Monitoring Board (DSMB) is convened annually or more often  
23  
24 if indicated.  
25  
26

### 27 ***Handling of withdrawals***

28  
29 Participants are informed of their right to withdraw at any time without consequences in the  
30  
31 informed consent forms and during the signing of consent forms. Participants will be withdrawn  
32  
33 from the study if any social, psychological, or physical conditions arise that may unduly increase  
34  
35 risk of participating in the study. Data will be analysed on an intention-to-treat basis.  
36  
37  
38

### 39 ***Unexpected Required Antibiotics***

40  
41 Given the effect of antibiotics on the gut microbiota composition, participants unexpectedly  
42  
43 requiring intensive antibiotic therapy while enrolled in the study will be withdrawn from the  
44  
45 study. Intensive antibiotic therapy is defined as intravenous, extended use (i.e.,  $\geq 2$  weeks), or  
46  
47 combined therapy (multiple broad-spectrum agents). Less intensive antibiotic use will be tracked  
48  
49 by self-administered survey and considered during the analyses.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Patient and public involvement**

Patients and members of the public were not involved in the design of the trial.

### **Ethics and dissemination**

The University of Alabama at Birmingham Institutional Review Board (IRB) approved this study, 15 May 2019, UAB IRB#30000320. The trial is registered with ClinicalTrials.gov: NCT04088708. A Data and Safety Monitoring Board (DSMB) convenes annually or more often if indicated. Any amendments will be submitted to the IRB and DSMB for approval. Research findings will be disseminated in peer-reviewed journals and conference presentations.

### **DISCUSSION**

The ROME study is the first randomized controlled exercise training study in fatigued breast cancer survivors testing exercise effects on gut microbiota composition while standardizing dietary intake with rigorous attention to energy balance. Our careful attention to diet and energy balance is critical to more fully understanding the role that exercise can play in altering dysbiosis in breast cancer survivors, a group at increased risk for detrimental changes in gut microbiota composition. Also, understanding the potential mechanistic links between aerobic exercise training, gut microbiota composition, and fatigue in cancer survivors has great potential to improve the lives of the breast cancer survivors suffering fatigue.

Thus, we describe a highly rigorous trial that is especially appropriate for studying exercise, gut microbiome and fatigue in breast cancer survivors because it integrates a standard attention control condition and energy balanced controlled feeding. The standard attention control condition is critical to detecting exercise effects on this patient-reported outcome beyond staff

1  
2  
3 attention alone.<sup>126</sup> Further, few randomized trials testing exercise effects on the gut microbiome  
4  
5 have attempted to standardize diet intake with energy balanced controlled feeding, a critical  
6  
7 element given the strong association between diet, body weight, and the gut microbiome  
8  
9 characteristics.<sup>49,53,127</sup>  
10  
11

12         Given the careful attention to the temporal relationships and randomized study design,  
13  
14 this study will explore mechanistic pathways heretofore most frequently studied in animal  
15  
16 models rather than humans. With regard to the potential mechanisms through which exercise  
17  
18 influences the gut microbiome, we will explore exercise induced changes to inflammation, the  
19  
20 autonomic nervous system, and the HPA axis. Exercise training in breast cancer survivors  
21  
22 positively impacts inflammatory markers.<sup>128</sup> In particular we have previously observed beneficial  
23  
24 changes in IL-10 and tumor necrosis factor (TNF)- $\alpha$ .<sup>25</sup> A better understanding of the  
25  
26 bidirectional communication between the microbiome and inflammation, HPA, and autonomic  
27  
28 nervous system is needed. Microbes influence cytokine production and T cell activation<sup>33,129</sup> and  
29  
30 they and their metabolic by-products can also directly stimulate immune cells with a resultant  
31  
32 influence on cytokine release.<sup>33,130</sup> Similarly, pro-inflammatory cytokines influence serotonin  
33  
34 availability, serotonin and norepinephrine synaptic reuptake pumps, HPA axis, and regional  
35  
36 brain activity.<sup>42</sup> Gut microbes also influence the autonomic nervous system through the vagus  
37  
38 nerve,<sup>48</sup> as exemplified by reduced anxiety and depression-related behavior in mice given  
39  
40 *Lactobacillus rhamnosus*, with this effect absent in vagotomized mice.<sup>131</sup> In a separate animal  
41  
42 study, mice pre-treated with a probiotic formulation (*Lactobacillus helveticus* R0052 and  
43  
44 *Bifidobacterium longum* R0175), then exposed to a water avoidance stressor, exhibited  
45  
46 attenuated HPA axis and autonomic nervous system activity.<sup>132</sup> Given that exercise alters the  
47  
48 microbiome, inflammation, HPA, and autonomic nervous system, a better understanding of the  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 direct and/or indirect relationships are needed.  
4

5         Recent interest related to our primary aim to test exercise effects on gut microbiome has  
6 grown. Allen et al.<sup>58</sup> observed significant changes in gut microbiome beta diversity after 6 weeks  
7 of supervised exercise training in healthy adults (20 to 45 years old) and showed the changes  
8 reversed post-intervention. Additionally, positive changes to the gut microbiome have been  
9 observed in older adults participating in exercise interventions.<sup>57,59</sup> Yet, the literature in cancer  
10 populations connecting exercise to changes in the microbiome warrants additional scrutiny.  
11  
12 Sampsell et al.<sup>133</sup> recently conducted a 12-week exercise intervention in 10 breast cancer  
13 survivors with reassessment after a 12-week washout period. No statistically significant pre-post  
14 differences in alpha or beta diversity were detected yet a follow-up mouse study yielded a trend  
15 toward lower tumor development in mice colonized with post-exercise microbiota vs. those  
16 colonized with pre-exercise microbiota.  
17  
18

19         Others report on the relationship between fatigue and gut microbiota composition in  
20 cancer survivors,<sup>134,135</sup> but we were the first to focus on breast cancer survivors and observe  
21 fatigue was associated with alpha diversity and differences in beta diversity representing shifts in  
22 taxa relative abundance.<sup>13</sup> Additionally, understanding the role of exercise on the gut microbiota  
23 composition in fatigue response can be leveraged to identify new therapeutic strategies  
24 warranting testing in larger trials. Further, exercise is a well-known therapy for alleviating  
25 fatigue<sup>136</sup> yet not all cancer survivors report fatigue improvements with exercise.<sup>26</sup> Thus, a better  
26 understanding of the potential mediating effects of the microbiome can lead to exercise  
27 recommendations that optimize fatigue reductions.  
28  
29

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54         As no research study is perfect, several limitations warrant discussion. Notably, the high  
55  
56  
57  
58  
59  
60

1  
2  
3 scientific rigor made possible by the supervised exercise and controlled feeding may limit  
4 translatability of the results to less controlled interventions. However, this is offset by the  
5  
6 opportunities for exploring potential mechanistic links related to exercise, gut microbiome, and  
7  
8 fatigue. Moreover, the study inclusion and exclusion criteria may limit generalizability of the  
9  
10 results to other cancer types or individuals with higher baseline cardiorespiratory fitness or BMI  
11  
12 over 50. Finally, the COVID-19 pandemic's detrimental impact on our anticipated sample size  
13  
14 may preclude detecting smaller effect sizes and mediating factors. This is offset by several a  
15  
16 priori design features that enhance study power: 1) controlled feeding (reduces variability), 2)  
17  
18 selecting low fit and fatigued individuals (greater chance of improvement), 3) manipulating the  
19  
20 exercise exposure (standardizes the exercise exposure), and 4) stratifying randomization by BMI  
21  
22 (reduces type 1 error and improves study power in trials with < 200 participants per study  
23  
24 condition<sup>137</sup>).

25  
26  
27 We will report findings in peer-reviewed journals and present them at conferences.  
28  
29  
30

### 31 32 33 34 35 **Figure captions**

36  
37  
38 Figure 1. Framework for testing exercise effects on gut microbiota and mechanistic links  
39  
40 between exercise, gut microbiota, and fatigue.

41  
42  
43 Figure 2. Study schema for testing aerobic exercise effects on gut microbiota composition and  
44  
45 potential mechanistic links in breast cancer survivors.

46  
47  
48 Figure 3. Participant screening, enrollment, and baseline assessment. A pre-screening telephone  
49  
50 interview determines the potential eligibility of the participant. The orientation visit includes  
51  
52 completion of administrative forms, lab-based screening informed consent, and release forms for  
53  
54 obtaining medical clearance. Once medical clearance is received by the study team, the  
55  
56  
57  
58  
59  
60



1  
2  
3 participant completes the lab-based screening visit, which includes collecting VO<sub>2</sub>peak and  
4  
5 BMI. If deemed eligible based on the screening visit, the individual will be invited to sign the  
6  
7 consent for full study participation and be scheduled for controlled feeding initiation. Baseline  
8  
9 assessment visit #1 is scheduled for at least one week after initiation of controlled feeding.  
10  
11  
12 Within seven days of visit #1, 1) the participant is asked to collect the fecal sample at home 2-3  
13  
14 days after visit #1 and promptly overnight ships it to the laboratory, and then 2) complete the  
15  
16 remaining assessment materials (e.g., fatigue survey) 2-3 days after collecting the fecal sample  
17  
18 and baseline visit #2 occurs to return these forms.  
19  
20  
21

22 Figure 4. Revised contingency power curve.  
23  
24  
25

## 26 References

- 27 1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An  
28 overview. *Int J Cancer*. Apr 5 2021;doi:10.1002/ijc.33588
- 29 2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN  
30 Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J*  
31 *Clin*. May 2021;71(3):209-249. doi:10.3322/caac.21660
- 32 3. Bodai BI, Nakata TE. Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome,  
33 and Survivorship. *Perm J*. 2020;24doi:10.7812/TPP/19.129
- 34 4. Sabiston CM, Brunet J, Vallance JK, Meterissian S. Prospective examination of  
35 objectively assessed physical activity and sedentary time after breast cancer treatment: sitting on  
36 the crest of the teachable moment. *Cancer Epidemiol Biomarkers Prev*. Jul 2014;23(7):1324-30.  
37 doi:10.1158/1055-9965.Epi-13-1179
- 38 5. Pradhan KR, Stump TE, Monahan P, Champion V. Relationships among attention  
39 function, exercise, and body mass index: a comparison between young breast cancer survivors  
40 and acquaintance controls. *Psychooncology*. Mar 2015;24(3):325-32. doi:10.1002/pon.3598
- 41 6. Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer  
42 survivors: prevalence, pattern and health consequences. *Obes Rev*. Apr 2011;12(4):282-94.  
43 doi:10.1111/j.1467-789X.2010.00805.x
- 44 7. Carter SJ, Hunter GR, Blackston JW, et al. Gut microbiota diversity is associated with  
45 cardiorespiratory fitness in post-primary treatment breast cancer survivors. *Exp Physiol*. Apr  
46 2019;104(4):529-539. doi:10.1113/EP087404
- 47 8. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J*. May 16  
48 2017;474(11):1823-1836. doi:10.1042/bcj20160510
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

9. Kelly DL, Lyon DE, Yoon SL, Horgas AL. The Microbiome and Cancer: Implications for Oncology Nursing Science. *Cancer Nurs*. May-Jun 2016;39(3):E56-62. doi:10.1097/ncc.0000000000000286
10. Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav Immun*. Aug 2015;48:186-94. doi:10.1016/j.bbi.2015.03.016
11. Fu J, Bonder MJ, Cenit MC, et al. The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. *Circ Res*. Oct 9 2015;117(9):817-24. doi:10.1161/circresaha.115.306807
12. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. *CA Cancer J Clin*. Jul 8 2017;67(4):326-344. doi:10.3322/caac.21398
13. Paulsen JA, Ptacek TS, Carter SJ, et al. Gut microbiota composition associated with alterations in cardiorespiratory fitness and psychosocial outcomes among breast cancer survivors. *Support Care Cancer*. May 2017;25(5):1563-1570. doi:10.1007/s00520-016-3568-5
14. Hollen PJ, Msaouel P, Gralla RJ. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. *Breast Cancer Res Treat*. Jun 2015;151(3):679-86. doi:10.1007/s10549-015-3420-5
15. Carreira H, Williams R, Dempsey H, Stanway S, Smeeth L, Bhaskaran K. Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom. *J Cancer Surviv*. Aug 2021;15(4):564-575. doi:10.1007/s11764-020-00950-3
16. Maass S, Brandenbarg D, Boerman LM, Verhaak PFM, de Bock GH, Berendsen AJ. Fatigue among Long-Term Breast Cancer Survivors: A Controlled Cross-Sectional Study. *Cancers (Basel)*. Mar 15 2021;13(6)doi:10.3390/cancers13061301
17. Jones JM, Olson K, Catton P, et al. Cancer-related fatigue and associated disability in post-treatment cancer survivors. *J Cancer Surviv*. Feb 2016;10(1):51-61. doi:10.1007/s11764-015-0450-2
18. Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. *Nat Rev Clin Oncol*. Oct 2014;11(10):597-609. doi:10.1038/nrclinonc.2014.127
19. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. *Breast Cancer Res Treat*. Oct 2007;105(2):209-19. doi:10.1007/s10549-006-9447-x
20. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, et al. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. *Breast Cancer Res*. Oct 19 2018;20(1):124. doi:10.1186/s13058-018-1051-6
21. Rogers LQ, Courneya KS, Anton PM, et al. Effects of a multicomponent physical activity behavior change intervention on fatigue, anxiety, and depressive symptomatology in breast cancer survivors: randomized trial. *Psychooncology*. Nov 2017;26(11):1901-1906. doi:10.1002/pon.4254
22. Dennett AM, Peiris CL, Shields N, Prendergast LA, Taylor NF. Moderate-intensity exercise reduces fatigue and improves mobility in cancer survivors: a systematic review and meta-regression. *J Physiother*. Apr 2016;62(2):68-82. doi:10.1016/j.jphys.2016.02.012
23. Mustian KM, Alfano CM, Heckler C, et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. *JAMA Oncol*. Jul 1 2017;3(7):961-968. doi:10.1001/jamaoncol.2016.6914

- 1  
2  
3 24. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in  
4 adults. *Cochrane Database Syst Rev*. Nov 14 2012;11(11):Cd006145.  
5 doi:10.1002/14651858.CD006145.pub3  
6  
7 25. Rogers LQ, Fogleman A, Trammell R, et al. Effects of a physical activity behavior  
8 change intervention on inflammation and related health outcomes in breast cancer survivors:  
9 pilot randomized trial. *Integr Cancer Ther*. Jul 2013;12(4):323-35.  
10 doi:10.1177/1534735412449687  
11  
12 26. Rogers LQ, Vicari S, Trammell R, et al. Biobehavioral factors mediate exercise effects  
13 on fatigue in breast cancer survivors. *Med Sci Sports Exerc*. Jun 2014;46(6):1077-88.  
14 doi:10.1249/mss.0000000000000210  
15  
16 27. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled  
17 physical activity trials in cancer survivors: a systematic review and meta-analysis. *J Cancer*  
18 *Surviv*. Jun 2010;4(2):87-100. doi:10.1007/s11764-009-0110-5  
19  
20 28. Inglis JE, Lin PJ, Kerns SL, et al. Nutritional Interventions for Treating Cancer-Related  
21 Fatigue: A Qualitative Review. *Nutr Cancer*. 2019;71(1):21-40.  
22 doi:10.1080/01635581.2018.1513046  
23  
24 29. Matsumoto M, Inoue R, Tsukahara T, et al. Voluntary running exercise alters microbiota  
25 composition and increases n-butyrate concentration in the rat cecum. *Biosci Biotechnol Biochem*.  
26 Feb 2008;72(2):572-6. doi:10.1271/bbb.70474  
27  
28 30. Clarke SF, Murphy EF, O'Sullivan O, et al. Exercise and associated dietary extremes  
29 impact on gut microbial diversity. *Gut*. Dec 2014;63(12):1913-20. doi:10.1136/gutjnl-2013-  
30 306541  
31  
32 31. Lambert JE, Myslicki JP, Bomhof MR, Belke DD, Shearer J, Reimer RA. Exercise  
33 training modifies gut microbiota in normal and diabetic mice. *Appl Physiol Nutr Metab*. Jul  
34 2015;40(7):749-52. doi:10.1139/apnm-2014-0452  
35  
36 32. Choi JJ, Eum SY, Rampersaud E, Daunert S, Abreu MT, Toborek M. Exercise attenuates  
37 PCB-induced changes in the mouse gut microbiome. *Environ Health Perspect*. Jun  
38 2013;121(6):725-30. doi:10.1289/ehp.1306534  
39  
40 33. Bermon S, Petriz B, Kajéniené A, Prestes J, Castell L, Franco OL. The microbiota: an  
41 exercise immunology perspective. *Exerc Immunol Rev*. 2015;21:70-9.  
42  
43 34. Campbell SC, Wisniewski PJ, Noji M, et al. The Effect of Diet and Exercise on Intestinal  
44 Integrity and Microbial Diversity in Mice. *PLoS One*. 2016;11(3):e0150502.  
45 doi:10.1371/journal.pone.0150502  
46  
47 35. Estaki M, Pither J, Baumeister P, et al. Cardiorespiratory fitness as a predictor of  
48 intestinal microbial diversity and distinct metagenomic functions. *Microbiome*. Aug 8  
49 2016;4(1):42. doi:10.1186/s40168-016-0189-7  
50  
51 36. Houghton D, Stewart CJ, Stamp C, et al. Impact of Age-Related Mitochondrial  
52 Dysfunction and Exercise on Intestinal Microbiota Composition. *J Gerontol A Biol Sci Med Sci*.  
53 Apr 17 2018;73(5):571-578. doi:10.1093/gerona/glx197  
54  
55 37. Verheggen RJHM, Konstanti P, Smidt H, Hermus ARMM, Thijssen DHJ, Hopman MTE.  
56 Eight-week exercise training in humans with obesity: Marked improvements in insulin  
57 sensitivity and modest changes in gut microbiome. *Obesity*. 2021;29(10):1615-1624.  
58 doi:<https://doi.org/10.1002/oby.23252>  
59  
60 38. Kern T, Blond MB, Hansen TH, et al. Structured exercise alters the gut microbiota in  
humans with overweight and obesity-A randomized controlled trial. *Int J Obes (Lond)*. Jan  
2020;44(1):125-135. doi:10.1038/s41366-019-0440-y

- 1  
2  
3 39. Roager HM, Hansen LB, Bahl MI, et al. Colonic transit time is related to bacterial  
4 metabolism and mucosal turnover in the gut. *Nat Microbiol*. Jun 27 2016;1(9):16093.  
5 doi:10.1038/nmicrobiol.2016.93  
6  
7 40. Dainese R, Serra J, Azpiroz F, Malagelada JR. Effects of physical activity on intestinal  
8 gas transit and evacuation in healthy subjects. *Am J Med*. Apr 15 2004;116(8):536-9.  
9 doi:10.1016/j.amjmed.2003.12.018  
10  
11 41. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social  
12 stressor alters the structure of the intestinal microbiota: implications for stressor-induced  
13 immunomodulation. *Brain Behav Immun*. Mar 2011;25(3):397-407.  
14 doi:10.1016/j.bbi.2010.10.023  
15  
16 42. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune  
17 mechanisms of behavioral comorbidities in patients with cancer. *J Clin Oncol*. Feb 20  
18 2008;26(6):971-82. doi:10.1200/jco.2007.10.7805  
19  
20 43. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects  
21 of exercise. *J Physiol Pharmacol*. Nov 2006;57 Suppl 10:43-51.  
22  
23 44. Lavín-Pérez AM, Collado-Mateo D, Hinojo González C, et al. High-intensity exercise  
24 prescription guided by heart rate variability in breast cancer patients: a study protocol for a  
25 randomized controlled trial. *BMC Sports Sci Med Rehabil*. Mar 8 2023;15(1):28.  
26 doi:10.1186/s13102-023-00634-2  
27  
28 45. Niederer D, Vogt L, Thiel C, et al. Exercise effects on HRV in cancer patients. *Int J*  
29 *Sports Med*. Jan 2013;34(1):68-73. doi:10.1055/s-0032-1314816  
30  
31 46. Toohey K, Pumpa K, McKune A, et al. The impact of high-intensity interval training  
32 exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and  
33 biomarkers of the stress systems. *BMC Cancer*. Aug 20 2020;20(1):787. doi:10.1186/s12885-  
34 020-07295-1  
35  
36 47. Russell E, Koren G, Rieder M, Van Uum S. Hair cortisol as a biological marker of  
37 chronic stress: current status, future directions and unanswered questions.  
38 *Psychoneuroendocrinology*. May 2012;37(5):589-601. doi:10.1016/j.psyneuen.2011.09.009  
39  
40 48. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the  
41 barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders.  
42 *Front Cell Neurosci*. 2015;9:392. doi:10.3389/fncel.2015.00392  
43  
44 49. Asnicar F, Berry SE, Valdes AM, et al. Microbiome connections with host metabolism  
45 and habitual diet from 1,098 deeply phenotyped individuals. *Nat Med*. Feb 2021;27(2):321-332.  
46 doi:10.1038/s41591-020-01183-8  
47  
48 50. Remely M, Tesar I, Hippe B, Gnauer S, Rust P, Haslberger AG. Gut microbiota  
49 composition correlates with changes in body fat content due to weight loss. *Benef Microbes*.  
50 2015;6(4):431-9. doi:10.3920/bm2014.0104  
51  
52 51. Ribeiro FM, Silva MA, Lyssa V, et al. The molecular signaling of exercise and obesity in  
53 the microbiota-gut-brain axis. *Front Endocrinol (Lausanne)*. 2022;13:927170.  
54 doi:10.3389/fendo.2022.927170  
55  
56 52. Javed I, Cui X, Wang X, et al. Implications of the Human Gut-Brain and Gut-Cancer  
57 Axes for Future Nanomedicine. *ACS Nano*. Nov 24 2020;14(11):14391-14416.  
58 doi:10.1021/acsnano.0c07258  
59  
60 53. Sampsell K, Hao D, Reimer RA. The Gut Microbiota: A Potential Gateway to Improved  
Health Outcomes in Breast Cancer Treatment and Survivorship. *Int J Mol Sci*. Dec 3  
2020;21(23)doi:10.3390/ijms21239239

- 1  
2  
3 54. Ryu J, Lee EY, Min J, et al. Effect of a 1-year tailored exercise program according to  
4 cancer trajectories in patients with breast cancer: study protocol for a randomized controlled trial.  
5 *BMC Cancer*. Mar 2 2023;23(1):200. doi:10.1186/s12885-023-10664-1  
6  
7 55. Newton RU, Christophersen CT, Fairman CM, et al. Does exercise impact gut microbiota  
8 composition in men receiving androgen deprivation therapy for prostate cancer? A single-  
9 blinded, two-armed, randomised controlled trial. *BMJ Open*. Apr 14 2019;9(4):e024872.  
10 doi:10.1136/bmjopen-2018-024872  
11 56. Yang Y, Shi Y, Wiklund P, et al. The Association between Cardiorespiratory Fitness and  
12 Gut Microbiota Composition in Premenopausal Women. *Nutrients*. Jul 25  
13 2017;9(8)doi:10.3390/nu9080792  
14  
15 57. Erlandson KM, Liu J, Johnson R, et al. An exercise intervention alters stool microbiota  
16 and metabolites among older, sedentary adults. *Ther Adv Infect Dis*. Jan-Dec  
17 2021;8:20499361211027067. doi:10.1177/20499361211027067  
18 58. Allen JM, Mailing LJ, Niemi GM, et al. Exercise Alters Gut Microbiota Composition  
19 and Function in Lean and Obese Humans. *Med Sci Sports Exerc*. Apr 2018;50(4):747-757.  
20 doi:10.1249/MSS.0000000000001495  
21 59. Morita E, Yokoyama H, Imai D, et al. Aerobic Exercise Training with Brisk Walking  
22 Increases Intestinal Bacteroides in Healthy Elderly Women. *Nutrients*. Apr 17  
23 2019;11(4)doi:10.3390/nu11040868  
24  
25 60. McArdle WD, Katch FI, Katch VL. *Exercise Physiology: Nutrition, Energy, and Human*  
26 *Performance*. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015.  
27 61. Fagundes C, LeRoy A, Karuga M. Behavioral Symptoms after Breast Cancer Treatment:  
28 A Biobehavioral Approach. *J Pers Med*. Aug 3 2015;5(3):280-95. doi:10.3390/jpm5030280  
29 62. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms,  
30 contributing factors, and treatment implications. *Brain Behav Immun*. Mar 2013;30  
31 Suppl(0):S48-57. doi:10.1016/j.bbi.2012.06.011  
32 63. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and  
33 therapeutic modulation of the gut microbiota. *Clin Exp Immunol*. Mar 2015;179(3):363-77.  
34 doi:10.1111/cei.12474  
35  
36 64. Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic  
37 inflammation. *Clin Chim Acta*. Jun 3 2010;411(11-12):785-93. doi:10.1016/j.cca.2010.02.069  
38 65. Al-Majid S, Gray DP. A biobehavioral model for the study of exercise interventions in  
39 cancer-related fatigue. *Biol Res Nurs*. Apr 2009;10(4):381-91. doi:10.1177/1099800408324431  
40 66. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. *Nat*  
41 *Rev Immunol*. Aug 5 2011;11(9):625-32. doi:10.1038/nri3042  
42 67. Donovan KA, Jacobsen PB, Small BJ, Munster PN, Andrykowski MA. Identifying  
43 clinically meaningful fatigue with the Fatigue Symptom Inventory. *J Pain Symptom Manage*.  
44 Nov 2008;36(5):480-7. doi:10.1016/j.jpainsymman.2007.11.013  
45 68. Dieli-Conwright CM, Mortimer JE, Schroeder ET, et al. Randomized controlled trial to  
46 evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer  
47 survivors: rationale, design, and methods. *BMC Cancer*. 2014/04/03 2014;14(1):238.  
48 doi:10.1186/1471-2407-14-238  
49 69. Kumar R, Eipers P, Little RB, et al. Getting started with microbiome analysis: sample  
50 acquisition to bioinformatics. *Curr Protoc Hum Genet*. Jul 14 2014;82:18 8 1-29.  
51 doi:10.1002/0471142905.hg1808s82  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 70. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc.*  
4 1982;14(5):377-81.
- 5 71. Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma  
6 collection: early detection research network consensus statement standard operating procedure  
7 integration working group. *J Proteome Res.* Jan 2009;8(1):113-7. doi:10.1021/pr800545q
- 8 72. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients:  
9 development and validation of the Fatigue Symptom Inventory. *Qual Life Res.* May  
10 1998;7(4):301-10. doi:10.1023/a:1024929829627
- 11 73. Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with  
12 physical function as the outcome. *J Clin Epidemiol.* Jun 2005;58(6):595-602.  
13 doi:10.1016/j.jclinepi.2004.10.018
- 14 74. Saligan LN, Kim HS. A systematic review of the association between immunogenomic  
15 markers and cancer-related fatigue. *Brain Behav Immun.* Aug 2012;26(6):830-48.  
16 doi:10.1016/j.bbi.2012.05.004
- 17 75. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a  
18 social signal transduction theory of depression. *Psychol Bull.* May 2014;140(3):774-815.  
19 doi:10.1037/a0035302
- 20 76. Thomas BC, Waller A, Malhi RL, et al. A longitudinal analysis of symptom clusters in  
21 cancer patients and their sociodemographic predictors. *J Pain Symptom Manage.* Mar  
22 2014;47(3):566-78. doi:10.1016/j.jpainsymman.2013.04.007
- 23 77. Taylor JM. Psychometric analysis of the Ten-Item Perceived Stress Scale. *Psychol*  
24 *Assess.* Mar 2015;27(1):90-101. doi:10.1037/a0038100
- 25 78. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*  
26 *Scand.* Jun 1983;67(6):361-70. doi:10.1111/j.1600-0447.1983.tb09716.x
- 27 79. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep  
28 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* May  
29 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4
- 30 80. Cook KF, Dunn W, Griffith JW, et al. Pain assessment using the NIH Toolbox.  
31 *Neurology.* 2013;80(11 Supplement 3):S49-S53. doi:10.1212/WNL.0b013e3182872e80
- 32 81. Morrill EF, Brewer NT, O'Neill SC, et al. The interaction of post-traumatic growth and  
33 post-traumatic stress symptoms in predicting depressive symptoms and quality of life.  
34 *Psychooncology.* Sep 2008;17(9):948-53. doi:10.1002/pon.1313
- 35 82. Leclercq S, Forsythe P, Bienenstock J. Posttraumatic Stress Disorder: Does the Gut  
36 Microbiome Hold the Key? *Can J Psychiatry.* Apr 2016;61(4):204-13.  
37 doi:10.1177/0706743716635535
- 38 83. Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA. Psychometric properties of  
39 the PTSD Checklist (PCL). *Behav Res Ther.* Aug 1996;34(8):669-73. doi:10.1016/0005-  
40 7967(96)00033-2
- 41 84. Cordova MJ, Andrykowski MA, Kenady DE, McGrath PC, Sloan DA, Redd WH.  
42 Frequency and correlates of posttraumatic-stress-disorder-like symptoms after treatment for  
43 breast cancer. *J Consult Clin Psychol.* Dec 1995;63(6):981-6. doi:10.1037//0022-006x.63.6.981
- 44 85. Forbes D, Creamer M, Biddle D. The validity of the PTSD checklist as a measure of  
45 symptomatic change in combat-related PTSD. *Behav Res Ther.* Aug 2001;39(8):977-86.  
46 doi:10.1016/s0005-7967(00)00084-x
- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 86. Parikh D, De Ieso P, Garvey G, et al. Post-traumatic stress disorder and post-traumatic  
4 growth in breast cancer patients--a systematic review. *Asian Pac J Cancer Prev*. 2015;16(2):641-  
5 6. doi:10.7314/apjcp.2015.16.2.641  
6  
7 87. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and  
8 Applications, Inc. accelerometer. *Med Sci Sports Exerc*. May 1998;30(5):777-81.  
9 doi:10.1097/00005768-199805000-00021  
10  
11 88. Sirard JR, Melanson EL, Li L, Freedson PS. Field evaluation of the Computer Science  
12 and Applications, Inc. physical activity monitor. *Med Sci Sports Exerc*. Mar 2000;32(3):695-700.  
13 doi:10.1097/00005768-200003000-00022  
14  
15 89. Godin G, Jobin J, Bouillon J. Assessment of leisure time exercise behavior by self-report:  
16 a concurrent validity study. *Can J Public Health*. Sep-Oct 1986;77(5):359-62.  
17  
18 90. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community.  
19 *Can J Appl Sport Sci*. Sep 1985;10(3):141-6.  
20  
21 91. Carter SJ, Baranuskas MN, Singh H, Martins C, Hunter GR. ARTE index revisited:  
22 linking biomarkers of cardiometabolic health with free-living physical activity in  
23 postmenopausal women. *Am J Physiol Regul Integr Comp Physiol*. Apr 1 2022;322(4):R292-  
24 R298. doi:10.1152/ajpregu.00075.2021  
25  
26 92. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of  
27 Cancer Therapy-Breast quality-of-life instrument. *J Clin Oncol*. Mar 1997;15(3):974-86.  
28 doi:10.1200/jco.1997.15.3.974  
29  
30 93. Gareau MG. Cognitive Function and the Microbiome. *Int Rev Neurobiol*. 2016;131:227-  
31 246. doi:10.1016/bs.irn.2016.08.001  
32  
33 94. Ehlers DK, Rogers LQ, Courneya KS, Robbs RS, McAuley E. Effects of BEAT Cancer  
34 randomized physical activity trial on subjective memory impairments in breast cancer survivors.  
35 *Psychooncology*. Feb 2018;27(2):687-690. doi:10.1002/pon.4438  
36  
37 95. Zelinski EM, Gilewski MJ. A 10-item Rasch modeled memory self-efficacy scale. *Aging*  
38 *Ment Health*. Jul 2004;8(4):293-306. doi:10.1080/13607860410001709665  
39  
40 96. Rogers LQ, Courneya KS, Verhulst S, Markwell S, Lanzotti V, Shah P. Exercise barrier  
41 and task self-efficacy in breast cancer patients during treatment. *Support Care Cancer*. Jan  
42 2006;14(1):84-90. doi:10.1007/s00520-005-0851-2  
43  
44 97. McAuley E, Mihalko S. Advances in sport and exercise psychology measurement.  
45 *Measuring exercise-related self-efficacy Fitness Information Technology*. 1998;1998:371-89.  
46  
47 98. Lewis CE, Raczynski JM, Heath GW, Levinson R, Hilyer Jr JC, Cutter GR. Promoting  
48 physical activity in low-income African-American communities: the PARR project. *Ethnicity &*  
49 *disease*. 1993:106-118.  
50  
51 99. Rogers LQ, McAuley E, Courneya KS, Verhulst SJ. Correlates of physical activity self-  
52 efficacy among breast cancer survivors. *Am J Health Behav*. Nov-Dec 2008;32(6):594-603.  
53 doi:10.5555/ajhb.2008.32.6.594  
54  
55 100. Rogers LQ, Shah P, Dunnington G, et al. Social cognitive theory and physical activity  
56 during breast cancer treatment. *Oncol Nurs Forum*. Jul 1 2005;32(4):807-15.  
57 doi:10.1188/05.Onf.807-815  
58  
59 101. Sallis JF, Grossman RM, Pinski RB, Patterson TL, Nader PR. The development of scales  
60 to measure social support for diet and exercise behaviors. *Preventive medicine*. 1987;16(6):825-  
836.  
102. Sallis JF, Hovell MF, Hofstetter CR, et al. A multivariate study of determinants of  
vigorous exercise in a community sample. *Preventive medicine*. 1989;18(1):20-34.

- 1  
2  
3 103. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data  
4 in clinical trials. *N Engl J Med*. Oct 4 2012;367(14):1355-60. doi:10.1056/NEJMSr1203730
- 5 104. Martin EA, Battaglini CL, Hands B, Naumann F. Higher-Intensity Exercise Results in  
6 More Sustainable Improvements for VO<sub>2</sub>peak for Breast and Prostate Cancer Survivors. *Oncol*  
7 *Nurs Forum*. May 2015;42(3):241-9. doi:10.1188/15.ONF.42-03AP
- 8 105. Motl RW, Backus D, Neal WN, et al. Rationale and design of the STEP for MS Trial:  
9 Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for  
10 Multiple Sclerosis. *Contemp Clin Trials*. Jun 2019;81:110-122. doi:10.1016/j.cct.2019.04.013
- 11 106. Hunter GR, Bickel CS, Fisher G, Neumeier WH, McCarthy JP. Combined aerobic and  
12 strength training and energy expenditure in older women. *Med Sci Sports Exerc*. Jul  
13 2013;45(7):1386-93. doi:10.1249/MSS.0b013e3182860099
- 14 107. Hunter GR, Fisher G, Neumeier WH, Carter SJ, Plaisance EP. Exercise Training and  
15 Energy Expenditure following Weight Loss. *Med Sci Sports Exerc*. Sep 2015;47(9):1950-7.  
16 doi:10.1249/MSS.0000000000000622
- 17 108. Bellg AJ, Borrelli B, Resnick B, et al. Enhancing treatment fidelity in health behavior  
18 change studies: best practices and recommendations from the NIH Behavior Change Consortium.  
19 *Health Psychol*. Sep 2004;23(5):443-51. doi:10.1037/0278-6133.23.5.443
- 20 109. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G\*Power 3.1:  
21 tests for correlation and regression analyses. *Behav Res Methods*. Nov 2009;41(4):1149-60.  
22 doi:10.3758/BRM.41.4.1149
- 23 110. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power  
24 analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. May  
25 2007;39(2):175-91. doi:10.3758/bf03193146
- 26 111. Bi R, Liu P. Sample size calculation while controlling false discovery rate for differential  
27 expression analysis with RNA-sequencing experiments. *BMC Bioinformatics*. Mar 31  
28 2016;17:146. doi:10.1186/s12859-016-0994-9
- 29 112. Pounds S, Cheng C. Sample size determination for the false discovery rate.  
30 *Bioinformatics*. Dec 1 2005;21(23):4263-71. doi:10.1093/bioinformatics/bti699
- 31 113. Liu P, Hwang JT. Quick calculation for sample size while controlling false discovery rate  
32 with application to microarray analysis. *Bioinformatics*. Mar 15 2007;23(6):739-46.  
33 doi:10.1093/bioinformatics/btl664
- 34 114. Navas-Molina JA, Peralta-Sanchez JM, Gonzalez A, et al. Advancing our understanding  
35 of the human microbiome using QIIME. *Methods Enzymol*. 2013;531:371-444.  
36 doi:10.1016/B978-0-12-407863-5.00019-8
- 37 115. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2:  
38 High-resolution sample inference from Illumina amplicon data. *Nat Methods*. Jul  
39 2016;13(7):581-3. doi:10.1038/nmeth.3869
- 40 116. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-  
41 independent, community-supported software for describing and comparing microbial  
42 communities. *Appl Environ Microbiol*. Dec 2009;75(23):7537-41. doi:10.1128/AEM.01541-09
- 43 117. Yilmaz P, Parfrey LW, Yarza P, et al. The SILVA and "All-species Living Tree Project  
44 (LTP)" taxonomic frameworks. *Nucleic Acids Res*. Jan 2014;42(Database issue):D643-8.  
45 doi:10.1093/nar/gkt1209
- 46 118. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R.  
47 PyNAST: a flexible tool for aligning sequences to a template alignment. *Bioinformatics*. Jan 15  
48 2010;26(2):266-7. doi:10.1093/bioinformatics/btp636
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 119. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for  
4 large alignments. *PLoS One*. Mar 10 2010;5(3):e9490. doi:10.1371/journal.pone.0009490  
5  
6 120. Lozupone C, Hamady M, Knight R. UniFrac--an online tool for comparing microbial  
7 community diversity in a phylogenetic context. *BMC Bioinformatics*. Aug 7 2006;7:371.  
8 doi:10.1186/1471-2105-7-371  
9 121. Li P, Stuart EA, Allison DB. Multiple Imputation: A Flexible Tool for Handling Missing  
10 Data. *Jama*. Nov 10 2015;314(18):1966-7. doi:10.1001/jama.2015.15281  
11 122. *R: A Language and Environment for Statistical Computing*. 2022. [https://www.R-](https://www.R-project.org/)  
12 [project.org/](https://www.R-project.org/).  
13 123. Chen EZ, Li H. A two-part mixed-effects model for analyzing longitudinal microbiome  
14 compositional data. *Bioinformatics*. Sep 1 2016;32(17):2611-7.  
15 doi:10.1093/bioinformatics/btw308  
16 124. Hayes AF. *Introduction to mediation, moderation, and conditional process analysis: A*  
17 *regression-based approach*. Guilford publications; 2017.  
18 125. Liguori G, & American College of Sports Medicine. . *ACSM's guidelines for exercise*  
19 *testing and prescription*. 11 ed. Lippincott Williams & Wilkins; 2020.  
20 126. Tock WL, Maheu C, Johnson NA. Considerations of Control Conditions Designs in  
21 Randomized Controlled Trials of Exercise Interventions for Cancer Survivors. *Can J Nurs Res*.  
22 Dec 2022;54(4):377-391. doi:10.1177/08445621211062467  
23 127. Hossain F, Majumder S, David J, Bunnell BA, Miele L. Obesity Modulates the Gut  
24 Microbiome in Triple-Negative Breast Cancer. *Nutrients*. Oct 19  
25 2021;13(10)doi:10.3390/nu13103656  
26 128. de Jesus Leite MA, Goncalves A, Portari G, et al. Application of physical exercise  
27 therapies in breast cancer survivors and their effects on the inflammatory profile: A narrative  
28 review. *J Bodyw Mov Ther*. Oct 2020;24(4):536-545. doi:10.1016/j.jbmt.2020.08.002  
29 129. Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol*.  
30 2002;20:197-216. doi:10.1146/annurev.immunol.20.083001.084359  
31 130. Rescigno M. Intestinal microbiota and its effects on the immune system. *Cell Microbiol*.  
32 Jul 2014;16(7):1004-13. doi:10.1111/cmi.12301  
33 131. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates  
34 emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proc*  
35 *Natl Acad Sci U S A*. Sep 20 2011;108(38):16050-5. doi:10.1073/pnas.1102999108  
36 132. Ait-Belgnaoui A, Colom A, Braniste V, et al. Probiotic gut effect prevents the chronic  
37 psychological stress-induced brain activity abnormality in mice. *Neurogastroenterol Motil*. Apr  
38 2014;26(4):510-20. doi:10.1111/nmo.12295  
39 133. Sampsell K, Wang W, Ohland C, et al. Exercise and Prebiotic Fiber Provide Gut  
40 Microbiota-Driven Benefit in a Survivor to Germ-Free Mouse Translational Model of Breast  
41 Cancer. *Cancers (Basel)*. May 31 2022;14(11)doi:10.3390/cancers14112722  
42 134. Hajjar J, Mendoza T, Zhang L, et al. Associations between the gut microbiome and  
43 fatigue in cancer patients. *Sci Rep*. Mar 12 2021;11(1):5847. doi:10.1038/s41598-021-84783-9  
44 135. Xiao C, Fedirko V, Beitler J, et al. The role of the gut microbiome in cancer-related  
45 fatigue: pilot study on epigenetic mechanisms. *Support Care Cancer*. Jun 2021;29(6):3173-3182.  
46 doi:10.1007/s00520-020-05820-3  
47 136. Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. Are exercise programs effective  
48 for improving health-related quality of life among cancer survivors? A systematic review and  
49 meta-analysis. *Oncol Nurs Forum*. Nov 1 2014;41(6):E326-42. doi:10.1188/14.Onf.E326-e342  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 137. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization  
4 for clinical trials. *J Clin Epidemiol*. Jan 1999;52(1):19-26. doi:10.1016/s0895-4356(98)00138-3  
5  
6  
7

## 8 **Supplementary materials**

10 Supplemental Material 1. Informed consent document to lab-based screening.

11 Supplemental Material 2. Informed consent document to full study.

12 Supplemental Material 3. Equations for calculating daily calorie needs for energy balanced  
13 controlled feeding used in the ROME study (R01CA235598)  
14  
15

## 17 **Acknowledgments**

18  
19  
20 The authors would like to thank Josh Graham, Kaitlyn Waugaman, Sydney McGlawn, Victoria  
21  
22 Roughsedge, and Ildiko Nyikos for their administrative assistance in the setup and ongoing  
23  
24 management of the study, and David Bryan for administrative support of assessments and  
25  
26 conducting fitness tests.  
27  
28  
29  
30

31 **Contributors:** Laura Q. Rogers conceived the study design, led and integrated the  
32  
33 multidisciplinary input, and achieved funding through the National Cancer Institute as the lead  
34  
35 investigator. Stephen J. Carter, Robert W. Motl, Gary R. Hunter, Nianjun Liu, Helen Krontiras,  
36  
37 Elliot J. Lefkowitz, and Bulent Turan helped design the final study protocol and choice of  
38  
39 outcome measures and provided intellectual contributions in their expert areas. Rebecca B. Little  
40  
41 led development of sample process tracking and operationalizing controlled feeding  
42  
43 implementation and fidelity monitoring; she also completed the initial draft of the manuscript.  
44  
45 Abby Cook and Erica Schleicher assisted with exercise intervention fidelity and adherence  
46  
47 tracking protocols. Abby Cook completed a literature review to guide data management related  
48  
49 to current medication use. All authors assisted with drafting the manuscript and have read, edited  
50  
51 and approved the final manuscript.  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Funding**

This study is supported by the following National Institute of Health grants: R01CA235598, P30DK056336, T32 A047888, UL1TR003096, and R25CA76023.

**Competing interests:** None declared.

**Patient consent for publication** Included as Supplemental Material 1 and Supplemental Material 2.

**Ethics approval** Ethics approval was obtained from the Institutional Review Board (IRB) of the University of Alabama at Birmingham (UAB IRB#30000320).

**Table 1.** Outcome measures for the primary and secondary study aims.

Aim	Outcome of Interest	Outcome Measure
<b>Primary Aim:</b> To determine the effects of a 10-week aerobic exercise training intervention compared to a flexibility/toning standard attention control on gut microbiota composition among breast cancer survivors with fatigue	Gut microbiota composition assessed by 16S rRNA	Diversity comparisons: <ul style="list-style-type: none"> <li>• <math>\alpha</math>-diversity</li> <li>• <math>\beta</math>-diversity</li> </ul> Taxa comparisons
<b>Aim 2a:</b> To test if exercise training affects the gut microbiota composition directly and/or indirectly through inflammation, autonomic nervous system, or hypothalamic-pituitary-adrenal (HPA) axis mediators.	Inflammation	Serum cytokines: <ul style="list-style-type: none"> <li>• interleukin [IL]-6</li> <li>• IL-10</li> </ul>
	Autonomic nervous system	Heart rate variability: <ul style="list-style-type: none"> <li>• Low frequency, high frequency, and low:high frequency ratio</li> <li>• Root mean square of successive RR interval differences (RMSSD)</li> </ul>
<b>Aim 2b:</b> To test if the exercise training effect on fatigue is direct and/or indirect through changes in the gut microbiota composition	Hypothalamic-pituitary-adrenal (HPA) axis	Hair cortisol
	Gut microbiota composition assessed by 16S rRNA	Diversity comparisons: <ul style="list-style-type: none"> <li>• <math>\alpha</math>-diversity</li> <li>• <math>\beta</math>-diversity</li> </ul> Taxa comparisons
	Fatigue	13-item multi-dimensional fatigue scale Fatigue Symptom Inventory (FSI)

**Table 2. Participant timeline** (Note: To facilitate temporal relationships, data collection is ordered within each assessment period as follows: #1 - outcomes other than fecal sample and fatigue survey, #2 - fecal sample 2 to 3 days after outcomes other than fatigue, and #3 - fatigue survey 2 to 3 days after fecal sample)

	Lab-based screening	Baseline Assessment		Exercise training or control	Follow-up assessments
Study week (preW = week leading up to randomization [0]; W = week after randomization)	preW3	preW2 – preW1	preW1 – 0	W1 – W10	W5, W10, & W15
Lab-based screening consent, obtain medical clearance, complete lab-based screening (e.g., VO <sub>2peak</sub> )	X				
Enrollment (consent for full participation)	X				
Controlled feeding diet (both study groups)		X	X	X	
Self-administered questionnaire		X			X
Fatigue survey			X		X
Fecal sample collection for gut microbiota composition (with 3-day diet record)			X		X
Medication log (7 days prior to blood draw)		X			X
Fasted blood draw, heart rate variability, hair sample		X			X
Resting energy expenditure		X			X
Walking economy		X			X
VO <sub>2peak</sub> , weight, body mass index (BMI)	X				X
Accelerometer with log sheet (7 days)		X			X
Dual-energy X-ray absorptiometry (DXA)		X			X
Randomization			X		
Exercise training or standard attention control				X	

**Table 3.** Aerobic exercise progression (based on maximum heart rate; high intensity added in later weeks to facilitate continued cardiorespiratory fitness improvement)

Week	Intensity	Max Heart Rate (%)	Duration (mins)	Frequency per Week
1 – 4	Moderate-intensity, continuous	60-75	20 - 35	3
5 – 7	Moderate-intensity, continuous	75	40	2
	High-intensity interval	85-90	20-22	1
8 – 10	Moderate-intensity, continuous	75	40	1
	High-intensity interval	85-90	22-28	2

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Framework for testing exercise effects on gut microbiota and mechanistic links between exercise, gut microbiota, and fatigue.

338x190mm (96 x 96 DPI)




Figure 2. Study schema for testing aerobic exercise effects on gut microbiota composition and potential mechanistic links in breast cancer survivors.

338x190mm (96 x 96 DPI)







Figure 3. Participant screening, enrollment, and baseline assessment. A pre-screening telephone interview determines the potential eligibility of the participant. The orientation visit includes completion of administrative forms, lab-based screening informed consent, and release forms for obtaining medical clearance. Once medical clearance is received by the study team, the participant completes the lab-based screening visit, which includes collecting  $VO_2$  peak and BMI. If deemed eligible based on the screening visit, the individual will be invited to sign the consent for full study participation and be scheduled for controlled feeding initiation. Baseline assessment visit #1 is scheduled for at least one week after initiation of controlled feeding. Within seven days of visit #1, 1) the participant is asked to collect the fecal sample at home 2-3 days after visit #1 and promptly overnight ships it to the laboratory, and then 2) complete the remaining assessment materials (e.g., fatigue survey) 2-3 days after collecting the fecal sample and baseline visit #2 occurs to return these forms.

338x190mm (96 x 96 DPI)



35 Figure 4. Revised contingency power curve.

36 226x198mm (72 x 72 DPI)

**Title of Research:** Role of Gut Microbe Composition in Psychosocial Symptom Response to Exercise Training in Breast Cancer Survivors

**UAB IRB Protocol #:** IRB-300003230

**Principal Investigator:** Laura Q. Rogers, M.D., M.P.H

**Sponsor:** National Cancer Institute (NCI)

### Pre-Study Participant Consent

<b>General Information</b>	You are being asked to take part in a research study. This research study is voluntary, meaning you do not have to take part in it. The procedures, risks, and benefits are fully described further in the consent form.
<b>Purpose</b>	The purpose of this portion is to find out if you are able to participate in the study to determine the effects of diet and exercise on the number, distribution, and types of bacteria in the gut of breast cancer survivors.
<b>Duration &amp; Visits</b>	You will be in this portion of the study for 1 hour. This portion is the first part of the screening visit for this study.
<b>Overview of Procedures</b>	This portion of the study will include the following procedures and assessments: <ul style="list-style-type: none"> <li>• Peak VO<sub>2</sub> Testing You will be asked to perform a graded treadmill or stationary bicycle test. You will walk on the treadmill or pedal on the bike at increasing intensity until you feel you can no longer walk. We will measure your total aerobic fitness by measuring oxygen consumed when performing this test.</li> <li>• Weight</li> <li>• Height</li> <li>• Body mass index (BMI)</li> <li>• Blood pressure</li> <li>• Heart rate</li> </ul>
<b>Risks</b>	The most common risks include: <ul style="list-style-type: none"> <li>• Muscle soreness</li> <li>• Fatigue (tiredness)</li> <li>• Shortness of breath during and/or after performance of peak VO<sub>2</sub></li> <li>• Dry mouth</li> <li>• Embarrassment during height and weight collection</li> </ul>
<b>Benefits</b>	You will not benefit directly from taking part in this portion of the study.
<b>Alternatives</b>	The alternative to this study is to not take part in it.

### Purpose of the Research Study

The purpose of this research study is to determine diet and exercise effects on the number, distribution, and types of bacteria in the gut of breast cancer survivors. This study will enroll 200 participants at UAB.

### Eligibility

You are eligible to participate in this study if you(r):

- Are a woman aged 18 to 74 years with a history of breast cancer stage 0, I, II, or III

- Are one to five years post completion of primary treatment for breast cancer (chemotherapy and/or radiation)
- Average fatigue over the past week is rated as  $\geq 3$  on a 1 to 10 Likert scale
- Are English speaking
- Have physician medical clearance for study participation
- Are able to ambulate (walk) without assistance
- Have not taken antibiotics for the past 90 days
- Are willing to avoid taking probiotics for the duration of the study
- Peak  $VO_2$  is  $\leq 30$  ml/kg/min (note: will measure peak  $VO_2$  if you meet all other criteria and consent to lab-based screening)

You are not eligible to participate in this study if you(r):

- Have metastatic or recurrent cancer
- Have another diagnosis of cancer in the past 5 years (not including skin or cervical cancer in situ)
- Unstable angina
- Have New York Heart Association class II, III, or IV congestive heart failure
- Have uncontrolled asthma
- Have interstitial lung disease
- Have current steroid use
- Have been told by a physician to only do exercise prescribed by a physician
- Have Dementia or organic brain syndrome
- Have Schizophrenia or active psychosis
- Have connective tissue or rheumatologic disease ( i.e., systemic lupus erythematosus, rheumatoid arthritis, amyloidosis, Reiter's syndrome, psoriatic arthritis, mixed connective tissue disease, Sjogren's syndrome, CREST syndrome, polymyositis, dermatomyositis, progressive systemic sclerosis, vasculitis, polymyalgia rheumatic, temporal arteritis)
- Anticipate elective surgery during the study period
- Anticipate changes in usual medications during the study period
- Plan to move residence out of the local area during the study period
- Plan to travel out of the local area for  $>1$  week during study participation
- Have contraindications to engaging in moderate-to-vigorous intensity aerobic exercise
- Are currently pregnant or anticipate pregnancy during study participation
- Live or work  $>50$  miles from study site or do not have transportation to study site
- Have a BMI  $>50$
- Anticipate needing antibiotics during the study period

### **Study Participation & Procedures**

If you agree to join the screening portion of the study, you will undergo Peak  $VO_2$  testing, have your height and weight measured to calculate your body mass index (BMI), and have your blood pressure and heart rate measured. If the results from the Peak  $VO_2$  test and the BMI results are within the eligibility criteria, and you sign the Consent Form for full study participation, you will be started on the controlled feeding diet.

### **Procedures**

**Height, Weight, Blood Pressure, and Heart Rate:** We will measure your height, weight, blood pressure, and heart rate, similar to how they are measured in a doctor's office.

**Peak VO<sub>2</sub> Testing:** Peak VO<sub>2</sub> will be measured while you perform a graded treadmill or stationary bicycle test. During this test, we will also measure your heart rate and blood pressure. This test requires you exercise until exhaustion.

### **Risks and Discomforts**

You may have some risks from taking part in this study.

The risks are:

Moderate likelihood:

- Muscle soreness
- Fatigue
- Shortness of breath during and/or after performance of peak VO<sub>2</sub>
- Dry mouth
- Embarrassment during height and weight collection.

Low likelihood:

- Injury to muscle, joint, ligaments, tendons, or bones
- Inconvenience
- Exacerbation of musculoskeletal condition
- Lightheadedness
- Dizziness
- Difficulty swallowing, coughing, or nausea when performing peak VO<sub>2</sub> test

Very low likelihood

- Cardiac ischemia or arrest during peak VO<sub>2</sub> test or exercise training

There may also be risks that are unknown at this time. You will be given more information if other risks are found.

### **Information for Women of Childbearing Potential**

Women who are pregnant or breastfeeding are not permitted to participate in this study. During the study, you may use any form of birth control that you wish; we simply ask that you not change the type of birth control that you use or its dose during the study.

### **Benefits**

You will not benefit directly from taking part in this portion of the study. Your participation may qualify you to screen for the entire research study.

### **Alternatives**

Your alternative is to not participate in the study.

## **Confidentiality and Authorization to Use and Disclose Information for Research Purposes**

Federal regulations give you certain rights related to your health information. These include the right to know who will be able to get the information and why they may be able to get it. The study doctor must get your authorization (permission) to use or give out any health information that might identify you.

### **What protected health information may be used and/or given to others?**

All medical information, including but not limited to information and/or records of any diagnosis or treatment of disease or condition, which may include sexually transmitted diseases (e.g., HIV, etc.) or communicable diseases, drug/alcohol dependency, etc.; all personal identifiers, including but not limited to your name, social security number, medical record number, date of birth, dates of service, etc.; any past, present, and future history, examinations, laboratory results, imaging studies and reports and treatments of any kind, including but not limited to drug/alcohol treatment, psychiatric/psychological treatment; financial/billing information, including but not limited to copies of your medical bills; any other information related to or collected for use in the research study, regardless of whether the information was collected for research or non-research (e.g., treatment) purposes; records about any study drug you received or about study devices used; and consent forms from past studies that might be in your medical record.

Your consent form will be placed in your medical record at UAB Health System or Children's of Alabama. This may include either a paper medical record or electronic medical record (EMR). An EMR is an electronic version of a paper medical record of your care within this health system. Your EMR may indicate that you are on a clinical trial and provide the name and contact information for the principal investigator.

If you are receiving care or have received care within this health system (outpatient or inpatient), results of research tests or procedures (i.e. laboratory tests, imaging studies and clinical procedures) may be placed in your existing medical record.

If you have never received care within this health system (outpatient or inpatient), a medical record will be created for you to maintain results of research tests or procedures.

Results of research tests or procedures may be placed in your medical record. All information within your medical record can be viewed by individuals authorized to access the record.

A description of this clinical trial will be available on [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.

### **Who may use and give out information about you?**

Information about your health may be used and given to others by the study doctor and staff. They might see the research information during and after the study.

### **Who might get this information?**

All Individuals/entities listed in the informed consent document(s), including but not limited to, the physicians, nurses and staff and others performing services related to the research (whether at UAB or elsewhere). Your information may also be given to the sponsor of this research. "Sponsor" includes any persons or companies that are working for or with the sponsor, or are owned by the sponsor, or are providing support to the sponsor (e.g., contract research organization).

Information about you and your health which might identify you may be given to:

- the Office for Human Research Protections(OHRP)
- the U.S. Food and Drug Administration(FDA)
- Department of Health and Human Services (DHHS)agencies
- Governmental agencies in othercountries
- Governmental agencies to whom certain diseases (reportable diseases) must bereported
- the University of Alabama at Birmingham - the physicians, nurses and staff working on the research study (whether at UAB or elsewhere); other operating units of UAB, UAB Hospital, UAB Highlands Hospital, University of Alabama Health Services Foundation, Children’s of Alabama, Eye Foundation Hospital, and the Jefferson County Department of Health, as necessary for their operations; the UAB IRB and its staff
- the billing offices of UAB and UAB Health Systems affiliates and/or Children’s of Alabama and its billing agents

### **Why will this information be used and/or given to others?**

Information about you and your health that might identify you may be given to others to carry out the research study. The sponsor will analyze and evaluate the results of the study. In addition, people from the sponsor and its consultants will be visiting the research site. They will follow how the study is done, and they will be reviewing your information for this purpose.

This research is covered by a Certificate of Confidentiality from the National Institutes of Health. The researchers with this Certificate may not disclose or use information, documents, or biospecimens that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information, documents, or biospecimens protected by this Certificate cannot be disclosed to anyone else who is not connected with the research except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or communicable diseases but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings, see below); if you have consented to the disclosure, including for your medical treatment; or if it is used for other scientific research, as allowed by federal regulations protecting research subjects.

The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the project that is needed for auditing or program evaluation by the National Cancer Institute which is funding this project or for information that must be disclosed in order to meet the requirements of the federal Food and Drug Administration (FDA). You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this research. If you want your research information released to an insurer, medical care provider, or any other person not connected with the research, you must provide consent to allow the researchers to release it.

The Certificate of Confidentiality will not be used to prevent disclosure as required by federal, state, or local law of child abuse and neglect, or harm to self or others.

The Certificate of Confidentiality will not be used to prevent disclosure for any purpose you have consented to in this informed consent document.

A federal law, called the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for health insurance companies, group health plans, and some employers to discriminate against you based on your genetic information. This law generally will protect you in the following ways:

- Health insurance companies and group health plans may not request your genetic information that we get from this research.
- Health insurance companies and group health plans may not use your genetic information when making decisions regarding your eligibility or premiums.
- Employers with 15 or more employees may not use your genetic information that we get from this research when making a decision to hire, promote, or fire you or when setting the terms of your employment.

Be aware that this federal law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance, nor does it protect you against genetic discrimination by all employers.

### **What if I decide not to give permission to use and give out my health information?**

By signing this consent form, you are giving permission to use and give out the health information listed above for the purposes described above. If you refuse to give permission, you will not be able to be in this research.

### **May I review or copy the information obtained from me or created about me?**

You have the right to review and copy your health information. However, if you decide to be in this study and sign this permission form, you will not be allowed to look at or copy your information until after the research is completed.

### **May I withdraw or revoke (cancel) my permission?**

Yes, but this permission will not stop automatically. The use of your personal health information will continue until you cancel your permission.

You may withdraw or take away your permission to use and disclose your health information at any time. You do this by sending written notice to the study doctor. If you withdraw your permission, you will not be able to continue being in this study.

When you withdraw your permission, no new health information which might identify you will be gathered after that date. Information that has already been gathered may still be used and given to others. This would be done if it were necessary for the research to be reliable.

### **Is my health information protected after it has been given to others?**

If you give permission to give your identifiable health information to a person or business, the information may no longer be protected. There is a risk that your information will be released to others. Including others outside of UAB, without your permission.

### **Voluntary Participation and Withdrawal**

Whether or not you take part in this study is your choice. There will be no penalty if you decide not to be in it. If you decide not to be in the study, you will not lose any benefits you are otherwise owed.

If you are a UAB student or employee, taking part in this research is not a part of your UAB class work or duties. You can refuse to enroll, or withdraw after enrolling at any time before the study is over, with no effect on your class standing, grades, or job at UAB. You will not be offered or receive any special consideration if you take part in this research.



1  
2 **Cost of Participation**  
3

4 There will be no cost to you for taking part in this study.  
5

6 **Payment for Participation**  
7

8 There will be no payment for this portion of the study.  
9

10 **Payment for Research-Related Injuries**  
11

12 UAB, UAB-Lakeshore Research Collaborative Exercise Center, and NCI have not provided for any payment if  
13 you are harmed as a result of taking part in this study. If such harm occurs, treatment will be provided.  
14 However, this treatment will not be provided free of charge.  
15  
16

17 **New Findings**  
18

19 You will be told by the study doctor or the study staff if new information becomes available that might affect  
20 your choice to stay in the study.  
21  
22

23 **Questions**  
24

25 If you have any questions, concerns, or complaints about the research or a research-related injury including  
26 available treatments, please contact the study doctor. You may contact Dr. Laura Rogers at 205-934-9735.  
27  
28

29 If you have questions about your rights as a research participant, or concerns or complaints about the  
30 research, you may contact the UAB Office of the IRB (OIRB) at (205) 934-3789 or toll free at 1-855-860-3789.  
31 Regular hours for the OIRB are 8:00 a.m. to 5:00 p.m. CT, Monday through Friday.  
32

33 **Legal Rights**  
34

35 You are not waiving any of your legal rights by signing this consent form.  
36  
37

38 **Signatures**  
39

40 Your signature below indicates that you have read (or been read) the information provided above and agree to  
41 participate in this portion of the study. You will receive a copy of this signed consent form.  
42  
43  
44

45 \_\_\_\_\_  
46 Signature of Participant

Date

47 \_\_\_\_\_  
48  
49 Signature of Person Obtaining Consent

Date

**Title of Research:** Role of Gut Microbe Composition in Psychosocial Symptom Response to Exercise Training in Breast Cancer Survivors

**UAB IRB Protocol #:** IRB-300003230

**Principal Investigator:** Laura Q. Rogers, M.D., M.P.H

**Sponsor:** National Cancer Institute (NCI)

### Full Study Participation Consent

<b>General Information</b>	You are being asked to take part in a research study. This research study is voluntary, meaning you do not have to take part in it. The procedures, risks, and benefits are fully described further in the consent form.
<b>Purpose</b>	The purpose of the study is to determine the effects of diet and exercise on the number, distribution, and types of bacteria in the gut of breast cancer survivors.
<b>Duration &amp; Visits</b>	<ul style="list-style-type: none"> <li>• You will be in this study for up to 21 weeks. There will be a total of 57 study visits:</li> <li>• 1 Screening visit (2 hours)</li> <li>• 2 Baseline visits (Baseline Visit 1: 3 hours, Baseline Visit 2: 1 hour)</li> <li>• 2 Mid-intervention visits (Mid-intervention Visit 1: 3.5 hours; Mid-intervention Visit 2: 1 hour)</li> <li>• 2 Post-intervention visits (Post-intervention Visit 1: 3.5 hours; Post-intervention Visit 2: 1 hour)</li> <li>• 2 Week-5 Post-intervention visits (Week-5 Post-intervention Visit 1: 3.5 hours; Week-5 Post-intervention Visit 2: 1 hour)</li> <li>• 4 Between Visits (All take about 30 minutes, and may be completed at your home)</li> <li>• Up to 30 Aerobic exercise training sessions or 30 flexibility/toning sessions (depending on the group you are assigned to). (Aerobic exercise training sessions: 20 – 60 minutes each, depending on your level of progression; Flexibility/toning sessions: 40 minutes each)</li> <li>• 11-13 Food Pick-up Visits (30 minutes per pick-up)</li> </ul>
<b>Overview of Procedures</b>	<ul style="list-style-type: none"> <li>• This study will include the following procedures and assessments:</li> <li>• Controlled feeding diet: You will be required to pick-up your food once a week from the Bionutrition Core at the University of Alabama at Birmingham (UAB) or the UAB-Lakeshore Research Collaborative Exercise Center. No outside food may be eaten during the 11 to 13 weeks you are on the controlled feeding diet.</li> <li>• Stool sample collection</li> <li>• Diet log for 3 days (diary of what you eat for 3 days)</li> <li>• Medication log (listing your medicines)</li> <li>• Fasted blood draw</li> <li>• Heart rate variability with impedance cardiography - non-invasive test using ECG leads</li> <li>• Peak VO<sub>2</sub> Testing – You will be asked to perform a graded treadmill or stationary bicycle test. You will walk on the treadmill or pedal on the bike at increasing intensity until you feel you cannot longer walk or pedal. We will measure your total aerobic fitness by measuring oxygen consumed when performing this test.</li> </ul>

	<ul style="list-style-type: none"> <li>• Resting Energy Expenditure - You will be asked to lie on your back for 30 minutes in a bed with a canopy system over your head. We will ask you to breathe normally during this time while we collect the exhaled air.</li> <li>• Walking Economy – You will be asked to perform a walking economy test. You will wear a hip-worn accelerometer while walking on a treadmill at slow pace for six minutes.</li> <li>• Hair sample collection</li> <li>• Body mass index, weight and height measurement</li> <li>• Blood pressure and heart rate</li> <li>• Wear an accelerometer for 7 days and keep accelerometer wear log - The accelerometer is a small monitor that will be worn around your waist. This monitor will collect data on how much you move during your daily living activities.</li> <li>• Dual Energy X-Ray Absorptiometry (DXA) scan</li> <li>• Randomized into aerobic or flexibility/toning exercise group</li> <li>• Self-administered survey (questions about how you feel and your medical history)</li> </ul>
<b>Risks</b>	<ul style="list-style-type: none"> <li>• The most common risks include:</li> <li>• Muscle soreness</li> <li>• Fatigue (tiredness)</li> <li>• Shortness of breath during and/or after exercise or performance of Peak VO<sub>2</sub></li> <li>• Dry mouth</li> <li>• Skin irritation from impedance cardiography and heart rate variability non-invasive chest electrode (similar to ECG) preparation</li> <li>• Feelings of claustrophobia during resting energy expenditure testing</li> <li>• Embarrassment during height and weight collection</li> <li>• Change in diet might cause gastrointestinal discomfort including, but not limited to general discomfort, bloating, gas, reflux, diarrhea and constipation.</li> </ul>
<b>Benefits</b>	You may or may not benefit directly from taking part in this study. However, this study may help us better understand how to reduce the great burden of suffering caused by fatigue after a cancer diagnosis in the future.
<b>Alternatives</b>	The alternative to this study is to not take part in it.

### **Purpose of the Research Study**

The purpose of this research study is to determine diet and exercise effects on the number, distribution, and types of bacteria in the gut of breast cancer survivors. This study will enroll 200 participants at UAB.

### **Study Participation & Procedures**

If you agree to join the study, you will be involved in the following procedures:

#### **Screening Visit (2 hours)**

During the screening visit, you will come to the Webb building in the morning time as you will need to come in a fasting state. At this visit you will undergo Peak VO<sub>2</sub> testing and have your weight and height taken to calculate your body mass index (BMI). If the results from the Peak VO<sub>2</sub> test and the BMI results are within the eligibility criteria, you will be started on the controlled feeding diet and be given a 7-day medication log sheet to complete. Participants will be shown a menu with all meals that will be delivered throughout the baseline testing and 10 weeks of exercise. Participants will have the ability to ask questions regarding food choices, and controlled feeding.

1  
2 Baseline Testing Visit 1 (3 hours)

3 Once you have completed at least 1 full week of the controlled feeding diet, you will come in to the Webb  
4 building in a fasted state for Baseline Testing Visit 1. At this visit, you will be asked to have your weight  
5 measured, provide your medication log for the prior 7 days and will have a fasted blood draw, heart rate  
6 variability with impedance cardiography test, resting energy expenditure test, walking economy test, and a  
7 hair sample collected. You will complete the DXA scan and a pregnancy test (if pre-menopausal). You will be  
8 asked to complete a survey about your medical history, mood, attitudes, sleep, etc. You will also start  
9 wearing an accelerometer, and will be required to wear it for 7 days while also keeping an accelerometer  
10 wear log.  
11

12  
13 Between Baseline Testing Visit 1 and 2 (30 minutes)

14 You will be asked to provide a fecal sample 2 to 3 days after Baseline Testing Visit 1, along with a 3-day diet  
15 record for the 2 days prior to and day of fecal sample collection. You will provide this fecal sample from the  
16 comfort of your own home, and mail the sample to us via pre-paid shipping materials.  
17

18  
19 Baseline Testing Visit 2 (1 hour)

20 You will come to the Webb building, Medical Towers, or UAB-Lakeshore Research Collaborative Exercise Center  
21 2 to 3 days after the fecal sample collection to return the accelerometer (and accelerometer log) and complete a  
22 brief self-administered survey about your energy level. These activities may be done through the mail if  
23 preferred. We will provide pre-paid shipping materials.  
24

25  
26 Mid-intervention Testing Visit 1 (3.5 hours)

27 At week 5 of the intervention, you will come to the Webb building for the mid-intervention visit. This visit will  
28 mirror that of the baseline testing visit 1 and the Peak VO<sub>2</sub> testing done during the screening visit.  
29

30  
31 Between Mid-intervention Testing Visit 1 and 2 (30 minutes)

32 You will be asked to provide a fecal sample 2 to 3 days after Mid-intervention Testing Visit 1, along with a 3-  
33 day diet record for the 2 days prior to and day of fecal sample collection. You will provide this fecal sample  
34 from the comfort of your own home, and mail the sample to us via pre-paid shipping materials.  
35

36  
37 Mid-intervention Testing Visit 2 (1 hour)

38 You will come to the Webb building, Medical Towers, or UAB-Lakeshore Research Collaborative Exercise Center  
39 2 to 3 days after the fecal sample collection to return the accelerometer (and accelerometer log) and complete a  
40 brief self-administered survey about your energy level. These activities may be done through the mail if  
41 preferred. We will provide pre-paid shipping materials.  
42

43  
44 Post-intervention and 5 Weeks Post-intervention Testing Visit 1 (3.5 hours)

45 At week 10 of the intervention and week 15 of the study (5 weeks post-intervention), you will come to the Webb  
46 building for the post-intervention and 5 week post-intervention testing. We will ask you to request/collect  
47 medical information (i.e., tumor characteristics) as well as medical clearance from your treating physician before  
48 this visit. These visits will mirror the Mid-intervention Testing Visit 1.  
49

50  
51 Between Post-intervention and 5 Weeks Post-intervention Testing Visit 1 and 2 (30 minutes)

52 You will be asked to provide a fecal sample 2 to 3 days after Post-intervention and 5 weeks Post-intervention  
53 Testing Visit 1, along with a 3-day diet record for the 2 days prior to and day of fecal sample collection. You  
54 will provide this fecal sample from the comfort of your own home, and mail the sample to us via pre-paid  
55 shipping materials.  
56

57  
58 Post-intervention and 5 Week Post-intervention Testing Visit 2 (1 hour)

59 You will come to the Webb building, Medical Towers, or UAB-Lakeshore Research Collaborative Exercise Center  
60 2 to 3 days after the fecal sample collection to return the accelerometer (and accelerometer log) and complete a

1  
2 brief self-administered survey about your energy level. These activities may be done through the mail if  
3 preferred. We will provide pre-paid shipping materials.  
4

5 *Aerobic Exercise Training Sessions (if you are randomized to this group)*

6 These sessions will take place at the UAB-Lakeshore Research Collaborative Exercise Center or at the UAB  
7 campus, and will be supervised by exercise specialists who have experience training cancer survivors. Each  
8 session will last 20 to 60 minutes depending on your level of progression (shorter duration in the first few  
9 weeks). These sessions will occur on nonconsecutive days of the week, and will be held 3 times per week.  
10

11  
12 *Flexibility/toning exercise Group (if you are randomized to this group)*

13 These sessions will take place at the UAB-Lakeshore Research Collaborative Exercise Center or at the UAB  
14 campus, and will be led by exercise specialists who have experience training cancer survivors. Each session will  
15 last about 40 minutes, and will be held 3 times per week.  
16

17  
18 *Weekly Food Pick Up*

19 Once a week, you will be required to come to UAB's campus or UAB-Lakeshore Research Collaborative Exercise  
20 Center to pick up your food. During the baseline assessment period and the 10-week intervention, and the  
21 post-intervention assessment period, you will consume only food prepared by the UAB Bionutrition Core as no  
22 "outside" foods are allowed. However, you may consume calorie-free beverages, such as water and black tea,  
23 or chew sugarless gum. You will not be given food after the post-intervention assessment or during the 5 weeks  
24 after finishing the post-intervention assessments.  
25

26 We ask that you do not change your usual physical activity or engage in additional exercise sessions outside of  
27 the study appointments while you are participating in this study.  
28

29  
30 If you agree to join the study, you will be in the study for up to 21 weeks.  
31

32 **Explanation of the Procedures**

33  
34 Weight, Height, Blood Pressure, and Heart Rate: We will measure your weight, height, blood pressure, and  
35 heart rate, similar to how they are measured in a doctor's office.  
36

37  
38 Fecal and Hair Sample Collection: To collect your stool at home, we will give you a collection kit at each visit  
39 prior to the collection. You will collect the sample per instructions provided to you, and ship it back to our site  
40 via pre-paid shipping materials. We will collect the hair sample when you come in for each follow-up visit. For  
41 the hair sample collection, we will cut a thin layer of hair from a point close to the scalp across a 4-5 centimeter  
42 length, and 6-8 centimeter length for shorter hair. We will obtain a minimum of 50 strands of hair.  
43

44 Diet Record: You will complete a diet record for the 2 days prior to and day of fecal sample collection.  
45

46  
47 7-day Medication Log: You will complete a 7-day medication log listing all medications taken within the 7 days  
48 prior to the fasted blood draw. This will be completed for the Baseline Testing Visit 1, Mid-intervention Testing  
49 Visit 1, and Post-intervention and 5-weeks Post-Intervention Testing Visits 1. We do ask that you refrain from  
50 taking sporadic or "as-needed" medications during these 7 days.  
51

52 Blood Draw: Fasting blood draws will be conducted to measure systemic markers of inflammation and health.  
53 You will need to be in a fasting state for 12 hours prior to the blood draw. We will take no more than 25 ml (5  
54 teaspoons) of blood.  
55

1  
2  
3 Heart Rate Variability, Impedance Cardiography, Resting Energy Expenditure, Walking Economy, and Peak VO<sub>2</sub>  
4 Testing: Heart rate variability and impedance cardiography will be measured using non-invasive chest electrodes.  
5 You will be asked to provide a urine sample prior to the heart rate variability test to measure your hydration.  
6 We will assess your resting metabolic rate (or energy expenditure) using a ventilated hood while lying quietly  
7 on a table (approximately 30 minutes). You must fast for at least 12 hours prior, complete no physical activity  
8 for 24 hours and avoid any caffeine or nicotine for at least 2 hours prior to this test.  
9 Please notify the staff if you have diabetes so special precautions can be taken to ensure your safety.  
10 Walking economy will be tested by having you walk for six minutes on a treadmill while wearing a  
11 motion sensor and breathing through a mouthpiece that measures your metabolism.  
12 Peak VO<sub>2</sub> will be measured by you walking on a treadmill or pedaling on a stationary bicycle while wearing  
13 a motion sensor and breathing through a mouthpiece that measures your metabolism.  
14 You will perform a graded treadmill or a stationary bicycle test while we measure your heart rate and  
15 blood pressure and you will walk or pedal until exhaustion.  
16  
17

18 Accelerometer activity: You will be asked to wear an accelerometer (motion sensor) at the waist for 7  
19 consecutive days while also keeping an accelerometer wear log.  
20  
21

22 Dual X-Ray Absorptiometry: DXA is a method to test body composition as well as bone density. In this  
23 procedure you will lie on your back on a padded table while a measuring device moves back and forth over  
24 your body from head to foot, taking about 30 minutes. You will be asked to lie still, but there is no discomfort  
25 in this procedure. DXA involves extremely low levels of radiation (x-ray) exposure. The amount of radiation  
26 involved is equivalent to one to two days of natural background radiation. Natural background radiation is  
27 radiation normally received from sources such as cosmic rays and natural radioactivity in building materials and  
28 the ground.  
29  
30

31 Urine Pregnancy Test: For pre-menopausal females, a urine pregnancy test will be required before each DXA  
32 scan.  
33

34 Self-administered Surveys: You will be asked to complete a questionnaire regarding your medical history,  
35 demographics, mood, attitudes, sleep, physical activity, etc.  
36  
37

38 You will be randomly picked (like the flip of a coin) by a computer to receive either aerobic or flexibility/toning  
39 exercise. The exercise schedules are as mentioned above. This is a single-blind study. This means the person  
40 performing the testing visits on you will not know which group you have been randomized to. We will ask you  
41 not to tell this person your group assignment.  
42

### 43 ***Incidental Findings***

44 We are performing imaging solely for the research purposes described above. It is not a clinical scan intended for  
45 diagnostic or therapeutic purposes. Under no circumstance will the investigator, research staff, or imaging staff  
46 interpret the scan as normal or abnormal. They are unable to make any medical comments about your scan. The  
47 scan will not be looked at or read for any healthcare treatment or diagnostic purpose. If you want your scan to  
48 be reviewed by a physician so the physician can look for medical issues, you can request a copy of your scan. We  
49 will provide an electronic copy at no charge.  
50  
51

### 52 ***Additional Information***

53 Your de-identified private information and de-identified biospecimens (private information and biospecimens  
54 with all identifiers removed) may be used for future research studies or distributed to another researcher for  
55 future research studies without additional informed consent. **This is only when there are no identifiers  
56 associated with the data or biospecimens.**  
57

The biospecimens obtained from you in this research, which may or may not include your identifiable private information, may be used for commercial profit. There are no plans to provide financial compensation to you should this occur.

The clinical results (including individual research results) will only be given to you upon request and after completion of the study.

### **Risks and Discomforts**

You may have some risks from taking part in this study.

*The risks are:*

*Moderate likelihood:*

- Muscle soreness
- Fatigue (tiredness)
- Shortness of breath during and/or after exercise or performance of Peak VO<sub>2</sub>
- Dry mouth
- Feelings of claustrophobia during resting energy expenditure testing
- Embarrassment during height and weight collection.
- Low levels of radiation (X-ray) exposure

*Low likelihood:*

- Injury to muscle, joint, ligaments, tendons, or bones
- Tripping or falling during exercise or while completing the fitness test
- Inconvenience
- Emotional stress while completing surveys or having blood drawn
- Exacerbation of musculoskeletal condition
- Mild bruising or soreness at the site of the blood draw
- Passing out during the blood draw
- Lightheadedness
- Dizziness
- Hypoglycemia when fasting (low blood sugar)
- Difficulty swallowing, coughing, or nausea when performing Peak VO<sub>2</sub> test
- Gastrointestinal discomfort due to a higher fiber content of the diet

*Very low likelihood:*

- Cardiac ischemia or cardiac arrest during peak VO<sub>2</sub> test or exercise training

There may also be risks that are unknown at this time. You will be given more information if other risks are found.

You will be assigned to a group by chance, which may prove to be less effective or to have more side effects than the other study group or alternatives.

### **Information for Women of Childbearing Potential**

Women who are pregnant or breastfeeding are not permitted to participate in this study. During the study, you may use any form of birth control that you wish; we simply ask that you not change the type of birth control that you use or its dose during the study.

### **Benefits**

You may or may not benefit directly from taking part in this study. However, this study may help us better understand how to reduce the great burden of suffering caused by fatigue after a cancer diagnosis in the future. You will be assigned to a group by chance, which may prove to have more or less benefits than the other study group.

### **Alternatives**

Your alternative is to not participate in the study.

### **Confidentiality and Authorization to Use and Disclose Information for Research Purposes**

Federal regulations give you certain rights related to your health information. These include the right to know who will be able to get the information and why they may be able to get it. The study doctor must get your authorization (permission) to use or give out any health information that might identify you.

#### **What protected health information may be used and/or given to others?**

All medical information, including but not limited to information and/or records of any diagnosis or treatment of disease or condition, which may include sexually transmitted diseases (e.g., HIV, etc.) or communicable diseases, drug/alcohol dependency, etc.; all personal identifiers, including but not limited to your name, social security number, medical record number, date of birth, dates of service, etc.; any past, present, and future history, examinations, laboratory results, imaging studies and reports and treatments of any kind, including but not limited to drug/alcohol treatment, psychiatric/psychological treatment; financial/billing information, including but not limited to copies of your medical bills; any other information related to or collected for use in the research study, regardless of whether the information was collected for research or non-research (e.g., treatment) purposes; records about any study drug you received or about study devices used; and consent forms from past studies that might be in your medical record.

Your consent form will be placed in your medical record at UAB Health System or Children's of Alabama. This may include either a paper medical record or electronic medical record (EMR). An EMR is an electronic version of a paper medical record of your care within this health system. Your EMR may indicate that you are on a clinical trial and provide the name and contact information for the principal investigator.

If you are receiving care or have received care within this health system (outpatient or inpatient), results of research tests or procedures (i.e. laboratory tests, imaging studies and clinical procedures) may be placed in your existing medical record.

If you have never received care within this health system (outpatient or inpatient), a medical record will be created for you to maintain results of research tests or procedures.

Results of research tests or procedures may be placed in your medical record. All information within your medical record can be viewed by individuals authorized to access the record.

A description of this clinical trial will be available on [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.



### Who may use and give out information about you?

Information about your health may be used and given to others by the study doctor and staff. They might see the research information during and after the study.

### Who might get this information?

All Individuals/entities listed in the informed consent document(s), including but not limited to, the physicians, nurses and staff and others performing services related to the research (whether at UAB or elsewhere). Your information may also be given to the sponsor of this research. "Sponsor" includes any persons or companies that are working for or with the sponsor, or are owned by the sponsor, or are providing support to the sponsor (e.g., contract research organization).

Information about you and your health which might identify you may be given to:

- the Office for Human Research Protections (OHRP)
- the U.S. Food and Drug Administration (FDA)
- Department of Health and Human Services (DHHS) agencies
- Governmental agencies in other countries
- Governmental agencies to whom certain diseases (reportable diseases) must be reported
- the University of Alabama at Birmingham - the physicians, nurses and staff working on the research study (whether at UAB or elsewhere); other operating units of UAB, UAB Hospital, UAB Highlands Hospital, University of Alabama Health Services Foundation, Children's of Alabama, Eye Foundation Hospital, and the Jefferson County Department of Health, as necessary for their operations; the UAB IRB and its staff
- the billing offices of UAB and UAB Health Systems affiliates and/or Children's of Alabama and its billing agents

### Why will this information be used and/or given to others?

Information about you and your health that might identify you may be given to others to carry out the research study. The sponsor will analyze and evaluate the results of the study. In addition, people from the sponsor and its consultants will be visiting the research site. They will follow how the study is done, and they will be reviewing your information for this purpose.

This research is covered by a Certificate of Confidentiality from the National Institutes of Health. The researchers with this Certificate may not disclose or use information, documents, or biospecimens that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information, documents, or biospecimens protected by this Certificate cannot be disclosed to anyone else who is not connected with the research except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or communicable diseases but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings, see below); if you have consented to the disclosure, including for your medical treatment; or if it is used for other scientific research, as allowed by federal regulations protecting research subjects.

The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the project that is needed for auditing or program evaluation by the National Cancer Institute which is funding this project or for information that must be disclosed in order to meet the requirements of the federal Food and Drug Administration (FDA). You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this research. If you want your research information released to an insurer, medical care provider, or any other person not connected with the research, you must provide consent to allow the researchers to release it.

1  
2  
3 The Certificate of Confidentiality will not be used to prevent disclosure as required by federal, state, or local  
4 law of child abuse and neglect, or harm to self or others.  
5

6 The Certificate of Confidentiality will not be used to prevent disclosure for any purpose you have consented to  
7 in this informed consent document.

8 A federal law, called the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for health  
9 insurance companies, group health plans, and some employers to discriminate against you based on your  
10 genetic information. This law generally will protect you in the following ways:

- 11 • Health insurance companies and group health plans may not request your genetic information that we get from  
12 this research.
- 13 • Health insurance companies and group health plans may not use your genetic information when making  
14 decisions regarding your eligibility or premiums.
- 15 • Employers with 15 or more employees may not use your genetic information that we get from this  
16 research when making a decision to hire, promote, or fire you or when setting the terms of your  
17 employment.  
18  
19

20  
21 Be aware that this federal law does not protect you against genetic discrimination by companies that sell life  
22 insurance, disability insurance, or long-term care insurance, nor does it protect you against genetic  
23 discrimination by all employers.  
24

#### 25 **What if I decide not to give permission to use and give out my health information?**

26 By signing this consent form, you are giving permission to use and give out the health information listed above  
27 for the purposes described above. If you refuse to give permission, you will not be able to be in this research.  
28  
29

#### 30 **May I review or copy the information obtained from me or created about me?**

31 You have the right to review and copy your health information. However, if you decide to be in this study and  
32 sign this permission form, you will not be allowed to look at or copy your information until after the research is  
33 completed.  
34

#### 35 **May I withdraw or revoke (cancel) my permission?**

36 Yes, but this permission will not stop automatically. The use of your personal health information will continue  
37 until you cancel your permission.  
38  
39

40 You may withdraw or take away your permission to use and disclose your health information at any time. You  
41 do this by sending written notice to the study doctor. If you withdraw your permission, you will not be able to  
42 continue being in this study.  
43

44 When you withdraw your permission, no new health information which might identify you will be gathered  
45 after that date. Information that has already been gathered may still be used and given to others. This would be  
46 done if it were necessary for the research to be reliable.  
47  
48

#### 49 **Is my health information protected after it has been given to others?**

50 If you give permission to give your identifiable health information to a person or business, the information may  
51 no longer be protected. There is a risk that your information will be released to others. Including others outside  
52 of UAB, without your permission.  
53

#### 54 **Voluntary Participation and Withdrawal**

55  
56  
57 Whether or not you take part in this study is your choice. There will be no penalty if you decide not to be in it.

1 If you decide not to be in the study, you will not lose any benefits you are otherwise owed.

2  
3  
4 You are free to withdraw from this study at any time. Your choice to leave the study will not affect your  
5 relationship with this institution. Contact the study doctor if you want to withdraw from the study.

6  
7 You may be removed from the study without your consent if the sponsor ends the study, if the study doctor  
8 decides it is not in the best interest of your health, or if you are not following the study rules.

9  
10  
11 If you are a UAB student or employee, taking part in this research is not a part of your UAB class work or duties.  
12 You can refuse to enroll, or withdraw after enrolling at any time before the study is over, with no effect on your  
13 class standing, grades, or job at UAB. You will not be offered or receive any special consideration if you take part  
14 in this research.

### 15 16 **Cost of Participation**

17  
18 There will be no cost to you for taking part in this study. All exams, medical care, food, and exercise or  
19 toning/flexing training related to this study will be provided to you at no cost during the 21 week study period.

### 20 21 22 **Payment for Participation**

23  
24 The total payment you may receive is \$600. You will be paid:

25  
26 \$150 for each assessment period for a possible total of \$600 (all testing visits within an assessment must be  
27 completed; assessment periods include Baseline, Mid-intervention, Post-intervention, and 5-weeks Post-  
28 intervention).

29  
30 In addition, you will receive 11 to 13 weeks of meals at no cost to you.

31  
32  
33 After completing the final assessment, you will be offered counseling from a registered dietitian regarding a  
34 diet plan that will help you maintain or lose weight, as appropriate. Similarly, you will be offered three free  
35 sessions (after completing the final assessment) with one of the ACSM certified Cancer Exercise Trainers, during  
36 which, you will receive instruction for continuing exercises at home.

37  
38  
39 Ask the study staff about the method of payment that will be used for this study (e.g., check, cash, gift card,  
40 direct deposit).

41  
42 You are responsible for paying any state, federal, Social Security or other taxes on the payments you receive.  
43 You will receive a form 1099 in January of the year following your participation in this study. This form is also  
44 sent to the IRS to report any money paid to you. No taxes are kept from your payment.

### 45 46 47 **Payment for Research-Related Injuries**

48  
49 UAB, UAB-Lakeshore Research Collaborative Exercise Center, and NCI have not provided for any payment if  
50 you are harmed as a result of taking part in this study. If such harm occurs, treatment will be provided.  
51 However, this treatment will not be provided free of charge.

### 52 53 **New Findings**

54  
55 You will be told by the study doctor or the study staff if new information becomes available that might affect  
56 your choice to stay in the study.

## **Optional Research**

### **Future Research Use of Private Information and/or Biospecimens**

We would like your permission to keep your private information (data containing personal information) and biospecimens (blood) collected in this study for future research. The future research may be similar to this study or may be completely different. Your private information and biospecimens will be stored indefinitely or until used.

Your private information and biospecimens will be labeled with a code that only the study doctor can link back to you. Results of any future research will not be given to you or your doctor.

You can take part in this study even if you decide not to let us keep your private information and biospecimens for future research.

If you give us permission now to keep your private information and biospecimens, you can change your mind later and ask us to destroy it. However, once we have analyzed your private information and biospecimens, we may not be able to take it out of our future research.

We may share your private information and biospecimens, so that others can use it in their research. Their research may be similar to this study or may be completely different. Once we have shared your private information and biospecimens with other researchers, we will not be able to get it back.

Future research use of your private information and biospecimens will be conducted in compliance with applicable regulatory requirements.

You will not find out the results of future research on your private information and biospecimens. Allowing us to do future research on your private information and biospecimens will not benefit you directly.

The private information and biospecimens used for future research may be used for commercial profit. There are no plans to provide financial compensation to you should this occur.

Initial your choice below:

\_\_\_\_\_ I agree to allow my private information and biospecimens to be kept and used for future research.

\_\_\_\_\_ I do not agree to allow my private information and biospecimens to be kept and used for future research.

Initial your choice below:

\_\_\_\_\_ I agree for my genetic and other relevant study data, such as health information, to be shared broadly in a coded form for future research or analysis.

\_\_\_\_\_ I do not agree for my genetic and other relevant study data, such as health information, to be shared broadly in a coded form for future research or analysis.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Questions**

If you have any questions, concerns, or complaints about the research or a research-related injury including available treatments, please contact the study doctor. You may contact Dr. Laura Rogers at 205-934-9735.

If you have questions about your rights as a research participant, or concerns or complaints about the research, you may contact the UAB Office of the IRB (OIRB) at (205) 934-3789 or toll free at 1-855-860-3789. Regular hours for the OIRB are 8:00 a.m. to 5:00 p.m. CT, Monday through Friday.

**Legal Rights**

You are not waiving any of your legal rights by signing this consent form.

**Signatures**

Your signature below indicates that you have read (or been read) the information provided above and agree to participate in this study. You will receive a copy of this signed consent form.

\_\_\_\_\_  
Signature of Participant

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature of Person Obtaining Consent

\_\_\_\_\_  
Date

## Supplemental Material 3

## Equations for calculating daily calorie needs for energy balanced controlled feeding used in the ROME study (R01CA235598)

### Step 1: Calculate a base equation (used for all participants with Step 2 adjusting it for participants randomized to the aerobic exercise condition)

To calculate total energy expenditure (TEE), insert resting energy expenditure (REE) measured by indirect calorimeter from the most recent study assessment into the following equations developed per race based on prior datasets generated in the laboratory of Dr. Gary Hunter.<sup>105,106</sup>

European Americans:  $TEE = 1124 + (.725 * REE)$

African Americans:  $TEE = 1074 + (.725 * REE)$

Note: The ROME study uses the European American equation for individuals of Asian descent.

### Step 2: Refine base equation for participants randomized to the aerobic exercise condition

Exercise energy expenditure for each workout based on the a priori exercise progression protocol ( $\dot{V}O_{2peak}$  in ml/kg/min and BDW [body weight] in kg) are entered into the equation with the weekly total averaged over 7 days (to get a daily average needed for the daily controlled feeding menu). This daily average is added to the base equation calculated under Step 1 to determine the daily calorie needs for participants randomized to the aerobic exercise condition.

Continuous training	Interval training (added in later weeks per protocol)
WK1: $3 * 0.05 * \dot{V}O_{2peak} * BDW/7$	
WK2: $3 * 0.0597 * \dot{V}O_{2peak} * BDW/7$	
WK3: $3 * 0.08 * \dot{V}O_{2peak} * BDW/7$	
WK4: $3 * 0.103 * \dot{V}O_{2peak} * BDW/7$	
WK5: $2 * 0.13 * \dot{V}O_{2peak} * BDW/7$	+ $1 * 0.0675 * \dot{V}O_{2peak} * BDW/7$
WK6: $2 * 0.13 * \dot{V}O_{2peak} * BDW/7$	+ $1 * 0.0675 * \dot{V}O_{2peak} * BDW/7$
WK7: $2 * 0.13 * \dot{V}O_{2peak} * BDW/7$	+ $1 * 0.0743 * \dot{V}O_{2peak} * BDW/7$
WK8: $1 * 0.13 * \dot{V}O_{2peak} * BDW/7$	+ $2 * 0.078 * \dot{V}O_{2peak} * BDW/7$
WK9: $1 * 0.13 * \dot{V}O_{2peak} * BDW/7$	+ $2 * 0.0844 * \dot{V}O_{2peak} * BDW/7$
WK10: $1 * 0.13 * \dot{V}O_{2peak} * BDW/7$	+ $2 * 0.0911 * \dot{V}O_{2peak} * BDW/7$

Note: Exercise-related energy expenditure is greater during first 4 weeks (vs. later weeks) because interval training decreases volume and thus, decreases energy expenditure required.

Note: Rationale for coefficients used to estimate energy expenditure during exercise as follows:

- The week 1 coefficient of 0.05 is based on:
  - Subjects train at 50%  $\dot{V}O_{2peak}$  (60% max heart rate is about 50%  $\dot{V}O_{2peak}$ ) or the proportion 0.5.
  - The  $\dot{V}O_{2peak}$  is in ml/kg/min and must be converted to l/kg/min, therefore we must divide by 1000.

- 1  
2  
3           ○ There are 5 kcal burned for each liter of oxygen used and the subjects train for 20  
4           minutes during the first week.

5 Therefore, the equation is  $0.5 * 5 * 20/1000 = 0.05$  for week 1. The same methods are used for  
6 subsequent weeks as the intensity (proportion  $\dot{V}O_{2peak}$ ) and duration increase.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**SPIRIT-Outcomes 2022 Checklist (for combined completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items)<sup>a</sup>**

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
<b>Administrative information</b>				
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	-	
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	-	
	2b	All items from the World Health Organization Trial Registration Data Set	-	
Protocol version	3	Date and version identifier	-	
Funding	4	Sources and types of financial, material, and other support	-	
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	-	
	5b	Name and contact information for the trial sponsor	-	
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	-	
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	-	
<b>Introduction</b>				
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	-	
	6b	Explanation for choice of comparators	-	
Objectives	7	Specific objectives or hypotheses	-	



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	-	
<b>Methods: Participants, interventions, and outcomes</b>				
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	-	
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	-	
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered (for specific guidance see TIDieR checklist and guide)	-	
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	-	
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	-	
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	-	
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
	12.1		Provide a rationale for the selection of the domain for the trial's primary outcome	
	12.2		If the analysis metric for the primary outcome represents within-participant change, define and justify the minimal important change in individuals	
	12.3		If the outcome data collected are continuous but will be analyzed as categorical (method of aggregation), specify the cutoff values to be used	
	12.4		If outcome assessments will be performed at several time points after randomization, state the time points that will be used for analysis	
	12.5		If a composite outcome is used, define all individual components of the composite outcome	
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	-	
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	-	
	14.1		Define and justify the target difference between treatment groups (eg, the minimal important difference)	
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	-	
<b>Methods: Assignment of interventions (for controlled trials)</b>				
Allocation:				
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	-	
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	-	
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	-	
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	-	
<b>Methods: Data collection, management, and analysis</b>				
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	-	
	18a.1		Describe what is known about the responsiveness of the study instruments in a population similar to the study sample	
	18a.2		Describe who will assess the outcome (eg, nurse, parent)	
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	-	
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	-	
	20a.1		Describe any planned methods to account for multiplicity in the analysis or interpretation of the primary and secondary outcomes (eg, coprimary outcomes, same outcome assessed at multiple time points, or subgroup analyses of an outcome)	
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	-	
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	-	
<b>Methods: Monitoring</b>				
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	-	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	-	
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	-	
<b>Ethics and dissemination</b>				
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	-	
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	-	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	-	
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	-	
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	-	
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	-	
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	-	
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	-	
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	-	
	31b	Authorship eligibility guidelines and any intended use of professional writers	-	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported <sup>b</sup>
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-	
<b>Appendices</b>				
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	-	
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	-	

<sup>a</sup>It is strongly recommended that this checklist be read in conjunction with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement paper for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license and is reproduced with permission.

<sup>b</sup>Indicates page numbers and/or manuscript location: to be completed by authors.

Peer review only